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The term aspirin is used in this thesis instead of acetylsalicylic acid (ASA).




Antiplatelet medication is known to decrease adverse effects in patients with atherothrombotic 
disease. However, despite ongoing antiplatelet medication considerable number of patients 
suffer from atherothrombotic events. 
The aims of the study were 1) to evaluate the individual variability in platelet functions and 
compare the usability of different methods in detecting it, 2) to assess variability in efficacy 
of antiplatelet medication with aspirin (acetylsalicylic acid) or the combination of aspirin and 
clopidogrel and 3) to investigate the main genetic and clinical variables as well as potential 
underlying mechanisms of variability in efficacy of antiplatelet medication.
In comparisons of different platelet function tests in 19 healthy individuals PFA-100® correlated 
with traditional methods of measuring platelet function and was thus considered appropriate 
for testing individual variability in platelet activity. 
Efficacy of ongoing 100mg aspirin daily was studied in 101 patients with coronary artery 
disease (CAD). Aspirin response was measured with arachidonic acid (AA)-induced platelet 
aggregation, which reflects cyclo-oxygenase (COX)-1 dependent thromboxane (Tx) A
2
 
formation, and PFA-100®, which evaluates platelet activation under high shear stress in the 
presence of collagen and epinephrine. Five percent of patients failed to show inhibition of 
AA-aggregation and 21% of patients had normal PFA-100® results despite aspirin and were 
thus considered non-responders to aspirin. 
Interestingly, the two methods of assessing aspirin efficacy, platelet aggregation and PFA-
100®, detected different populations as being aspirin non-responders. It could be postulated 
that PFA-100® actually measures enhanced platelet function, which is not directly associated 
with TxA
2
 inhibition exerted by aspirin. 
Clopidogrel efficacy was assessed in 50 patients who received a 300mg loading dose of 
clopidogrel 2.5 h prior to percutaneous coronary intervention (PCI) and in 51 patients who 
were given a loading dose of 300mg combined with a five day treatment of 75mg clopidogrel 
daily mimicking ongoing treatment. Clopidogrel response was assessed with ADP-induced 
aggregations, due to its mechanism of action as an inhibitor of ADP-induced activation. When 
patients received only a loading dose of clopidogrel prior to PCI, 40% did not gain measurable 
inhibition of their ADP-induced platelet activity (inhibition of 10% or less). Prolongation 
of treatment so that all patients had reached a plateau of inhibition exerted by clopidogrel, 
decreased the incidence of non-responders to 20%. 
Polymorphisms of COX-1 and GP VI, as well as diabetes and female gender, were associated 
with decreased in vitro aspirin efficacy. Diabetes also impaired the in vitro efficacy of short-
term clopidogrel. Decreased response to clopidogrel was associated with limited inhibition 
by ARMX, an antagonist of  P2Y
12
-receptor, suggesting  the reason for clopidogrel resistance 
to be receptor-dependent.
Conclusions: Considerable numbers of CAD patients were non-responders either to aspirin, 
clopidogrel or both. In the future, platelet function tests may be helpful to individually select 




Atherothrombotic disease is the most common cause of mortality in developed countries. 
Atherosclerosis in connected with obliterative lesions ranging from minor stenosis to total 
occlusions. These lesions cause a variety of rheological changes, leading to increased 
shear forces and thus enhanced risk of thrombus formation. Acute thrombosis occurs when 
plaque rupture causes platelet activation and formation of a platelet plug at the injury site. 
Atherosclerotic changes in arteries are universal, but the major clinical manifestations of the 
disease are symptoms originating either from occluded coronary arteries, cerebral or carotid 
arteries, peripheral arteries or combination of these depending on where they form. Thus, acute 
formation of thrombi can respectively cause heart infarction, stroke or critical limb ischemia. 
Platelets play a critical role in thrombus formation especially in the arterial environment. 
Occurrences of acute events are also influenced by lipids, inflammation and vasoactivity, which 
have all been linked to platelet activation. Platelets have also been shown to take part in the 
development of atherosclerosis and postulated to regenerate stenosis of arteries which have 
been treated with angioplasty or stenting (see Le Breton et al 1996, see Ruggeri 2002).
Several antiplatelet drugs have been developed to inhibit platelet activity in acute thrombotic 
situations as well as to prevent adverse events. Antiplatelet therapy is one of the most effective 
therapies for treatment of atherothrombotic disease (see Patrono et al 2004). Considering the 
recently proved role of platelets in atherosclerosis the long-term use of antiplatelet drugs could 
also be postulated to slow down progression of the disease.
Aspirin was discovered over 100 years ago for analgesia. Later on it was shown to inhibit platelet 
activity and is the still most commonly used antiplatelet drug. It has been shown to decrease the 
risk of atherothrombotic events by 25% (see Antithrombotic Trialists´ Collaboration (ATC) (2002). 
Recently, an ADP-receptor inhibitor, clopidogrel, was developed. It is at least as effective as 
aspirin and their combination has proven beneficial in acute thrombotic states (CAPRIE Steering 
Committee 1996, CURE investigators 2001, Steinhubl et al 2002). In addition, clopidogrel has 
been shown to have a better efficacy and safety profile than previous alternatives to aspirin 
(CAPRIE 1996).
Despite antiplatelet medication considerable numbers of patients suffer from atherothrombotic 
events (ATC 2002). Of the patients who have undergone coronary artery angioplasty 1% 
develop stent thrombosis (Cutlip et al 2001). Due to this sustained incidence of thrombosis 
the phenomenon of individually variable responses to antiplatelet medication has become of 
interest lately. As knowledge of platelet function and of factors affecting it has increased, as 
well as the availability and user-friendliness of platelet function tests, the subject has become 
salient. Different environmental and genetic factors are known to affect an individual’s platelet 
activity and are beginning to be better understood, at the same time new antiplatelet drugs 
have been developed, thus offering actual alternatives to aspirin.
In conclusion, there are patients who do not seem to achieve adequate protection against 
atherothrombotic events by the present antiplatelet medication and increased knowledge of 
this phenomenon would help us to detect patients at increased risk. If these patients could 
be detected by platelet function tests or genetic testing, enhanced or alternative antiplatelet 
medication could be prescribed. At the same time a population of patients suffer from bleeding 
events due to the efficacy of antiplatelet medication, which is excessive for their individual 
needs. Thus, tailored antiplatelet medication would benefit individuals at both ends of the 
range of variation when it comes to the efficacy of antiplatelet medication.
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REVIEW OF THE LITERATURE
1 Platelet structure and functions
1.1 Platelet structure
Platelets are small, approximately 2µm in diameter, anucleated cells that derive from 
megacaryocyte cytoplasm. Their development is controlled mainly by thrombopoietin, but also 
many cytokines and hormones (see Kauhansky 1995). Platelets circulate for approximately 10 
days, before removal by macrophages (see George 2000). Numbers of platelets in blood vary 
between 150-350 109/L. The main functions of platelets include normal hemostasis as well as 
vessel constriction and repair. Platelets also participate in pathophysiological processes such 
as thrombosis, bleeding, inflammation, tumor growth and promotion of atherosclerosis (see 
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Figure 1. Different functions of platelets. Platelets are involved in many pathophysiological processes 
in addition to hemostasis and thrombosis. Modified from Harrison (2005).
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1.2 Platelet activation
As platelets are activated they change from their normal disc shape to a sphere with long dendritic 
extensions (Fig 2). The shape change is brought about by actin and myosin in platelet cytoplasm 
(see George 2000). During the shape change secretory granules are organized into the center 
of the platelet. Platelets have three types of secretory granules; dense granules, α-granules and 
lysosomes (Table 1). The contents of secretory granules are either produced by platelets and 
megakaryocytes or acquired from plasma via endocytosis and pinocytosis facilitated by the 
canalicular system. Secretory granules release their contents into plasma during platelet activation, 
which enhances further activation. The granule contents also have procoagulant activities (see 
Rendy & Brohard-Bohn 2001).
active receptor for collagen, is also involved in initial
platelet adhesion to the subendothelial matrix.8,9 The
most abundant surface protein, glycoprotein IIb-IIIa,
requires conformational change during platelet
activation to express receptor function, mainly for
fibrinogen.7 Fibrinogen binding to glycoprotein IIb-IIIa
mediates platelet aggregation.
These reactions define the clinical manifestations of
bleeding disorders. Patients with thrombocytopenia have
petechiae and mucocutaneous bleeding, resulting from
unsealed small endothelial lesions. By contrast, patients
with coagulation disorders, such as haemophilia, do not
have petechiae or excessive bleeding from small cuts
because platelet adhesion and aggregation are sufficient
to seal these lesions. Haemostasis for larger wounds
requires fibrin formation to reinforce the platelet
aggregate. Therefore, in contrast to platelet disorders,
coagulation disorders are characterised by the delayed
occurrence of large haematomas.
The complementary role of platelets and coagulation
factors in haemostasis is well illustrated by the bleeding-
time test, the measurement of the duration of bleeding
from a small forearm incision. Bleeding times are longer
than normal in patients with severe thrombocytopenia or
platelet-function disorders, but they are normal, or
almost normal, in patients with haemophilia. Aspirin,
which causes partial impairment of platelet function,
causes a slight increase in bleeding time in some healthy
individuals. However, when patients with severe
haemophilia were given aspirin, the combination of
impaired platelet function and deficient fibrin formation
caused extremely prolonged bleeding even from these
small wounds; several patients ultimately required factor
VIII infusions to stop the bleeding.11
Platelet circulation
Platelets survive for about 10 days on average; younger
platelets have greater functional ability. The spleen
continually but transiently sequesters about a third of
circulating platelets. Splenomegaly, particularly when
caused by passive congestion due to increased portal
venous pressure, greatly increases the fraction of
platelets retained in splenic sinusoids, without
decreasing overall platelet survival time. This retention
causes the mild thrombocytopenia associated with liver
cirrhosis and portal hypertension.12 Most platelets are
removed from the circulation after senescence, but a
constant small fraction is continually removed by
involvement in the maintenance of vascular integrity.
Bleeding disorders
Bleeding can result from defective platelet function or
from thrombocytopenia. The abnormalities must be
severe for clinically important bleeding to occur, since
haemostasis has many redundant functions. For example,
the congenital absence of the platelet fibrinogen receptor,
glycoprotein IIb-IIIa, has a profound effect on laboratory
assessment of platelet function (panel 1), yet patients
without this glycoprotein typically have only intermittent
and minor bleeding.13 Also the normal platelet number,
150–350�109/L (150 000–350 000/�L), far exceeds what
is essential for haemostasis. Figure 2 shows the severity of
bleeding in relation to the severity of thrombocytopenia
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Figure 1: Electron micrograph of resting and activated platelets
Top photographs are scanning electron micrographs demonstrating the disc shape of normal circulating platelets (left, �20 000) and the more
spherical form of activated platelets with many long pseudopodia (right, x10 000). Lower left photograph is a transmission electron micrograph of the
cross-section of a resting platelet (�21 000) with a matched drawing labelling the normal subcellular structures. Lower right photograph (�30 000) of
an activated platelet shows the constriction of the microtubular ring around the centralised granules and the formation of pseudopodia. Electron
micrographs courtesy James G White and Marcy Krumwiede, University of Minnesota. Reproduced with permission from: George JN. Haemostasis and
fibrinolysis. In: Stein JH, et al, eds. Internal medicine, 5th edn. St Louis: Mosby, 1998: 534–40.
Copyright © 2000. All rights reserved.
Figure 2. Top photographs are scanning electron micrographs demonstrating the disc shape of normal 
circulating platelets and the spherical form of activated platelets ith pseudopodia (x 10 000-20 000). 
Lower transmission electron micrographs of resting and activated platelets, respectively (x 21 000-30 
000). In activated platelets the normal structures presented in the drawing of a normal platelet change 
as pseudopodia form and a micr tubular ring constricts centralizing secretory granules. Electron 
micrographs are courtesy of JG White and M Krumwiede, University of Minnesota. Reproduced from 
George (1998) with permission.
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Table 1. The major granule contents and membrane components of platelets.
Modified from Rendu & Brohard-Bohn (2001). GF=growth factor, * Receptors are also expressed at 
the platelet plasma membrane
1.3 Platelet adhesion and aggregation
Platelet activation is induced at the site of vessel wall injury, which is represented by rupture of 
an atherosclerotic plaque. As the vessel wall is injured subendothelial collagen and other platelet 
activating factors such as von Willebrand factor (vWf) are exposed (Fig 3). Initially plasma vWf 
binds to exposed collagen. The first contact between platelet receptors and matrix components 
depends to a large extent on the shear stress at the site of injury. In conditions of low shear stress 
matrix proteins cause activation at the injury site. In conditions of high shear stress, as in arteries, 
activation and adhesion depend largely on glycoprotein (GP) Ib-V-IX complex, which interacts 
with immobilized vWf. This interaction causes initial tethering of circulating platelets to the 
vessel wall. Thus, platelets slow down and roll over a vWf-coated surface. The rolling ends with 
firm attachment through GP Ia/IIa, which has become available via activation of rolling platelets. 
Firm attachment mediated by GP Ia/IIa also allows low-affinity GP VI to interact with collagen. 
Lysosomes – Clearing factors
•   acid proteases, acid hydrolases
Cytoplasm
• factor XIII, tissue factor pathway   
 inhibitor
Dense granules – Pro-aggregation factors
Major granule contents
•  ADP, ATP
•  serotonin (5-HT), histamine
•  Ca2+, Mg2+
Granule membrane components
•  P-selectin
•  receptors*: GP IIb/IIIa, GP Ib 
Alpha-granules – Adhesion and repair
Major granule contents
• Platelet-specific proteins
 -platelet factor 4, 
 β-thromboglobulin
• Adhesive glycoproteins
 - fibrinogen, vWf, thrombospondin,   
 fibronectin, vitronectin
• Hemostasis factors, co-factors and   
 inhibitors
 - fibrinogen, factors V, VII,    
 XI, XIII, protein S, plasminogen,   
 plasminogen activator inhibitor 1
• Mitogenic and angiogenic factors
 - platelet derived GF, vascular    
 endothelial GF, transforming GF-β
• Other proteins
 - albumin, immunoglobulins
 Granule membrane components
• P-selectin
• Receptors*: GP IIb/IIIa, GP Ib/IX,   
 GP VI, PECAM
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Interactions of platelet GP VI with collagen induce further collagen-dependent activation of 
platelets. However, recent studies have suggested that the differential roles of GP Ia/IIa and GP 
VI are not this simple, but are in fact modulated by changes at the extracellular matrix of the 
vessel wall induced by specific metalloproteinases, and that both of these receptors participate 
in adhesion and aggregation alike (see Ruggeri 2002, see Farndale et al 2004) (Fig 4).
The initial adhesion is followed by recruitment of additional platelets into the growing platelet 
plug. Platelets are activated by factors at the injury site, but more importantly further activation 
is mediated by agonists released from the secretory granules of previously activated platelets. 
Adenosine-diphosphate (ADP) and thromboxane (Tx) A
2
 are crucial secondary mediators of platelet 
activation. As platelets are activated GP IIb/IIIa-receptors undergo conformational changes to 
become active. Activated GP IIb/IIIa mediates platelet-platelet interaction, aggregation, by several 
ligands of which fibrinogen is most abundant (Bennett & Vilaire 1979, see Michelson 2003).
After a platelet plug has been formed, it is then stabilized to prevent premature disaggregation. 
It has been suggested that outside-in signalling through cell surface integrins and tyrosine 
kinases of receptors have central roles in this phase of thrombus formation. Platelets also 
participate in localization, amplification and maintenance of the coagulant response at the 
injury site (Ilveskero et al 2001, see Michelson 2003).
Figure 3. Antithrombotic and prothrombotic molecules synthesized by endothelial cells and platelets. 
Antithrombotic factors circulate in plasma and are excreted from endothelium and platelets to limit the 
thrombus to the site of injury. Prothrombotic factors are excreted from endothelial cells and activated 
platelets, platelet activation mediates also coagulation process and prothrombotic constituents revealed 
at the injured vessel wall initiate thrombus formation. Modified from Ruggeri (2002). 
Main adhesive proteins in plasma;
vWf, fibrinogen, fibronectin
Coagulation process
including thrombin and fibrin
Platelet-derived agonists
and adhesive proteins;





of the vessel wall:
Intima – vWf, fibrinogen,
fibronectin, thrombospondin,
laminin, vitronectin, tissue
factor, collagen type IV
Media – collagen type I
and III
Adventitia – collagen type I
and III, tissue factor
Plasma antithrombotic factors;
antithrombin III, tissue factor








Review of the literature
15
Platelets also regulate their own activation at the site of a platelet plug to prevent uncontrolled 
expansion of the thrombi. Platelet-endothelial cell adhesion molecule-1 (PECAM-1) is 
an inhibitory receptor which mediates the inhibitory pathway. In addition, antithrombotic 
factors circulate in plasma and are secreted by platelets (see Ruggeri 2002) (Fig 3). Nitric 
oxide, prostacyclin and endothelial ecto-nucleotidase (NTPDase) are believed to be the most 
important endothelial regulators of the platelet activity. Nitric oxide and prostacyclin cause 
platelet inhibition and vasodilatation and NTPDase neutralizes the prothrombotic releseate 
of platelets by metabolism of ADP (see Tan et al 2004, Marcus et al 2005.
1.4 Coagulation 
Coagulation of blood has classically been described as a cascade dependent on adequate levels 
of coagulation proteins. However, recent advances in research have suggested a new model 
of coagulation as a cell-regulated overlapping process (Fig 5). Platelets support procoagulant 
reactions and vascular endothelial cells maintain anticoagulant properties of the vasculature. 
In healthy vessels the tissue factor pathway inhibitor (TFPI) inhibits coagulation factors. The 
complex formed by thrombin binding to thrombomodulin and protein C/protein S as well as an 
another complex of endothelial surface heparinoids and antithrombin act as anticoagulants at the 
site of injury, preventing excessive formation of thrombi (see Monroe & Hoffman 2005).
Blood flow
1 2 3 4 5
Figure 4. A traditional model of platelet activation and adhesion to immobilized collagen.
1) Binding of vWf molecules onto the collagen surface
2) Platelets moving on the surface – GPIb-V-IX complex and vWf interact
3) Tight binding of platelets on collagen by GP Ia/IIa
4) Collagen-induced activation of platelets by GP VI
5) Formation of a platelet aggregate – mediated by activated GP IIb/IIIa and its ligands vWf and 
fibrinogen. Activated platelets release prothrombotic agents which further activate other platelets.
Reaction steps 3 and 4 occur almost simultaneously and recent studies suggest that both GP Ia/IIa and 
GP VI participate in adhesion and collagen-induced activation alike. Modified from Jung & Moroi 
(2000).
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Figure 5A) Classical view of the extrinsic and intrinsic pathways of coagulation. HK=high-molecular 
weight kininogen, PK=prekallikrein, II=prothrombin, IIa= thrombin.
B) Coagulation as a process controlled by cells. On the surface of tissue factor-bearing cells factor 
VIIa bound to tissue factor (TF) activates factor X. Activated factor Xa binds to factor Va and this 
complex activates factor II to IIa. Tissue factor on the cell surface also activates IX. On the surface 
of the platelet factor IXa is activated by factor XIa. Factor is IXa activated either at the surface of 
platelet or tissue factor bearing cell binds to surface VIIIa. Complex of IXa and VIIIa activates factor 
X, which binds to factor Va forming a complex. This complex activates factor II to IIa. Modified from 
Monroe & Hoffman (2005).
2 Platelet receptors
2.1 Collagen receptors 
Several glycoprotein receptors are present at the platelet surface. A number of these have 
been proposed as collagen receptors, but at present GP Ia/IIa and GP VI are believed to be 
the main ones responsible for collagen induced platelet activation. Fibrillar collagen of types 
I and III are the major constituents of the blood vessel wall, although type IV is also present 
in basement membranes (see Kehler 1995). These collagen types are also the most able to 
activate platelets and to cause adhesion and aggregation (see Sixma et al 1997).
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, causes initial platelet adhesion to the subendothelial matrix. 
It requires activation by thrombin-, collagen- or ADP- pathways to become operational. It has 
been suggested that activation via thrombin- and ADP-pathway may result in two different 
conformations of activated GP Ia/IIa with different ligand activity (Jung & Moroi 2000). While 
the activation with ADP has been suggested independent of Ca2+ the activation by collagen, 
especially collagen monomers, is dependent on physiological concentrations of Mg2+ and Ca2+ 
(Siljander & Lassila 1999, Jung & Moroi 2001). The role of GP Ia/IIa in platelet adhesion on 
collagen is emphasized in environments of high shear (Alberio & Dale 1999). Monomeric 
collagen provides an important tool for studying the role of GP Ia/IIa as at physiological cation 
concentrations it is responsible for platelet adhesion (Siljander & Lassila 1999). In comparison, 
the second collagen receptor GP VI is reported to adhere only to fibrillar collagen (see Jung 
& Moroi 1998). Indeed, modulation of the collagens revealed at an injury site is believed to 
mediate variable roles of GP Ia/IIa and GP VI in adhesion to collagen. Variation in GP Ia/IIa 
activity has been shown to have clinical importance, and has been associated with the C807T 
polymorphism of the GP Ia/IIa gene (Kunicki et al 1993, Kritzik et al 1998). In addition, the 
C807T polymorphism has been associated with increased risk for atherothrombotic events 
(Carlsson et al 1999, Moshfegh et al 1999). However, regarding the role of these polymorphisms 
as predictors of atherothrombotic disease the multifactorial nature of the disease needs to be 
taken into account.
GP VI participates in initial platelet adhesion and activation in circulating blood in addition to 
the GP Ib-IX-V complex (see Andrews & Berndt 2004). In fact, it seems to be topographically 
associated with GP Ib-IX-V (see Farndale et al 2004). Patients deficient in GP VI lack the ability 
to form thrombi on a collagen surface under flow conditions, but clinically present with only 
mild bleeding tendencies (see Moroi & Jung 2004). However, the T13254C polymorphism 
of GP VI has been associated with myocardial infarction (Croft et al 2001). The differential 
roles of GP Ia/IIa and GP VI in initial platelet adhesion and aggregation related to collagen 
have not yet been indisputably determined. 
2.2 Adhesion receptors 
In addition to collagen receptors, there are other adhesion receptors such as GP Ib-V-IX 
complex, GP IIb/IIIa and receptors for fibronectin, vitronectin and thrombospondin. The GP 
Ib-V-IX complex causes tethering of platelets to perivascular vWf. This enables platelets to 
slow down at the point of vascular injury and to interact with collagen. GP Ib-V-IX is a complex 
of glycoproteins and the N-terminal globular domain of GP Ibα is the major ligand-binding 
region. Patients lacking GP Ib or GP IX have Bernard-Soulier syndrome which causes bleeding 





, is the most abundant adhesion receptor. It requires a conformational 
change caused by platelet activation through adhesion receptors (GP Ib, GP VI, GP Ia/IIa), 






) receptors to 
become active. GP IIb/IIIa binds mainly fibrinogen, but also vWf, fibronectin, vitronectin and 
thrombospondin. As GP IIb/IIIa binds to vWf, especially in flow conditions, it offers a second 
mechanism of platelet adhesion to the vessel wall in addition to GP Ib-V-IX. The receptor 
mediates aggregation by binding fibrin and vWf. GP IIb/IIIa function is Ca2+-dependent. 
Patients with hereditary Glanzmann´s thrombastenia have decreased or functionally abnormal 
GP IIb/IIIa which causes bleeding symptoms (see Andrews & Berndt 2004).
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2.3 Purinergic receptors
Purinergic receptors play an important role in thrombus formation under conditions of high 
shear stress. These receptors mediate activation by platelet derived ADP excreted from secretory 
granules of activated platelets. They constitute an autocrine mechanism for promotion of 
platelet aggregation (see Gachet 2005).
The purinergic-receptor family consists of P2X ligand gated channels (P2X
1-7
) and G-protein-
coupled  P2Y receptors (P2Y
1,2,3,4,11,12,13,14
) of which 7 and 8 subtypes, respectively,  have been 











) have been detected in platelets at 





 regulates Ca2+-dependent signalling events, initiating platelet shape change 
and activating GP IIb/IIIa dependent platelet aggregation (Fig 6). These receptors initiate 
aggregation, reinforce the actions of the P2Y
12
-receptor in response to ADP and participate in 
platelet aggregation induced by collagen and other platelet agonists (see Gachet 2005).
The P2Y
12
 receptor is activated by ADP causing completion of aggregation of platelets in 
synergistic action with P2Y
1, 
ADP-dependent amplification of aggregation induced by other 
agonists (TxA
2
, thrombin, collagen chemokines or immune complexes), potentiation of the 
release reaction and stabilization of thrombi (see Gachet 2005). P2Y
12
-receptor is coupled to 
Gι causing inhibition of adenylate cyclase and thus also cyclic adenosine 3´,5´-monophosphate 
(cAMP) formation (see Gachet 2001) (Fig 6). Activation of the P2Y
12
-receptor causes 
inhibition of phosphorylation of the vasodilator stimulated phosphoprotein (VASP), mediated 
by cAMP-dependent protein kinase (PKA). Thus P2Y
12
-receptor activation causes a decrease 
in the negative regulatory effect of GP IIb/IIIa normally caused by dephosphorylation of the 
VASP. Activation of P2Y
12
 also causes stimulation of phosphatidyl inositol-3 kinase (PI-3K), 
which activates small GTPase RapIb and PKB/Akt, all three of which participate in platelet 
aggregation (see Gachet 2005).




 receptors at the same time is a requirement for normal 
ADP-induced aggregation, and antagonism of either one causes a dramatic inhibition of platelet 
aggregation (Jin & Kunalipuli 1998).
The P2X
1
-receptor is a ligand gated cation channel activated by adenosine triphosphate (ATP) 
(Fig 6). It causes rapid Ca2+ entry associated with platelet shape change and centralization of 
secretory granules. P2X
1 
is unable to cause platelet aggregation by itself, but enhances collagen- 
and shear-induced aggregation. Indeed, flow conditions have been found to be critical for the 
full efficacy of the receptor (see Gachet 2005).
2.4 Thrombin receptors
Thrombin is a potent platelet activator which catalyzes cleavage of amino-terminal domains of 
G-protein coupled protease-activated receptors (PARs). Proteolysis of PAR-receptors causes 
tethered ligands to be exposed at the N-terminus of the receptor, which triggers signalling (Vu 
et al 1991 a & b, see Coughlin 1999). Of the three thrombin-activated PAR-receptors PAR-1 
and PAR-4 are expressed in human platelets (Kahn et al 1999).
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 , while the P2X
1
 receptor is activated by ATP. P2Y
1
 receptor is coupled to G
q
, causes Ca2+, shape 




 receptor causes completion and potentiation 
of the aggregation. P2Y
12
 receptor-mediated adenylate cyclase inhibition is not directly responsible for 
the activation of the GP IIb/IIIa and subsequent aggregation. Dephosphorylation of the vasodilator-
stimulated phosphoprotein (VASP), which negatively regulates GP IIb/IIIa, and a PI3K-dependent 
activation of the small GTPase Rap1B and PKB/Akt are involved in P2Y
12
 receptor-mediated aggregation. 
Reproduced from Gachet (2005), with permission.
PAR-1 is a high affinity receptor, activated by low concentrations of thrombin (<2nM) (Kahn 
et al 1999). It uses GP Ibα as a cofactor for cleavage and also acts synergistically with ADP 
to amplify its responses (see Gachet et al 1997, De Candia 2001, see Adam et al 2003). ADP 
is released from dense granules when a platelet is activated by a primary agonist. Thus ADP-
receptors, including P2Y
12
, become functional and part take in thrombin-induced aggregation. 
ADP has been shown to be responsible for stabilization of thrombin-induced aggregates 
(Cattaneo et al 1990). PAR-4 is a low affinity receptor activated by higher concentrations of 
thrombin independently of ADP (see Adam et al 2003). 





) is a potent platelet activator, produced as COX enzymes convert 
arachidonic acid (AA) to prostaglandin (PG)H
2
 , which can be further converted by 















 synthesis is caused by platelet activation by other agonists 
and the product acts rapidly in situ as it has a short half-life of 30 seconds. TxA
2
 itself causes 
further platelet activation (see Dogné et al 2004).
The TxA
2
- receptor, officially called TP-receptor, belongs to the G-protein coupled receptor 
family. Classically they are characterized by signalling via G
q
, but also via other proteins. 
2004). Platelets express only P2X1 subunits. One character-
istic of the P2X1 receptor is to become very quickly
desensitized, thereby hampering the study of its function in
platelet activation in vitro (Savi et al., 1997; Vial et al.,
1997; Jin et al., 1998a; Takano et al., 1999). However, when
desensitization is prevented by the addition of high
concentration of apyrase (ATP-diphosphohydrolase
E.C.3.6.1.5.), the selective P2X1 receptor agonist, alpha,
beta-methylene-ATP (ahMeATP), induces a rapid calcium
influx associated to a transient shape change in human
platelets (Rolf et al., 2001; Rolf & Mahaut-Smith, 2002) and
centralization of secretory granules, although release has not
been detected (Oury et al., 2002; Toth-Zsamboki et al.,
2003). Unable to promote platelet aggregation by itself, the
P2X1 receptor has been shown to participate to collagen and
shear-induced aggregation (Oury et al., 2001, 2004;
Cattaneo et al., 2002; Hechler et al., 2003; Toth-Zsamboki
et al., 2003). The main feature of this receptor is the
requirement of flow conditions to evidence its role i
platelet activation and thrombus formation, as could be
demonstrated in vitro on collagen-coated surfaces. Studies
of P2X1-deficient mice further established its role in
thrombosis of small arteries (Hechler et al., 2003). Recently,
synthesis of a new potent antagonist of the P2X1 receptor,
NF449, an analogue of suramin, has been reported, which
displays good selectivity for the P2X1 receptor versus the
P2X3, P2X7 (Hulsmann et al., 2003), P2Y1, P2Y2, and
P2Y11 receptor subtypes (Braun et al., 2001; Kassack et al.,
2004) and has been found to inhibit platelet activation by
ahMeATP (Hechler et al., 2004).
3. The platelet P2 receptors as
molecular targets for antithrombotic drugs
3.1. The P2Y12 receptor as a
target for old and new antiplatelet drugs
The very restricted tissue distribution of this receptor
makes it a very attractive targ t for selective antiplatelet
drugs (Hollopeter et al., 2001). Long before its cloning, the
pharmacological importance of this receptor in haemostasis
an thrombosis was well recognized. This is due to the fact
that the potent antithrombotic thienopyridine compounds
ticlopidine and clopidogrel, of which an active liver
metabolite selectively targets the P2Y12 re eptor (Savi et
al., 2000; Hollopeter et al., 2001), were used as molecular























Fig. 1. The current model of platelet activation by ADP and ATP. Three P2 receptors have been identified on blood platelets. Two are ADP receptors, namely,
the P2Y1 and P2Y12 receptor, while the P2X1 receptor is activated by ATP. The P2X1 receptor is responsible for rapid calcium influx and platelet shape change
in response to ATP and contributes to platelet activation by low concentrations of collagen. The P2Y1 and P2Y12 receptors are essential for normal aggregation
in response to ADP: The Gq-coupled P2Y1 receptor is responsible for intracellular calcium mobilization, shape change, and initiation of aggregation; the Gi-
coupled P2Y12 receptor is responsible for the completion of the aggregation to ADP and potentiation of aggregation and secretion by agents such as collagen,
thrombin, serotonin, thromboxane A2, or immune complexes. P2Y12 receptor-mediated adenylyl cyclase inhibition is not directly responsible for the activation
of the aIIbh3 integrin and subsequent aggregation. Dephosphorylation of the vasodilator-stimulated phosphoprotein (VASP), which negatively regulates
aIIbh3, and a PI3K-dependent activation of the small GTPase Rap1B and PKB/Akt are involved in P2Y12 receptor-mediated aggregation. The P2Y12 receptor
is the target of the antithrombotic drugs ticlopidine and clopidogrel.
C. Gachet / Pharmacology & Therapeutics 108 (2005) 180–192184
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Two different isoforms of the receptor exist, both coded by the same gene, but generated by 
alternative splicing (Hirata et al 1991, see Dogné et al 2004).
2.6 Adrenergic receptors
Both adrenergic and dopaminergic receptors are expressed in human platelets. Actions of 
catecholamines are mediated by α
2
-adrenergic receptors, potentiating the effects of other 
agonists and in high concentrations inducing platelet aggregation and secretion (see Anfossi & 
Trovati 1996). In physiological conditions epinephrine mainly acts as by potentiating platelet 
activation induced by other agonists (Lanza et al 1988). Interestingly, epinephrine significantly 
potentiates shear-induced platelet activation dependable on vWf and GP Ib (Goto et al 1992 & 
1996, Mustonen & Lassila 1996). Adrenergic receptors are linked, via G proteins, to the same 
intracellular pathways as P2Y
12
 (Jin & Kunapuli 1998). Epinephrine is therefore postulated to 
synergize with ADP-induced responses mediated by P2Y
1
-receptors (see Conley & Delaney 
2003). The α
2A
-receptor has the highest affinity of adrenergic receptors and epinephrine is 
the most potent catecholamine affecting platelet function (see Anfossi & Trovati 1996). The 
number of α
2A
-receptors has been suggested to change with different conditions (see Kerry & 
Scurton 1985).  Epinephrine has also been shown to attenuate the aspirin efficacy treatment 
(Mustonen et al 2001). 
Dopaminergic receptors are classified to postsynaptic D
1
-like receptors, interacts with Gs 
protein and influence the activation of adenylate cyclase, and presynaptic D
2
-like receptors, 
which inhibit cAMP synthesis via Gi proteins as well as cause hydrolysis of phospatidyl inositol, 
activate K+ channels and modulate intracellular Ca2+ levels (see Anfossi & Trovati 1996).
2.7 5HT2-receptor
Platelets have a serotoninergic receptor 5HT
2
, activation of which causes rise in cytoplasmic 
Ca2+ and a shape change. Serotonin is a weak agonist of platelets and act synergistically with 
other platelet agonists (Baumgartner & Born 1968, Pletsher A 1987).
3 Assessment of platelet function
3.1 Platelet function tests
Several techniques for measuring platelet function have been developed. Traditionally they 
have been used to assess platelet function defects and bleeding tendency prior to surgery. 
Recently, platelet function tests have been used in atherothrombotic disease to predict clinical 
outcomes and to monitor antiplatelet drugs (see Michelson 2004). Platelet function tests in 
atherothrombotic disease have been established in research use and not as much in clinical 
practice, as the evidence to support their use on a regular basis is still inadequate. 
All techniques of measuring platelet activation and aggregation are sensitive to several 
variables. Normal platelet function consists of activation, adhesion, spreading, release reactions, 
aggregation, exposure of a procoagulant surface, microparticle formation and clot retraction 
(Fig 7). Different test reflect all these variables alternatively and their sensitivity and specificity 
in doing so vary. The large number and variety of either pathological or drug mediated platelet 
defects challenge the platelet function tests. Phlebotomy, anticoagulation, sample transit and 
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handling in the laboratory are all sources of potential artefacts as platelets are easily activated, 
but also desensitized (see Harrison 2005).
Several challenges for measuring platelet activation exist (Table 2). However, the interest in 
platelet function tests has recently increased with new, plausible objectives like monitoring 
of efficacy of antiplatelet medication.
Figure 7. Platelet activation and functions. Resting platelets circulate in blood and their activation is 
inhibited by local antithrombotic factors such as an intact endothelial surface. At activation platelets 
change shape. Adhesion to prothrombotic matrix revealed under injured endothelium follows. Activation 
of platelets causes release reactions, where platelets release the mostly prothrombotic contents of their 
secretory granules. Platelet activation enables aggregation, which causes platelets to attach to already 
adhered platelets, thus forming a platelet clot and localizing the formation of a thrombus. Platelets 
also have procoagulant properties, which enhance coagulation forming fibrin clot which stabilizes 
the thrombus. Strong platelet activation causes microparticle formation and shedding. Microparticles 
contain prothrombotic and antithrombotic proteins. Platelets participate in clot retraction as their 
actin and myosin cause contraction of the platelets. Clot retraction stabilizes the clot and participates 
in the initiation of wound healing.
Resting platelet Activation Adhesion Release reaction
Aggregation Exposure of
procoagulant surface
Microparticle formation Clot retraction
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Basis of test Name of the test Advantages Disadvantages Clin ASA Clopi
In vivo 
cessation of 
blood flow by 
platelet plug
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blood flow by 
platelet plug
PFA-100® Simple, rapid; 
low sample 
volume; high 










Table 2. Platelet function tests.
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platelet function and 
clinical endpoints
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Basis of test Name of the test Advantages Disadvantages Clin ASA Clopi
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Modified from Michelson (2004), Harrison (2005) and Hankey & Eikelbloom (2006).
Clin= reported to predict clinical outcomes, ASA= monitoring of aspirin, clopi= monitoring of clopidogrel, 
U.D= under development, VASP= vasodilator-stimulated phosphoprotein, CV= coefficient of variation, 
RPFA= rapid platelet function analyzer, AA=arachidonic acid, vWf=von Willebrand factor.
3.2 Blood sample anticoagulation
Blood obtained from patients for platelet function tests needs to be anticoagulated to prevent 
it from clotting within minutes of blood collection. Citrate, PPACK (D-phenylalanyl, L-
prolyl-L-arginine choloromethyl ketone), hirudin and heparin are most commonly used to 
anticoagulate whole blood or platelet rich plasma (PRP). The role of Ca2+ in normal platelet 
function and Ca2+ chelation by common anticoagulants is one of the specific challenges of 
platelet function measurement (Phillips et al 1997, Andre et al 2003). Citrate is often used 
as an anticoagulant due to its availability in clinical practice. However, citrate causes the 
chelation of Ca2+ and Mg2+, which are necessary for normal platelet function. For example, 
monomeric collagen is unable to activate platelets in the absence of Mg2+ (Siljander & 
Lassila 1999). Platelet activation induced by ADP or epinephrine are known to be enhanced 
in environment of low Ca2+, when compared with physiological conditions (Lages & 
Weiss 1981, Lalau Keraly et al 1988, Packham et al 1989). In citrate anticoagulated blood 
ADP causes two phases of platelet aggregation. The secondary aggregation is caused by 
ADP-induced Tx formation and platelet release reaction, neither of which occurs under 
physiological concentrations of divalent cations (Pacham et al 1987 & 1989). In addition, 
primary phase of platelet aggregation is diminished in conditions of low Ca2+ concentrations 
when compared with physiological ones (Packham et al 1989). Due to the Tx formation 
under low Ca2+ concentrations, ADP-induced platelet aggregation has been used to detect 
Tx inhibition by aspirin.
Other anticoagulants can also be used, but they all have their specific problems for testing 
platelet function. PPACK, hirudin and heparin affect the physiological role of thrombin as 
they act as thrombin-inhibitors. Heparin is known to activate platelets under certain conditions 
(May & Heptinstall 2004). Choice of anticoagulant is also known to affect measured inhibition 
exerted by antiplatelet agents such as GP IIb/IIIa-inhibitors and P2Y12-receptor antagonists 
(Phillips et al 1997, May & Heptinstall 2004).
3.3 Platelet aggregation studies
Platelet aggregometry, despite its development already in the 1960´s, is still considered as the 
gold standard of assessing platelet activation (Born 1962, Born & Cross 1963, see Born & 
Patrono 2006). Traditionally, turbidometric measurements of platelet aggregation are performed 
in platelet rich plasma separated from erythrocytes and white blood cells by centrifugation. 
Platelets are then activated by different agonists (eg. collagen, ADP, epinephrine). Platelet 
activation and aggregation are measured by increased light transmittance through the PRP 
solution as platelets, which in the beginning were spread out evenly in plasma, clump together 
in the cuvettes. In whole blood aggregations the sample is analysed with electrical impedance 
or light scattering (see Harrison 2005). Choice of anticoagulant influences the results obtained 
in platelet aggregation studies (see section 3.2).
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The limitations of aggregation studies are that age, gender, race, medication and hematocrit 
levels are known to affect platelet aggregation responses. In addition, physical and mental stress 
as well as diet have been found to influence platelet activity, thus at least partly explaining 
the day-to-day variability presented in aggregation studies (see George & Shattil 1991). Even 
when the many pre-analytical and analytical variables affecting the results are controlled, the 
accuracy and reproducibility of the aggregations have limitations. Reproducibility is also 
limited by the fact that there is no standardisation when it comes to aggregation studies, thus 
agonists, scales and geometry of the optical system can vary from one laboratory to another 
(see Michelson 2004, see Harrison 2005).
 
Platelet aggregation tests have been found to be insensitive to small aggregate formation. When 
traditional aggregations in platelet-rich-plasma are studied the removal of the homeostatic 
properties of erythrocytes leads to deterioration in platelet function over time and the process 
of centrifugation may cause platelet activation or desentization (see Storey & Heptinstall 
1999).
3.4 PFA-100® platelet function analyser
PFA-100® is a platelet function analyser (Dade-Behring AG, Düdingen, Switzerland) which was 
released in 1995 and has become one of the most studied new automated tests for measuring 
platelet function (see Favaloro 2002). PFA-100® measures platelet-related primary hemostasis 
in whole blood under high shear-rate conditions (4000 1/s) (Kundu et al 1995, Mammen et al 
1998). Platelets interact with a collagen mesh spiked with either ADP (CADP) or epinephrine 
(CEPI), resulting in occlusion of an aperture in the respective cartridge. The results are 
expressed as closure times. The PFA-100® method has been suggested to be useful in detection 
of vWD and assessment of the antiplatelet effects of aspirin (see Cattaneo et al 1999, Feuring 
et al 1999, Favaloro et al 1999, see Favaloro 2002, Homoncik et al 2000).
PFA-100® measurements are usually performed in citrate anticoagulated blood. The 
concentration of 3.2% citrate has been recommended with the exception of measuring the 
antiplatelet effect of aspirin, where results obtained using 3.8% citrate anticoagulation have 
presented greater stability (see Jilma 2001, see Favaloro 2002).
PFA-100® has been called “in vitro bleeding time”, but is actually more sensitive and has better 
reproducibility than bleeding time (Marshall et al 1997, Fressinaud et al 1998). VWf plays a 
major role in hemostasis occurring in the PFA-100® system (Chakroun et al 2004). In addition, 
PFA-100® is sensitive to many variables including the number of platelets, hematocrit, drug 
and dietary effects (see Jilma 2001). Low hematocrit or platelet count (under 0.1 or 10 x 109/L, 
respectively) will cause non-closure in the PFA-100® and thus preclude its normal use (see 
Harrison 2000, see Jilma 2001). The hematocrit levels correlate directly with closure times 
in PFA-100® (Escolar et al 1999).
PFA-100® is sensitive to some, but not all, blood-based deficiencies or defects. It lacks 
sensitivity to disorders of coagulation and fibrinogen defects, including hemophilia. Its 
sensitivity to defective platelet function depends on the severity of the disturbance. However, 
as noted earlier, PFA-100® has high sensitivity to disturbances in levels or properties of vWf 
(see Favaloro 2002) (Fig 8).
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Figure 8. Schematic illustration of the interpretation of PFA-100®. In PFA-100® blood flows at high 
shear rate through an aperture coated with collagen and either epinephrine (CEPI) or ADP (CADP). 
The time for the aperture to occlude is monitored and called the closure time (CT). vWf=von Willebrand 
factor. Modified from Favaloro (2002).
3.5 Perfusion studies
Platelet perfusion studies assess platelet activation by collagen and shear stress followed by 
consequent adhesion and following aggregation in vitro. Studies are performed with whole 
blood and thus provide a close to physiological environment for studying platelet function in 
a high shear environment comparable with arteries (1600 s-1 ) (Baumgartner 1973 and 1976, 
Turitto 1975, Turitto & Baumgartner 1975, Hall et al 1998). Immobilized collagen as the 
adhesive surface models the site of vascular damage (Baumgartner 1976). As perfusion studies 
are extremely time-consuming and require the expertise of the performing person they are 
only used in research laboratories and not in clinical practice. In comparison with aggregation 
studies perfusions provide interaction with other cells in whole blood as well as the high shear 
rate. Perfusion studies are versatile as the adhesive surface of collagen can be replaced by 
other adhesive materials and platelet function in response to added factors can also be studied. 
Hence perfusion studies are sensitive, but have variable reproducibility.
Automatized analyzers such as PFA-100® and IMPACT cone and plate(let) analyzer® have been 
developed to provide tests which have similar physiological shear forces as perfusion studies, 
but are easier to execute and have better reproducibility. However, with these tests some of 
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3.6 Assessment of aspirin efficacy
The term aspirin resistance has been introduced to describe sustained platelet activity despite 
aspirin medication. The sustained activity can be divided into TxA
2
-induced platelet activity 
and increased platelet function which is independent of TxA
2
 formation. As aspirin inhibits 
TxA
2
 formation and thus abolishes activity dependent on it, the former type has been suggested 
to be labelled pharmacologic aspirin resistance (see Wong et al 2004). The latter type has been 
proposed to be labelled functional aspirin resistance, as this phenomenon is characterized 
by increased platelet function mediated by activating pathways  other than TxA
2
 (see Wong 
et al 2004). 
Recent studies assessing the prevalence and relevance of aspirin resistance have used different 
methods to determine aspirin resistance, which have included methods specific to TxA
2
 
formation and those measuring general platelet activity. Thus, the definition of aspirin resistance 
needs to be defined more clearly, as suggested by Wong et al (see 2004) and discussed further 
in section 5.1.
Several factors, such as the method chosen to measure platelet aggregation or activation, 
time allowed to measure platelet aggregation and different, often arbitrary, cut-off values to 
define resistance, influence measurement of platelet function when non-specific methods are 
used (see Cattaneo 2004). In addition, it has been suggested that when measuring efficacy 
of antiplatelet medication the tests should be performed both before and after drug intake, 
otherwise baseline platelet activity influences the results obtained (see Steinhubl et al 2005). 
However, termination of antiplatelet medication from patients with atherothrombotic disease 
is unethical and thus in practice this study design is often impossible to execute.
Due to the relatively large role of poor compliance to antiplatelet therapy in aspirin resistance, 
it has also been suggested that the role of non-compliance should be controlled by measurement 
of plasma concentrations of aspirin and salicylate (Poulsen et al 2005). This could be performed 
by high performance liquid chromatography to detect aspirin and salicylate in plasma within 
the first 10 h of ingestion (Cerletti et al 2003). However, measurement of plasma aspirin 
concentrations is severely limited by its short half life of only 20min.
AA-induced aggregation
Arachidonic acid (AA)-induced aggregation could be considered as the gold standard for 
assessing aspirin response, since it directly evaluates the capability of COX-1 to produce 
TxA
2
 subsequent to platelet aggregation (Gum et al 2003). Therefore this method, although 
time-consuming, is valuable for detecting aspirin efficacy. Sustained AA-induced aggregation 
has also been associated with clinical endpoints in aspirin-treated patients (Gum et al 2003). 
The use of AA-induced aggregation in determining aspirin resistance in previous studies has 
been criticized due to the use of high concentrations of AA, suspected to cause platelet lysis 
(detectable in an aggregometer by enhanced light transmission), and the fact that overall AA-
induced aggregation is the result of  TxA
2
 and other agonists secreted by platelet granules 
(see Cattaneo 2004).
Platelet aggregation induced by several other agonists such as TxA
2
-mimetics, collagen 
and ADP have also been used to determine aspirin resistance. These agonists, however, are 
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not specific to aspirin’s mechanism of action and are only partially TxA
2
-dependent. Thus, 
they measure general platelet activity instead of aspirin efficacy (see Hankey & Eikelboom 
2006).
PFA-100® platelet function analyser
As PFA-100® has been reported to detect aspirin use it has been suggested as a method for 
monitoring the antiplatelet effect of aspirin. The closure time of the epinephrine-stimulated 
cartridge should be prolonged in aspirin-treated patients. The manufacturer of the PFA-100® 
refers to 170 s as the limit of detecting aspirin efficacy with a sensitivity of 95%.The closure 
time is followed for maximally 300 s (Feuring et al 1999, Homoncik et al 2000).
However, in the case of aspirin response, other mechanisms compensate and surpass the need 
for TxA
2
 production when platelets are challenged in the PFA-100® system. It is well accepted 
that aspirin does not affect shear stress-induced platelet aggregation, one of the important 
features in the PFA-100® system (see Cattaneo 2004). In addition, the role of vWF is pivotal 
and high plasma levels associate with decreased closure times (Chakroun et al 2004). Then 
again, patients with cardiovascular disease and diabetes are known to have increased plasma 
levels of vWf (see Manucci 1998). The roles of GP Ib and GP IIb/IIIa are emphasized in PFA-
100® due to high shear forces (Watala et al 2003). Thus, PFA-100® offers a means to measure 
platelet function which, however, is not specific to aspirin and can be overcome by several 
factors such as increased levels of vWF detected in cardiovascular disease and diabetes.
In studies comparing PFA-100® and AA-induced aggregation in detecting aspirin resistance, 
different populations of patients have been found as aspirin resistant (Hezard 2002, Gum et 
al 2003). It seems that PFA-100® is not specific for aspirin resistance. In a study by Andersen 
et al (2002) aspirin resistance measured with PFA-100® was not associated with Tx levels, 
but instead aspirin response was associated with P-selectin levels and the general secretory 
function of platelets (Andersen et al 2002). This refers to the fact that aspirin resistance 
measured with PFA-100® describes general platelet activity and not TxA
2
-dependent activity. 
Thus according to Wong et al (see 2004), aspirin resistance measured with PFA-100® could 
be termed as functional aspirin resistance.
Blood or urine TxB2 levels
As most platelet function tests measure general platelet function in which TxA
2
 production 
is of marginal importance, Tx levels have been suggested as a measurement of aspirin effect 
(see Cattaneo 2004). TxB
2, 
the stable metabolite of TxA
2
, can be measured from plasma, serum 
or urine. However, urinary TxB
2
 levels, concentration of 11-dehydro-thromboxane B
2
, is not 
platelet specific and depends also on renal function (Riutta et al 1992). As serum TxB
2
 levels 
reflect both platelet and extra-platelet sources of Tx generation, they have been speculated 
not to be specific for aspirin (see Hankey & Eikelboom 2006).
3.7 Assessment of clopidogrel efficacy
ADP-induced aggregation
ADP-induced aggregation has been the most used tool for assessing the clopidogrel efficacy, 
due to clopidogrel´s mechanism of action as an antagonist of ADP-receptor P2Y
12
 (see Cattaneo 
2004). However, it has been criticized because it is not a specific measurement of P2Y
12
-inhibition. 
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The inhibitory effect of clopidogrel can be overcome by platelet activation via other pathways, 
including platelet activation via the other ADP-receptor P2Y
1
 (see Cattaneo & Gachet 1999, 
Cattaneo et al 2004). In fact, P2Y
1
-receptor has been shown to activate platelets synergistically 





 for significant platelet activation (see Conley & Delaney 2003). In addition, the activity 
of P2Y
1
 has been shown to vary widely in patients whose P2Y
12
-receptors are blocked or in 
otherwise healthy individuals with a genetic P2Y
12
-receptor deficiency (see Cattaneo 2004).
Other methods of studying platelet activation
Flowcytometric measurement of GP IIb/IIIa activation has been found to associate with 
response to thienopyridines (Hezard et al 2002). However, this test is not specific to ADP-
induced activation and especially to inhibition of the P2Y
12
-receptor. ADP-evoked fibrinogen 
binding has also been suggested as a test for clopidogrel efficacy, however, it is not specific 
to P2Y
12
-activation, but also depends on GP IIb/IIIa activation (Järemo et al 2002, Schumann 
et al 2005).
Several studies have failed to measure clopidogrel efficacy with PFA-100®, despite the fact that 
in the CADP-cartridge platelet activation is induced by ADP in addition to collagen (Hezard 
et al 2002, Mueller et al 2003).





suggested for reliable monitoring of clopidogrel efficacy (see Cattaneo 2004, Almsherqi et al 
2005). Normally activation of the P2Y
12
-receptor would inhibit cAMP production and thus 
cAMP-dependent protein kinase (PKA)-mediated phosphorylation of vasodilator stimulated 
phosphoprotein (VASP) (Fig 6). As clopidogrel acts via P2Y
12
-receptor its effect could be 
assessed by cAMP levels or VASP phosphorylation (Schwarz et al 1999). However, changes 
of these determinants are also to some extent dependent on activation of the epinephrine 
receptor α2A, which could produce some features of P2Y
12
 signalling by repressing cAMP 




Aspirin was first synthesized in 1897 by German chemist Felix Hoffman and today it has an 
important position as an antiplatelet agent, among other indications. The antiplatelet effect of 
aspirin was first described by Morris in 1967. Aspirin exerts its effect by inhibiting the activity of 
prostaglandin (PG) H-synthase-1 and -2, also known as cyclooxygenase (COX)-1 and 2.  COX-
1 is known to predominate in platelets. Thus, in activated platelets COX-1 utilizes arachidonic 
acid (AA) to produce PGH
2
, which is further converted to TxA
2
, a potent platelet activator, as 





2α. and PGI2. The anti-platelet effect of aspirin 
is exerted by the irreversible inhibition of the COX-1 enzyme, inhibiting the production of 
TxA
2
 (Roth et al 1975). The irreversibility is caused by acetylation of strategic serine residues 
(Ser529 in COX-1 and Ser516 in COX-2) of COX-channel causing prevention of substrate 
access to the catalytic site of the enzyme. Anucleated platelets are unable to resynthesize the 
enzyme and thus depend on platelet turnover for its expression (see Patrono et al 2004).
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Aspirin inhibits COX-1 in 1/100 to1/50 concentrations compared to COX-2 (Cipollone et 
al 1997). Thus, smaller doses of aspirin are sufficient to inhibit COX-1, while inhibition of 
COX-2 is left incomplete. COX-2, which is inducibly expressed mostly in leukocytes and 
connective tissue cells and constitutively in certain organs, is not markedly affected by small 
aspirin doses (50-325mg) administered once daily.
Aspirin has been postulated to also have effects unrelated to TxA
2
 inhibition. Platelet inhibition 
not related to COX-1 inhibition, enhancement of fibrinolysis, suppression of plasma coagulation 
and anti-inflammatory effects, have been reported (see Patrono et al 2004). Enhancement 
of fibrinolysis is caused by N-acetylation of lysyl residues of fibrinogen by aspirin (dose 
>650mg twice daily) (Björnsson et al 1989). Suppression of coagulation could be caused 
by vitamin K- counter effect of large doses of aspirin (>1500mg/d), inhibition of thrombin 
generation (dose >500mg) or acetylation of one or more clotting factors (Quick & Cleasceri 
1960, Szczeklik et al 1996, see Patrono et al 2004). Anti-inflammatory effects of aspirin are 
not only due to inhibition of COX-2 activity but aspirin also modifies the interaction between 
platelets and either neutrophils or erythrocytes, protects endothelial cells from oxidative stress 
and improves endothelial dysfunction (López-Farré et al 1995, Podhaisky et al 1997, Santos 
et al 1997, Husain et al 1998, see Patrono et al 2004).
Pharmacokinetics
Aspirin is absorbed in the stomach and upper intestine. Normally peak plasma levels are 
reached within 30-40 min of aspirin uptake. However, when enterocoated aspirin is used the 
peak levels are reached between 3-4 h. Aspirin is rapidly cleared from the circulation; half-
life of acetylsalicylic acid is 15-20 min. As the effects on Tx synthesis are irreversible they 
last for the life-span of platelets, gradually decaying if dosage is not repeated. As 10% of 
platelets are replaced every day, it has been estimated that after 5-6 days 50% of the platelets 
function normally. 
Bleeding and other adverse effects
Bleeding complications are common in patients receiving aspirin therapy. The risk of major 
hemorrhage is approximately 1-2%. Aspirin-induced gastro-intestinal (GI) toxicity depends on 
the dose. GI toxicity is postulated to be caused by inhibition of PG synthesis and direct damage 
to gastric and intestinal mucosa, not by bleeding directly associated with TxA
2
 inhibition (see 
Roth & Caverly 1994). Thus, low-doses (100-300mg/d) used for inhibiting platelet activity are 
associated with a 2% risk of GI bleeding, which is similar to other antiplatelet agents.
In contrast to the widely held belief, enteric-coated aspirin has not been proven safer compared 
to plain or buffered aspirin in relation to GI toxicity. Kelly et al (1996) showed 2.6, 2.7 and 
3.1 times increased risks of upper GI bleeding with plain, enteric-coated and buffered aspirin, 
respectively, in a case-control study of 550 patients using daily aspirin doses lower than 
325mg/d. Similar results have been reported by others (see Patrono et al 2004).
Primary prevention
Aspirin has been evaluated in six primary prevention trials (US Physicians, Primary prevention 
Project, Hypertension Optimal Treatment, UK Doctors, Thrombosis Prevention Trial and Swedish 
Angina Pectoris Aspirin Trial) including healthy, hypertensive, high-risk and stable angina 
patients. These trials showed that the level of cardiovascular risk is the major determinant of the 
absolute benefit of aspirin therapy, and aspirin use can be recommended only if a patient’s risk for 
coronary events is above 1.5% per year (Sanmuganathan et al 2001, see Patrono et al 2004).
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Secondary prevention
Risk reduction of 20-25% in adverse events has been shown with long-term aspirin use in 
patients with previous atherothrombotic events or in other high-risk categories (ATC 2002). 
In a large meta-analysis antiplatelet medication was associated with decreases in reinfarction, 
death and stroke in 18 7888 patients with a history of myocardial infarction, 18 270 patients 
with a history of cerebrovascular events and 9214 patients with peripheral arterial disease (Fig 
9) (ATC 2002). These results were obtained from a number of different antiplatelet agents 
combined, but aspirin was the drug most commonly studied and there was no clear evidence 
of differences between aspirin and other antiplatelet drugs (ATC 2002) (Fig 10).
Aspirin in acute atherothrombotic syndromes
The antithrombotic effect of aspirin has been well established.  The ISIS-2 (International Study 
of Infarct Survival) study proved the efficacy of a single 162.5mg dose at the time of acute 
coronary symptoms in preventing further atherothrombotic events and at the same time the 
treatment was shown to be safe (ISIS-2 Collaborative group 1988). Proportional risk reduction 
of adverse events was 30 %.
The aspirin efficacy in acute stroke has also been established with a risk reduction of 
approximately 11% (ATC 2002). In meta-analysis of altogether 40 821 patients with acute 
stroke there was a significant reduction of new strokes as well as cardiovascular deaths. 
Hemorrhagic and ischemic stroke were also separately assessed in almost all of these patients 
and antiplatelet medication seemed to increase hemorrhagic strokes by 1.9 per 1000 patients, 
but this was counter balanced with a reduction of ischemic strokes to 6.9 per 1000 patients 
(ATC 2002). 
Aspirin in atrial fibrillation
Oral anticoagulation with warfarin is beneficial in reducing the risk of stroke in patients with 
atrial fibrillation (The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators 
1990). In comparison with warfarin, aspirin (75-325mg/d) was found to be significantly less 
effective in preventing stroke. However, aspirin caused a risk reduction of 25% and thus its use in 
patients unable to receive anticoagulation therapy is recommended (see Patrono et al 2004).
Summary
Aspirin is beneficial in both acute atherothrombotic events and in the prevention of thrombosis 
in patients with stable atherothrombotic disease. The benefits of antithrombotic medication in 
these patients at the population level overcome the risks of adverse-effects. However, subgroups 
of patients who suffer from either thrombotic or bleeding complications exist.
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bleeding was estimated at about three additional such
bleeds per 1000 allocated antiplatelet therapy, and
more detailed analysis of the international stroke trial
suggested that much of this excess occurred when
antiplatelet therapy was given in conjunction with
heparin (absolute excess 9 (2) per 1000 with heparin v
2 (1) per 1000 without heparin).18
Effects in other high risk categories
In the previous cycle of analyses,1 information was
available on serious vascular events from 104 trials
among about 20 000 patients with various other
conditions associated with an increased risk of vascular
events. Subsequently, more information has become







































Heterogeneity between 7 subtotals other than acute stroke: χ2=15.4, df=6; P=0.02 1.5


































































































































































































Fig 4 Proportional effects of antiplatelet therapy on vascular events in 195 trials in high risk patients subdivided by disease category. Stratified
ratio of odds of an event in treatment groups to that in control groups is plotted for each group of trials (black square) along with its 99%
confidence interval (horizontal line). Meta-analysis of results for each main category and for all trials (and 95% confidence interval) is
represented by an open diamond. Adjusted control totals have been calculated after converting any unevenly randomised trials to even ones by
counting control groups more than once, but other statistical calculations are based on actual numbers from individual trials
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Figure 9. Pr p rtional effects of antiplatelet ther py on vascular event in 195 trials in high risk 
patients subdivided by disease category. Stratified ratio of odds of an event in treatment groups to 
that in control groups is plotted for each group of trials (black square) along with its 99% confidence 
interval (horizontal line). Meta-analysis of results for each main category and for all trials (and 95% 
confidence in erval) is represe d as an open diamond. Adjust d control totals have been c lculated 
after converting any unevenly randomised trials to even ones by counting control groups more than 
once, but other statistical calculations are based on actual numbers from individual trials. Reproduced 
from the Antithrombotic Tri l sts´ Collaboration (2002), with permission.
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Figure 10. Direct comparisons of proportional effects of different antiplatelet regimens on vascular 
events in high-risk patients. Only meta-analyses involving a total of 500 or more high risk patients are 
shown. *Includes one trial comparing 1400mg/day v 350mg/day, and another comparing 1000mg/day 
v 300mg/day among patients with who were also given dipyridamole. †Includes two trials comparing 
75-325mg aspirin daily v <75mg aspirin daily and one trial of 500-1500mg aspirin daily v <75mg 
aspirin daily. ‡Includes cilostazol, sulotroban, trapidil, E5510, eptifibatide and GR32191B. Stratified 
ratio of odds of an event in regimen 1group to that in regimen 2 group is plotted for each group of trials 
(black square) along with its 99% confidence interval (horizontal line). Meta-analysis of results for 
all trials for particular comparison (and 95% confidence interval) is represented by an open diamond. 
Reproduced from the Antithrombotic trialists´ Collaboration (2002), with permission.
4.2 Clopidogrel
Mechanism of action 
Clopidogrel is a thienopyridine derivative which irreversibly inhibits platelet P2Y
12
-receptor 
(Hollopeter et al 2001). It is a prodrug which requires metabolism by liver cytochrome P450 
1333 (2.0%) antiplatelet v 31/1371 (2.3%) adjusted con-
trol; NS) were recorded in these trials, so the size of any
bleeding hazards cannot be reliably estimated.
Diabetes mellitus is also associated with n
increased risk of vascular events, even in the absence of
diagnosed cardiovascular disease. Much of the new
information comes from the early treatment diabetic
retinopathy study,28 i which 3711 people with diabetes
(and, generally, no history of myocardial infarction or
stroke) were allocated to receive 650 mg aspirin daily
or placebo. Overall, among 4961 patients with diabetes
in nine trials (compared with 1365 patients in seven
trials previously1), antiplatelet therapy was associated
with only a 7% (8%) proportional reduction in serious
vascular events (which remains consistent, however,
with the reduction of about one quarter observed
overall). None of the trials reported major extracranial
bleeds, but the early treatment diabetic retinopathy
study indicated that aspirin did not increase the risk of
vitreous or retinal haemorrhage.29
Relatively small numbers of patients with carotid
atherosclerosis have been studied. The overall results
in five trials of antiplatelet therapy after carotid endar-
terectomy and one among patients with asymptomatic
carotid disease (36/339 (10.6%) antiplatelet v 43/337
(12.8%) adjusted control; 19% (22%) reduction; NS) are
consistent with those observed in other patients at high
risk of stroke.
Comparisons of different antiplatelet regimens
Many small trials compared different antiplatelet
drugs, but the analysis in figure 5 is restricted to direct
randomised comparisons in which a total of at least
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Fig 5 Direct comparisons of proportional effects of different antiplatelet regimens on vascular events in high risk patients. Only meta-analyses
involving a total of 500 or more high risk patients are shown. *Includes one trial comparing 1400 mg/day v 350 mg/day,30 and another
(excluding those with acute stroke) comparing 1000 mg/day v 300 mg/day among patients who were also given dipyridamole.31 †Includes two
trials comparing 75-325 mg aspirin daily v <75 mg aspirin daily32 33 and one trial of 500-1500 mg aspirin daily v <75 mg aspirin daily.34
‡Includes cilostazol, sulotroban, trapidil, E5510, eptifibatide, a d GR32191B. Strati ie ratio of odds of an event in r gimen 1 group to that in
regimen 2 group is plotted for each group of trials (black square) along with its 99% confidence interval (horizontal line). Meta-analysis of
results for all trials for a particular comparison (and 95% confidence interval) is represented by an open diamond
Papers
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to its active form before achieving its antiplatelet effect (Savi et al 1994b and 2000). Inhibition 
of P2Y
12
-receptors is caused by formation of a disulfide bridge between the reactive thiol 
group of clopidogrel´s active metabolite and one or more cysteine residues of the platelet 
P2Y
12
-receptor (Ding et al 2003, Savi et al 2006).
Clopidogrel selectively inhibits ADP-induced platelet activation but has also been shown to 
have an inhibitory effect on platelet activation by other agonists such as epinephrine. This is 
most likely due to blocking of the effect of secondarily released ADP (Gawaz et al 1996). ADP 
has an important role in thrombus formation as the escalating process of secondary activation 
of platelets is caused by agonists such as ADP released from the primarily activated platelets. 
However, it has been postulated that increased concentrations of platelet agonists other than 
ADP, such as Tx and thrombin, will cause platelet activation despite P2Y
12
-receptor inhibition 
(see Patrono et al 2004).
Pharmacokinetics 
Clopidogrel is absorbed and metabolised relatively rapidly. The plasma elimination half-life of 
the main systemic metabolite of clopidogrel, SR26334, is 8 h, but because of its irreversible 
mechanism of action a once daily administration of clopidogrel is sufficient (Savi et al 2000). 
In healthy volunteers platelet function increased gradually after discontinuation of clopidogrel 
treatment and was restored in 7 days (Weber et al 2001). Elimination of clopidogrel is 50% 
renal and 46% gastrointestinal.
In small studies with healthy individuals a 75mg daily dose was found to cause a plateau of 
platelet inhibition compared with doses ranging between 25 and 150mg, and at the same time 
be safer than 100 or 150mg doses when assessed with bleeding time (Thebault et al 1999b). 
In the same study the 75mg daily dose seemed to cause a steady state of platelet inhibition in 
3 to 7 days after initiation of clopidogrel treatment (Thebault et al 1999b). Because of the lag 
in achieving the full platelet inhibitory effect loading doses have been introduced. In a similar 
setting of healthy individuals 300 to 400mg loading doses were found to be more effective 
compared to smaller loading doses (Savcic et al 1999). The effect of the loading dose seemed 
to be achieved within 2 h (Savcic et al 1999). However, in later studies including patients 
with coronary artery disease (CAD) the adequacy of these dosages and their timing has been 
questioned.
Bleeding and other adverse  effects
Bleeding complications are obviously the most common adverse effects of clopidogrel 
treatment, however, they did not significantly differ from those of aspirin when clopidogrel 
was used instead of or in combination with low-dose aspirin (CAPRIE 1996, CURE 2001, 
Creager 1998). The overall incidence of bleeding complications was 9.3% in the CAPRIE 
study (1996) and the incidence of severe bleeding complications was 1.4% in patients on 
clopidogrel and 1.6% in patients on aspirin.  In the CURE study (2001) non-life threatening, 
severe bleeding complications occurred more frequently with the combination of aspirin and 
clopidogrel than with aspirin alone. The incidence of life threatening bleeding complications 
did not differ between groups. 
In addition, bloating, cramping, diarrhoea and rash were the most common adverse effects. 
Severe adverse effects, such as neutropenia (0.04%), thrombotic thrombocytopenic purpura 
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(1/200 000), and severe thrombosytopenia (0.2%), were rare and significantly less common 
than with ticlopidine (CAPRIE 1996, CURE 2001). 
Primary prevention
Use of clopidogrel in the primary prevention of atherothrombotic diseases has not been 
specifically studied. The CHARISMA study comprised two patient populations: those with 
documented atherothrombotic disease and those at high risk due to multiple risk factors. The 
latter group received antiplatelet medication for primary prevention of atherothrombotic 
events. Use of antiplatelet agents such as aspirin is beneficial in primary prevention in patients 
with multiple risk factors (ATC 2002). Thus, the combination of clopidogrel and aspirin was 
expected to have increased beneficial effects in comparison with aspirin alone. However, in 
the CHARISMA study in patients with risk factors the combination treatment compared to 
aspirin alone did not decrease the risk of adverse vascular events. In addition, in the primary 
prevention group the overall risk for death was increased significantly with the combination 
treatment compared to aspirin (5.4% vs. 3.8%) (Bhatt et al 2006).
Secondary prevention
The CAPRIE study (1996) was the first large phase III trial, to test the efficacy and safety of 
clopidogrel in comparison with aspirin. Modestly better clopidogrel efficacy in comparison 
with aspirin was found, but the difference between these antiplatelet drugs was not large 
(P=0.04). After a 1.9 year follow-up the relative risk reduction with clopidogrel instead of 
aspirin treatment was 8.7% (5.32% vs. 5.83%). In a subanalysis it was shown, however, that 
patients with peripheral arterial disease (PAD) gained a superior benefit from clopidogrel 
when compared with patients with either primary cardio- or cerebrovascular disease (RRR 
23.8%). In concordance, the benefit of clopidogrel over aspirin seemed to be increased in 
high-risk patients (Bhatt et al 2001). Clopidogrel was found to have a similar safety profile to 
aspirin. While the efficacy in secondary prevention with clopidogrel and aspirin was similar, 
the financial aspects of treatment in unselected populations become of interest as the cost of 
clopidogrel treatment was approximately 7 times that of aspirin (Gorelick et al 1999). 
In the CHARISMA study (2006) some of the patients had documented atherothrombotic disease 
with either cardiovascular, cerebrovascular manifestations or symptomatic PAD (Bhatt et al 
2006). In these patients the combination of aspirin and clopidogrel had similar efficacy and 
safety as aspirin treatment alone. 
The clopidogrel efficacy versus the combination of clopidogrel and aspirin in patients with 
cerebrovascular complications was assessed in the MATCH study (Diener et al 2004). No 
differences in efficacy of the study regimens were observed. In addition, the combination 
treatment was associated with increased risk of life-threatening complications with an absolute 
risk increase of 1.3% (Diener et al 2004).
Also in patients with atrial fibrillation and one or more risk factors for stroke the traditional 
treatment with oral anticoagulation was found to be superior to the combination of aspirin and 
clopidogrel, in fact the study was stopped because of the clear evidence (ACTIVE investigators 
2006). In patients with contraindications to oral anticoagulation the ongoing ACTIVE A trial 
has set out to determine the efficacy of combination treatment in comparison with aspirin 
alone (The ACTIVE Steering Committee 2006).
Review of the literature
36
Clopidogrel as adjuvant treatment in PCI
The CLASSICS study compared combinations of either ticlopidine or clopidogrel with aspirin 
after either elective or unplanned coronary stenting in patients with CAD (Bertrand et al 2000). 
The two study regimens were found to be equally effective, but clopidogrel was safer than 
ticlopidine. Later Bhatt et al (2002a) conducted meta analysis of trials comparing ticlopidine 
and clopidogrel after percutaneous coronary intervention (PCI) and found the latter to be 
significantly better with decreased incidence of cardiac adverse events (4.0% vs. 2.1%) and 
mortality (1.1% vs. 0.5%) (Bhatt et al 2002a).
In the PCI-CURE trial of patients with acute coronary syndrome 10-day pre-treatment with 
clopidogrel prior to PCI was associated with 30% risk reduction of the combined endpoint of 
cardiovascular death, myocardial infarction (MI) and urgent revascularization (4.5% vs. 6.4 
% in clopidogrel vs. placebo in addition to aspirin groups) (Mehta et al 2001). In addition, the 
combination of clopidogrel and aspirin was found to be superior in reducing cardiovascular 
morbidity and mortality during an 8 month treatment when compared to short-term treatment 
(RR 17%).
In elective patients the CREDO study proved that prolonged 1 year clopidogrel treatment after 
PCI reduced adverse events when compared with 1 month short-term treatment (27% RRR) 
(Steinhubl et al 2002). It also showed that a 300mg loading dose of clopidogrel administered 
more than 6 h prior to PCI caused 39% risk reduction of adverse events compared to no pre-
treatment.
Clopidogrel has established a firm position in the treatment of CAD patients after PCI. Its 
efficacy and safety in addition to aspirin were shown in the CREDO (Steinhubl et al 2002) 
and CURE (2001) studies. The use of clopidogrel is currently recommended both prior to and 
after PCI (Bhatt et al 2002a, Steinhubl et al 2002).
Combination treatment with aspirin and clopidogrel was proven to be beneficial in patients 
with acute coronary syndromes also when treated conservatively (CURE 2001). Beneficial 
effects of aggressive antiplatelet therapy in acute situations with GP IIb/IIIa inhibitors and 
clopidogrel have been shown. In addition, no significant excess bleeding was found in patients 
who underwent coronary artery bypass grafting (CABG) if dual antiplatelet medication with 
aspirin was stopped more than 5 days prior to the procedure (CURE 2001).
Clopidogrel in acute atherothrombotic syndromes
The CURE trial (2001) compared the efficacy and safety of the combination of clopidogrel 
and aspirin to aspirin alone in patients with acute coronary syndromes without ST-segment 
elevation. The risk of atherothrombotic events in patients with dual antiplatelet medication 
was reduced 20% when compared with aspirin alone (9.3% vs. 11.4 %). The risk reduction 
rate for MI was most evident. In subgroup analyses it was found that patients with previous 
PCI had the most significant (40%) risk reduction.
The efficacy of combination treatment in acute cardiovascular syndromes has been shown 
when used in adjunction with standard treatments such as fibrinolytic therapy (COMMIT 
collaborative group 2005). Clopidogrel in addition to aspirin caused a 9% reduction in 
atherothrombotic events compared with aspirin alone in patients with acute MI (COMMIT 
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2005). Patients undergoing primary PCI were excluded, however, after the randomization 
to the study groups the patients received a variety of treatments (procedures, fibrinolysis, 
conservative treatment). Similar results were obtained in the CLARITY-TIMI trial which 
assessed the efficacy of the combination of aspirin and clopidogrel compared to aspirin in 
patients with acute MI, who received fibrinolytic therapy. In these 3491 patients who were 
also treated with fibrinolytics the absolute reduction of atherothrombotic complications in the 
group with combination treatment was 6.7% (Sabatine et al 2005).
The CARESS study evaluated the efficacy of the combination aspirin and clopidogrel instead 
of  aspirin alone and found it to be more effective in reducing cerebral microemboli detected 
by Doppler ultrasound in patients with >50% carotid artery stenosis with recent transient 
ischemic attack (TIA) or stroke. Because of the small size of the study (N=110) the result was 
unable to reach clinical significance (Markus et al 2005).
Summary
Clopidogrel is beneficial in reducing atherothrombotic events in patients with acute thrombotic 
syndromes and elective PCI (Table 3). However, in primary and secondary prevention of 
patients with increased risk for thrombosis, it is not superior to aspirin (Table 3). The differences 
between these patient groups could result from enhanced platelet activity, and thus a need for 
more potent antiplatelet medication, in patients with acute plaque rupture or artificial vessel wall 
damage caused by PCI. Therefore, it could be postulated that in stable disease compensatory 
mechanisms overcome the need for and benefit of enhanced antiplatelet medication and in an 
unstable set up the excessive platelet activity is more successfully inhibited by the combination 
of aspirin and clopidogrel, thus causing clinical benefit. As the risk of bleeding with antiplatelet 
medication is obvious, use of extensive antiplatelet medication without significant benefit is 
not justified. Thus, based on recent studies, it seems that at the moment the use of clopidogrel 
can be recommended only in acute situations. However, as in the case of aspirin, subgroups 
of patients who would potentially receive increased benefit from clopidogrel and patients who 
are at unacceptable risk for bleeding if treated with clopidogrel, exist. 
Table 3. Summary of large, prospective, randomized studies on clopidogrel. 
Title Patients, design Setting Results
   
   
   
   




IE Clopidogrel versus 
Aspirin in Patients 





19 185 patients with 
recent stroke, recent 
MI or symptomatic 
PAD
1) clopi 75mg/d + 
placebo
2) ASA 325mg/d + 
placebo
For 1-3 years
- Clopi is more 
effective than ASA 
in reducing risk of 
atherothrombotic 
events
- Clopi is at least as 
safe as ASA
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1 020 patients after 
stent placement
(either elective or 
acute procedures)
In addition to ASA 
375mg/d
1) clopi LD 300mg + 
75mg/d
2) clopi 75mg/d
3) ticlopidine 250mg 
twice a day
For 28 days
-Clopi and ticlopidine 
combined with ASA 
are equally effective 
-Clopi is safer than 
ticlopidine
-Loading dose 
of clopi is well 
tolerated
   
   
   
   
   
   




E Clopidogrel in 




N Eng J Med 2001
12 562 patients with 
ACS, without ST-
segment elevation
In addition to ASA 
75mg-375mg




-Addition of clopi is 
beneficial regardless 
of ASA dose in all 
patients with ACS.
 
- Bleeding risks 
increase with 
increasing ASA dose
   
   
   
   
   
   
   
   
   
   
   
   
   
   






E CURE - subgroup
Mehta et al
Lancet 2001
2 658 patients with 
ACS who underwent 
PCI
In addition to ASA 
75-325mg/d
1) 10 days prior to 
PCI clopi 75mg/d
+ 28 days of open 
label thienopyridine 
+ 8 months of 
clopi 75mg/d
2) placebo 
+ 28 d open-label 
thinopyridine 
Altogether for 9 
months
 
- Prolonged treatment 
with clopi is superior 
to no 1 month 
treatment
 -Pre-treatment 
with clopidogrel is 
beneficial
   
   
   
   
   
   
   
   
   
   
   
   
   





O The Clopidogrel 
for the Reduction 
of Events During 
Observation 
Steinhubl et al 
JAMA 2002
2 116 patients to 
undergo elective PCI
In addition to ASA 
81-325mg/d
1) clopi LD 300mg + 
75mg/d (12 months)
2) no loading dose 
+ clopi 75mg/d (28 
days)
+placebo (ad 12 
months)
Altogether for 12 
months
-Long term (1-year) 
clopi reduces 




prior to PCI does not 
have an effect
-Loading dose >6h 
prior to PCI is 
associated with 
decreased risk of 
adverse events
Title Patients, design Setting Results
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Management of 
atherothrombosis 
with clopidogrel in 
high-risk patients 
with recent transient 
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N Eng J Med 2005
3 491 patients with 
ST-elevation MI
In addition to 
fibrinolytic therapy 
and ASA




-Clopi treatment in 
addition to ASA 
was associated 





   
   
   






 W Atrial fibrillation 
clopidogrel trial 
with irbesartan 




6 706 patients with 
atrial fibrillation + 









is superior to 
combination 
treatment
-Study was stopped 
early, because of 
clear evidence
   
   
   
   
   
   
   
   
   
   







A Clopidogrel for high 
atherothrombotic 





N Eng J Med 2006
15 603 patients with 
atherothrombotic 
disease or at high risk






-In whole study 
population the 
efficacy  and safety 
of clopi+ASA vs. 
ASA did not differ




was found inferior 
and less safe to 
compared to ASA 
alone
LD=loading dose, ASA= aspirin, clopi= clopidogrel.
Title Patients, design Setting Results
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4.3 Other ADP-antagonists 






, are potential targets for antiplatelet 
medication although P2Y
12
-receptors antagonists have been the most studied (Table 4). Prodrugs 
ticlopidine and clopidogrel were the first ADP-receptor inhibitors in clinical use. Later, ARC 
compounds, group of ADP-receptor inhibitors, which are also active in vitro, were developed. 
Cyclopentyl-triazolo-pyrimidine AZD6140 was further developed from ARC compounds and 
is now being launched as an oral antiplatelet agent (see van Giezen & Humphries 2005).
P2Y
1
-receptor antagonism has a beneficial effect in reducing thrombus formation and promising 
preliminary studies on animals with antagonising MRS compounds have been performed and 
further studies are in progress (Lenain et al 2003, Hechler et al 2006). P2X
1
 has also been 
suggested as a potential target for antiplatelet medication, and a newly identified antagonist 
NF449 has an inhibitory effect on platelet activation in vitro (Kassack et al 2004, Hechler et 
al 2005).
Ticlopidine and prasugrel
Ticlopidine and clopidogrel are structurally related thienopyridines. Ticlopidine was the first 
P2Y
12
-receptor antagonist used clinically. Plasma levels of ticlopidine increase on repeated 
twice-daily dosing over 2 to 3 weeks. As ticlopidine has lag in full onset of action is not useful 
when rapid antiplatelet effect is needed. Its efficacy has been shown in clinical studies as a 
single antiplatelet drug or in combination with aspirin in patients with different manifestations 
of atherothrombotic disease. However, ticlopidine therapy has been associated with several 
adverse effects, some severe (hypercholesterolemia, neutropenia, thrombocytopenia, aplastic 
anemia and thrombotic thrombocytopenic purpura).  In comparison with ticlopidine clopidogrel 
has a favourable adverse effect profile and accelerated onset of action (see Patrono et al 
2004).
Prasugrel, also known as CS-747 or LY640315, is a new thienopyridine compound. Prasugrel 
is orally administered and irreversible in action by its active metabolite R-138727 (Niitsu et 
al 2005). At present there are ongoing phase 3 studies comparing prasugrel with clopidogrel 
in patients undergoing PCI or with MI (Wiviott et al 2006). Previously it has been reported to 
be more potent and to have more rapid onset of action than clopidogrel (Wiviott et al 2005).
AR-C69931MX
AR-C69931MX (ARMX) is an ATP analogue, ARC compound and specific antagonist of the 
P2Y
12
-receptor and unlike clopidogrel is active in vitro (see Storey 2001). In vitro the maximal 
effect of ARMX is achieved at a 100nM concentration (Goto et al 2002, Storey et al 2002). 
ARMX inhibits aggregation, granule secretion, P-selectin expression and procoagulant activity 
of platelets (see Storey 2001). After development into an intravenous antiplatelet agent it has 
been renamed cangrelor. It has been proposed in clinical use with acceptable efficacy and safety 
profile as well as reversible action and short half life (see Storey 2001, Jacobsson et al 2002, 
Greenbaum et al 2006). In previous studies ARMX has also been found to be more effective 
in inhibiting platelet activation than clopidogrel and its onset of action is rapid (Storey et al 
2002). ARMX has been found also to inhibit the P2Y
13
-receptor (Marteau et al 2003, see van 
Giezen & Humphries 2005).
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Table 4. Compounds targeted for inhibiting ADP-induced activation of platelets. 
Compounds P2Y1 P2Y12 Reference
Antagonists
A2P5P + Boyer et al 1996
A3P5P + Boyer et al 1996
A3P5PS + Boyer et al 1996
MRS-2179 + Boyer et al 1998, Brown et al 2000
MRS-2279 + Nandanan et al 2000
MRS-2500 + Kim et al 2003, Cattaneo et al 2004
AR-C66096MX + Ingall et al 1999, Humphries et al 2000 
AR-C67085MX + Ingall et al 1999, Humphries et al 2000 
AR-C69931MX + Ingall et al 1999, Humphries et al 2000 
C1330-7 + Hollopeter et al 2001
INS compounds +
AZD6140 + Peters & Robbie 2004, van Giezen & Humphries 2005
NF449 + Kassack et al 2004
Inhibitors
Ticlopidine + Savi & Herbert 2000
Clopidogrel + Savi & Herbert 2000, Savi et al 2000
CS-747 + Sugidachi et al 2000, Niitsu et al 2005
Modified from Gachet (2001 and 2005).
4.4 Dipyridamole
Dipyridamole is a pyrimidopyrimide derivative. It has antiplatelet properties, but its mechanism 
of  action is not exactly known. It inhibits cyclic nucleotide phosphodiesterase, which results 
in accumulation of its substrate, platelet-inhibiting cyclic adenosine 3´,5´- monophosphate 
(cAMP) (Smith & Mills 1970). Another suggestion is that dipyridamole blocks the uptake of 
adenosine, which would cause stimulation of adenylate cyclase and thus increase cAMP. In 
addition, direct stimulation of PGI
2
 synthesis and inhibition of its degradation by dipyridamole 
have been shown (Moncada & Korbut 1978). Dipyridamole also has vasodilatory effects.
Conventional formulations of dipyridamole had variable bioavailability and thus a new 
modified-release formulation has been developed (see Patrono et al 2004). Clinical trials with 
the conventional form together with aspirin or dipyridamole alone have achieved questionable 
efficacy. However, trials using the reformulated drug have shown improved efficacy in patients 
with cerebrovascular manifestations of atherothrombotic disease. In both the ESPS2-study 
(1996) and recent ESPRIT study the combination of aspirin and dipyridamole was found to 
be superior to aspirin alone in preventing vascular events after ischemic stroke (Diener et al 
1996, The ESPIRIT study group 2006). In ESPIRIT study the incidence of adverse events was 
13% in combination group and 16% in patients with aspirin treatment (ESPIRIT 2006).
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4.5 GP IIb/IIIa antagonists
As their name implies the GP IIb/IIIa antagonists inhibit the platelet GP IIb/IIIa receptor 
responsible for aggregation. GP IIb/IIIa antagonists inhibit platelet aggregation regardless 
of the platelet activating agent (Coller et al 1989). The GP IIb/IIIa antagonists include 
monoclonal antibodies against the receptor, naturally occurring and synthetic peptides, as 
well as peptidomimetic and nonpeptide mimetics that compete with receptor ligands (eg. 
fibrinogen, vWf). The safety and efficacy of different parenteral GP IIb/IIIa antagonists, 
abciximab, tirofiban and eptifibatide, have been proven in several clinical trials in patients 
with acute coronary syndromes undergoing PCI (see Casserly & Topol 2002). This group 
of antiplatelet medication has been shown to improve both long- and short- term outcome 
after PCI performed in both acute and stable settings. Benefit in patients with acute coronary 
syndrome who are not scheduled for early revascularization has not been shown, although 
in subgroup analyses in some studies diabetic patients seemed to benefit from parenteral GP 
IIb/IIa antagonists (Roffi et al 2001, see Patrono et al 2004).
Oral GP IIb/IIIa antagonists have also been developed (xemilofiban, orbofiban, sibrafiban and 
lotrafiban) but in trials of over 40 000 patients they were not more effective than aspirin nor 
caused additional benefit on top of aspirin and may in fact increase mortality (see Patrono et 
al 2004).
5 Variability in aspirin efficacy 
5.1 Definition, prevalence and relevance of non-response to aspirin
Definition 
Although aspirin has been shown to decrease atherothrombotic events in high risk patients 
a considerable number still suffer from cardiovascular events while on aspirin (ATC 2002). 
The response to aspirin treatment varies among individuals as measured by different platelet 
function tests and bleeding time (Buchanan et al 2000, Gum et al 2001 and 2003, Zimmermann 
et al 2003), and the term “aspirin resistance” has been used to describe lack of measurable 
antiplatelet effect in laboratory tests (see Patrono 2003). Recently, however, there have been 









 dependent platelet activation (see Cattaneo 2004, 
see Hankey & Eikelboom 2006), hence the terms pharmacological aspirin resistance to describe 
TxA
2
 dependent failure of aspirin and functional aspirin resistance to describe increased 
platelet activity in platelet function tests despite aspirin (see Wong et al 2004). Previously 
the term clinical aspirin resistance has also been used for situations where atherothrombotic 
complications occur despite aspirin medication. However, the term treatment failure is more 
precise in these cases and that phenomenon can also be observed with other drugs. A feature 
of aspirin resistance highlighted in recent reviews is the presumable, continuous nature of 
the phenomenon instead of a dichotomized on-off nature (see Hankey & Eikelboom 2006). 
This is a natural assumption considering the variability of all natural phenomena as well as 
different drug responses. 
The definition of aspirin resistance as failure of aspirin to inhibit TxA
2
 production derives 
from aspirin´s mechanism of action. As aspirin is supposed to inhibit COX-1, which normally 






), it should prevent or significantly 
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 production has been measured from serum, plasma 
or urine with the help of its stable metabolites TxB
2
 and 11-dehydro TxB
2
 to diagnose aspirin 
resistance. In these cases, subjects have been defined as aspirin resistant if they have increased 
levels of plasma, serum or urine TxB
2
 while on aspirin (see Patrono 2003). However, in patients 
with measurable Tx levels non-compliance to aspirin treatment needs to be ruled out. This 
type of aspirin resistance could be labeled pharmacological aspirin resistance according to 
Wong et al (see 2004).
The second, popular method of defining aspirin resistance, which is equivalent to functional 
aspirin resistance according to Wong et al (see 2004), has been the use of platelet function tests. 
Different platelet function tests, agonists and cut-off levels of defining aspirin resistance have 
been used. In previous studies platelet activation by ADP, thrombin and collagen have among 
other methods been used to determine aspirin resistance.  Platelet aggregometry induced by AA 
has historically been proposed as the gold standard for defining aspirin resistance and is still 
the most widely used method (see Hankey & Eikelboom 2006). Due to the fact that AA induces 
aggregation only if it can be converted to Tx by COX-1, the aspirin resistance measured with 
AA-induced aggregation could in fact be labeled pharmacological resistance. In general, the 
definition of aspirin resistance is problematic due to the fact that a standardized, reproducible 
valid, specific, easy to perform and affordable method does not exist. The problems associated 
with the previously mentioned methods were discussed in section 3.
Three different types of aspirin resistance have also been proposed by Weber et al (2002). 
In patients with pharmacokinetic resistance oral aspirin medication does not inhibit platelet 
function or TxA
2
 synthesis, but addition of in vitro aspirin results in inhibition of TxA
2
 synthesis 
and platelet activation. This type could be caused or mimicked by inadequate intake or dose 
of aspirin, reduced absorption of the drug or increased platelet turnover. Pharmacodynamic 
resistance causes neither in vivo nor in vitro response to aspirin and would be caused at the 
cellular level by eg. extra-platelet sources of TxA
2
 production, altered binding to COX-1 or 
genetic polymorphisms affecting COX enzymes. The third type, pseudo-resistance, manifests 
itself as lack of inhibition of platelet activity despite complete inhibition of TxA
2
 formation, 
thus representing activation of platelets mediated by pathways other than TxA
2
 (Weber et al 
2002). Thus, pharmacokinetic and pseudo resistance would fall into the category of functional 
aspirin resistance according to Wong et al (see 2004). 
Prevalence
Based on different studies the prevalence of aspirin resistance has been estimated to be 5.5-
61% (Table 5) (see Hankey & Eikelboom 2006). Response to aspirin has been measured in 
patients with different manifestations of atherotrombotic disease and is poor in approximately 
20%. The prevalence depends on the method used to determine aspirin resistance as well as 
the group of patients studied (see also section 3.5). In patients studied at the postoperative 
stage or with more severe or unstable disease the prevalence is increased compared to the 
stable patients (Zimmermann et al 2003, Payne et al 2004).
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Table 5. Prevalence of aspirin resistance reported in selected studies.










Buchanan et al 
2000
CAD, CABG 289 325 Bleeding time 55
Peters et al 2001 CAD, stable 19 100 PFA-100® 63
Macchi et al 2002 CAD, stable 72 160 PFA-100® 29
Andersen et al 
2002
CAD, stable 129 75-160 PFA-100® 37
Christiaens et al 
2002
CAD, stable 50 >75 PFA-100® 20





Macchi et al 2003 CAD, stable 72 160 PFA-100® 29
Gum et al 
2003





Wang et al 2003 CAD, stable 422 81-325 Ultegra RPFA® 23
Chen et al 2004 CAD, 
elective PCI
151 80-325 Ultegra RPFA® 19





Mueller et al 
1997




Ziegler et al 2002 PAD 52 100 PFA-100® 10
Grotemeyer et al 
1993
CVD 180 1500 Platelet 
reactivity index
33
Helgason  et al 
1994





Grundmann et al 
2003
CVD 53 100 PFA-100® 34




Sane et al 
2002




Modified from Poulsen et al (2005).
aggr.=platelet aggregation, Ultegra RPFA®=Ultegra Rapid Platelet Function Assay®, PFA-100®=Platelet 
Function Analyser-100®, CAD=coronary artery disease, CVD=cerebrovascular disease, PAD=peripheral 
arterial disease, CHF=chronic heart failure. 
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Relevance
The relevance of poor aspirin response in platelet function tests and studies assessing aspirin 
resistant TxA
2
 generation will become important only if these findings can be reliably proved 
to associate with increased risk of atherothrombotic events. Interestingly, poor response to 
aspirin has recently been associated with clinical end points of cardiovascular, cerebrovascular 
and peripheral arterial disease in small studies, which could predict existence of such 
phenomenon.
Grotemeyer et al (1993) studied 181 patients with previous stroke. The authors state that in 
90% of acute stroke patients platelet activation is known to be increased, but can be inhibited 
by 500mg of aspirin. Platelet activity was studied 12 h after stroke and oral dose of 500mg 
aspirin. Patients who at that time had increased activity assessed with the platelet reactivity 
index had increased risk of atherothrombotic events during the 24-month follow-up period. The 
severe limitations of this study were that platelet function was assessed only at one time point 
and the method used was unspecific, thus it is unknown if the increased platelet activity was 
a consequence of limited response to aspirin or simply reflects significantly increased platelet 
activity that was perhaps decreased by aspirin to some degree. In addition, platelet activity is 
known to be increased in acute atherothrombotic settings and thus these settings represent an 
extreme challenge for antiplatelet medication. It is unknown whether the increased platelet 
activity at the time of measurement was the reason or consequence of acute thrombotic event 
(Grotemeyer et al 1993).
Mueller et al (1997) studied 100 patients with intermittent claudication who were on 100mg/d 
aspirin treatment. Patients who developed re-stenosis of the percutaneous balloon angioplasty 
site during the 18-month follow-up had increased platelet activation in function measurements 
by ADP- and collagen-induced platelet aggregation. In all patients AA-induced aggregation 
was inhibited by aspirin. As platelet aggregation induced by AA, rather than by other agonists, 
can be considered more specific to aspirin, the results reflect association of re-stenosis with 
generally increased platelet activity and not specifically with aspirin resistance.
In the study by Eikelboom et al (2002) the aspirin efficacy was assessed by measurement of 
urine TxB
2
 in patients with atherothrombotic disease. In this study 488 patients who suffered 
from thrombotic complications during the 5-year follow-up period were compared with 488 
matched controls. TxB
2
 levels associated with the incidence of clinical events. However, 
the dose of aspirin was not specified and patient compliance was not controlled. In addition, 
possible drug interactions were not assessed. Despite the previously mentioned short comings 
of the study, this relatively large assessment was significant as one of the first studies proving 
a trend of association between aspirin resistance and clinical treatment failure.
Gum et al (2003) reported that aspirin resistance measured with AA-induced aggregation, but 
not with PFA-100®, was associated with increased risk of atherothrombotic events in patients 
with CAD during follow-up of 2 years. Aspirin resistant patients had a 4.1 risk ratio for death, 
MI or cerebrovascular accident compared to aspirin responders. This study has been criticized 
for the lack of a comparison group and thus for only descriptive study design. However, in 
this study the AA-induced aggregation, a quite specific measurement of aspirin function, was 
found to be associated with aspirin efficacy to prevent clinical endpoints.
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Grundmann et al (2003) assessed the aspirin resistance of 53 patients with either coronary or 
cerebrovascular manifestations of atherothrombotic disease. Thirty-five of them had had acute 
cerebrovascular symptoms within 3 days and 18 had been asymptomatic for the previous 24 
months. Aspirin resistance was defined as failure of aspirin to prolong closure time in PFA-100®. 
Symptomatic patients had increased prevalence of aspirin resistance compared to asymptomatic 
patients. The authors concluded that aspirin resistance defined by PFA-100® could contribute 
to clinical treatment failure. The study by Grundmann et al (2003) was confronted with similar 
limitations as the study by Grotemeyer et al (1993). These are also the same problems that 
affect most studies on aspirin resistance, including those described later in this section.
Andersen et al (2002) studied the antiplatelet efficacy of 160mg/d aspirin (N=73) and the 
combination of 74mg/d aspirin and warfarin (INR 2.8-4.2) (N=58) in patients with previous 
acute MI. Aspirin efficacy in both treatment groups was detected by PFA-100® with a cut off 
point of 196s. The patients were followed up for 4 years and no difference in occurrence of 
atherothrombotic events in non-responders compared to responders to aspirin was found (36% 
vs. 24%) (Andersen et al 2002).
Non-response to aspirin has also been assessed with Ultegra-RPFA® and found to be associated 
with elevated incidence of myonecrosis after coronary intervention, despite the additional 
inhibition by a loading dose of clopidogrel (Chen et al 2004).  
Ajzenberg et al (2005) studied the platelet activity of patients with recent stent thrombosis right 
after PCI. They found that these patients had increased platelet activity compared to controls 
and healthy subjects, despite dual antiplatelet medication with aspirin and clopidogrel. The 
limitation of the study was that as the platelet activity in the patients was measured within days 
(mean 4.5 d) of the incident the platelet activity could be at least partly associated with the recent 
thrombotic event. Thus no definite conclusions can be drawn on the role of increased platelet 
activity as a factor contributing to the incidence of stent thrombosis based on this study.
Wenaweser et al (2005) studied 23 patients with stent thrombosis after PCI and compared them 
with 50 matched patients who had undergone PCI but not suffered from stent thrombosis as 
well as 9 healthy volunteers. In this small study aspirin resistance measured with AA-induced 
aggregation seemed more common but was not significantly so in patients who had suffered 
from stent thrombosis than in patients who had not (48% vs. 32%). However, when patients 
with stent thrombosis were compared with healthy volunteers the difference was evident (48% 
vs. 0%, P=0.01).  Clopidogrel resistance measured with ADP-induced aggregation did not 
differ between the three groups.
Summary
Aspirin resistance measured with different methods has been associated with clinical endpoints 
in several small studies. Although larger, more reliable studies are needed it seems that 
association between increased platelet activity as well as true aspirin resistance measured 
with specific methods (AA-induced aggregation and TxB
2
 generation) and increased risk of 
atherothrombotic endpoints exists. The current situation calls for exact determination of aspirin 
resistance and recommendations for its measurement. Larger, prospective studies using these 
definitions are also needed in the future to determine the relevance of aspirin resistance and 
mechanisms behind it.
Review of the literature
47
5.2 Reasons for variability in aspirin efficacy 
Aspirin resistance and the reasons behind it have recently been widely studied. Several extensive 
reviews have also been published (see Patrono 2003, Cattaneo 2004, Wong et al 2004, Rocca 
& Patrono 2005, Szczeklik et al 2005, Hankey & Eikelboom 2006, Wang et al 2006). The 
reasons for poor response to aspirin treatment can be roughly categorized to clinical, cellular 
and genetic reasons (Table 6).
Table 6. Potential mechanisms of aspirin resistance – including both TxA
2









• Increased platelet   
 turnover
• Hypercholesterolemia









-   Insufficient suppression      
of COX-1
-   Over-expression of 
COX-2
- Extra-platelet sources 
 of TxA
2
- Generation of 8-iso-
PGF
2α
• Alternate pathways of 
platelet activation













•   COX-1 
 polymorphisms
•   GP IIb/IIIa receptor 
polymorphism
•   Collagen receptor 
 polymorphism
•   vWf receptor 
 polymorphisms
Modified from Bhatt (2005) and Wang et al (2006). 
Clinical factors
Poor compliance to aspirin has been suggested to explain aspirin resistance. It has been 
reported that up to 40% of patients with cardiovascular disease have poor compliance to 
antiplatelet treatment (Carney et al 1998). Others have reported frequencies between 9 and 
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16% (Cotter et al 2004, Schwartz et al 2005). In a recent study 3% of patients undergoing 
PCI were found non-compliant to aspirin despite oral assurance (Tantry et al 2005).  However, 
poor compliance does not explain the entire phenomenon as in a study by Grundmann et al 
(2003) 34% of patients with cerebrovascular disease were found to be resistant to aspirin 
despite supervised aspirin dosing. Underdosing has also been proposed as a mechanism of 
aspirin resistance. However, data on the subject is conflicting. Drug-interactions with non-
steroidal anti-inflammatory drugs (NSAID), especially ibuprofen, have been reported and 
could thus partly explain poor response to aspirin (Catella Lawson et al 2001). Inadequate 
systemic bioavailability in the case of aspirin cannot be explained by metabolic differences 
as most of aspirin’s effects take place in presystemic circulation (see Hankey & Eikelboom 
2006). However, hypotheses exist on decreased absorption of aspirin in stomach and upper 
intestine in relation to anti-acid medication. The formulation of the aspirin preparation has 
been suggested to affect absorption and thus aspirin efficacy (Maree et al 2005b). Indeed, in a 
study of 129 patients with cerebrovascular disease the use of enteric-coated aspirin correlated 
with an increased proportion of aspirin resistant patients when compared with uncoated 
preparation (Alberts et al 2004).
Different disease states, such as hyperglycemia, hypercholesterolemia, acute coronary syndromes 
and heart failure, have been associated with increased platelet activation or decreased aspirin 
efficacy (Fitzgerald et al 1986, Szczeklik et al 1996, Davi et al 1999, ATC 2002, Sane et al 
2002, Friend et al 2003). Increased TxA
2 
levels have been shown in patients with inflammation 
or atherosclerosis (Catella et al 1986, Nakamura et al 2001). In addition, smoking has been 
associated with aspirin resistance, increased platelet activity and altered Tx metabolism (Lassila 
et al 1988, see Cambria-Kiely & Gandhi 2002, see Hankey & Eikelboom 2006).
Unexplained findings of changed response to aspirin after coronary artery or carotid surgery 
have been reported (Zimmermann et al 2003, Payne et al 2004). In patients whose aspirin 
response prior to surgery has been normal, postoperative Tx formation and enhanced platelet 
activation have been detected despite addition of in vitro aspirin (Zimmermann et al 2003). 
Increased platelet turnover has been suggested to explain part of the phenomenon, but it does 
not explain the lack of effect of additional in vitro aspirin dosing. Possibly increased thrombin 
activity or catecholamine surge in the preoperative phase could counteract the phenomenon 
of enhanced platelet activation despite aspirin.
Loss of the antiplatelet effect with long-term use, a phenomenon called tolerance, has been 
detected in patients using aspirin. Patients initially responding well to aspirin develop 
decreased response during follow up (Helgason et al 1994, Pulcinelli et al 2004). The reasons 
for this phenomenon have been postulated to be progressing atherosclerosis and reduction of 
compliance over time (see Hankey & Eikelboom 2006).
Cellular factors
It can be hypothesized that non-platelet sources of TxA
2
, such as endothelial cells, macrophages, 
monocytes and the kidneys, might be a reason for aspirin resistance. Aspirin resistant Tx 
formation could result from extra-platelet sources of TxA
2
, transient expression of COX-2 
and generation of 8-iso-PGF
2α (Weber et al 1999, Cipollone et al 2000).
 
Platelet activation via pathways which are not TxA
2
-dependent has been postulated to be 
behind aspirin resistance, which could be labelled functional aspirin resistance. Platelets 
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can also be activated by other agonists and factors such as collagen (GP Ia/IIa, GP VI), 
shear stress and vWf (GP Ib/V/IX), ADP (ADP-receptors), thrombin and epinephrine. More 
enhanced responses to agonists such as collagen and ADP has been found in aspirin resistant 
patients than in aspirin responders (Kawasaki et al 2000, Macchi et al 2003). Increased levels 
of catecholamines, especially in stressful situations with increased adrenergic surge, could 
activate platelets and decrease response to aspirin (Hjemdahl et al 1994, Mustonen & Lassila 
1996, Christiaens et al 2002).
Interactions with platelets and erythrocytes contribute to platelet activity. Presence of 
erythrocytes has been shown to induce TxA
2
 formation and the release reaction of platelets 
(Santos et al 1991, Valles et al 1991). Santos et al (1997) described that aspirin initially 
decreased the erythrocyte-induced enhancement of platelet activity but after 2-3 weeks this 
inhibition was lost. 
Resolvins, a family of bioactive omega-3 fatty acid metabolites, have anti-inflammatory 
properties and their generation is enhanced by COX-2 acetylation by aspirin, thus offering 
an explanation for aspirin’s anti-inflammatory properties (Serhan et al 2002, Arita et al 2005). 
It has been suggested that deficiency of these products could influence the therapeutic failure 
of aspirin (see Wang et al 2006).
Genetic factors
Mutations or polymorphisms of genes coding for COX-1, different factors of Tx synthesis, 
GP receptors, vWf receptor and the P2Y
1
-receptor have been suggested to explain aspirin 
resistance at least partially (see Hankey & Eikelboom 2006).
Summary
Different clinical, cellular and genetic factors have been suggested to explain variability in 
responses to aspirin medication (Table 6). Larger studies on clinical relevance of aspirin 
resistance measured with platelet function tests are to be performed to establish its clinical 
relevance. However, as atherothrombotic disease is the leading cause of mortality in developed 
countries it is a phenomenon that might prove to have widespread consequences. 
5.3 Dosing
Aspirin has been shown to be effective as an antiplatelet agent at low doses between 50 and 
100mg/d. Low-dose aspirin has been shown to reduce MI or death in patients with unstable 
and chronic angina, reduce stroke and death in patients with cerebrovascular manifestations of 
atherothrombotic disease, prevent thrombotic complication in patients with peripheral arterial 
disease as well as reduce post-operative thrombotic complications in patients undergoing 
carotid endarterectomy (see Patrono et al 2004).
Even low-dose aspirin has been shown to inhibit the COX-1 enzyme by over 95% and this 
effect has been proven stable over time (Roth et al 1975, Patrignani et al 1982, Fitzgerald 
et al 1983). As a low-dose of 80mg/d has been shown to inhibit serum Tx levels by 95%, 
an additional benefit was found with a 160mg dose increasing the inhibition of Tx to 99% 
(Cerletti et al 2003). Theoretically, higher doses could be beneficial as the effects of aspirin 
unrelated to TxA
2
 have been shown to be dose dependent (see Patrono et al 2004). However, 
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these mechanisms are not exactly understood and are believed to be much less important than 
inhibition of COX-1 (see Patrono et al 2004).
The variable extent of platelet inhibition has been observed with different aspirin doses 
when measured with platelet function test. An increase from <100mg/d to >300mg/d causes 
enhancement of the antiplatelet effect (Toghi et al 1992, Hart et al 2003, Lee et al 2005).
Doses between 300-1200mg/d in patients with cerebrovascular disease have been shown to 
be clinically effective and no difference was found between varying doses (Farrel et al 1991). 
Similar results were found in another study including patients with previous TIA or stroke 
and comparing doses of 30 and 283mg/d and patients with unstable angina or undergoing 
CABG with doses of 100-1300mg (Dutch TIA study group 1991, see Patrono et al 2004). In 
patients undergoing carotid endarterectomy lower doses of 81-325mg/ were superior to 650-
1300mg/d (Taylor et al 1999).
In a meta analysis by the Antithrombotic Trialist´s Collaboration low doses of aspirin seemed 
as effective as higher doses (ATC 2002) (Fig 10). In addition, there is evidence that doses 
of approximately 300m/d produce fewer GI side effects than those of 1200mg/d (Farrel et al 
1991). However, conflicting data exist on the differences in incidence of adverse effects with 
different aspirin doses (Derry & Loke 2000).
Nonetheless, inadequate dosing has been proposed as the reason behind decreased response 
to aspirin in some patients. It has been suggested that increasing the daily aspirin dose of 
aspirin resistant patients could offer a solution for the problem. Indeed, several authors have 
reported that stepwise increases in aspirin dose could overcome a diminished response to 
aspirin (Helgason et al 1994, Cerletti et al 2003).
 
Summary
At the population level increasing the dose of aspirin does not seem to increase its clinical 
benefits. However, it is possible that in some individuals with decreased response to aspirin 
higher doses might be beneficial. Nevertheless, further larger intervention studies are needed 
before definite conclusions can be drawn.
5.4 Non-platelet sources of TxA2
Increased levels of TxA
2
, and thus the possibility of platelet activation despite aspirin 
medication, have been detected in aspirin resistant patients. As aspirin inhibits the COX-1 
enzyme responsible for TxA
2
 synthesis in platelets non-platelet sources of TxA
2 
have been 
suggested to be behind the phenomenon. In fact, TxA
2
 can also be produced by circulating 
monocytes, endothelial cells and macrophages within atherosclerotic plaques (Ziegler et al 




 by COX-2 and is then converted to TxA
2
 
by thromboxane synthase, which is present in high quantities in monocytes and macrophages. 
This reaction has been suggested to be pronounced in inflammatory states, where COX-2 
production has been upregulated, eg. atherosclerosis (Ziegler et al 2004). Normally, COX-
2 is undetectable, but it is induced by cytokines, endotoxins, growth promoters and tumor 
promoters and can be expressed in different tissues including atherosclerotic vessels (Baker 
et al 1999).
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Other factors suggested possibly to affect aspirin independent TxA
2 
synthesis are oxygen 
free radicals as they catalyze the formation of F
2
-isoprostanes from AA (Patrono et al 2005). 
Increased levels of F
2
-isoprostanes, which are prostaglandin F
2
-like compounds, have been 
found in smokers and patients with CAD, hypercholesterolemia and diabetes (Morrow et 
al 1995, Davi et al 1997 and 1999, Cipollone et al 2000). In addition, platelet activation 
is amplified by increased levels of F
2




2α, have been suggested to act as precursors for Tx and be 
formed by mechanisms catalysed by thromboxane synthase. The formation of F
2
-isoprostanes 
from AA by oxygen free radicals is independent of COX-1, thus bypassing the inhibitory effect 




 can be produced by monocytes, macrophages and endothelial cells via COX-2 and 
induce platelet activity. F
2
-isoprostanes, which are generated via a non-enzymatic pathway 
from AA, contribute to the formation of TxA
2 
and in addition they possess platelet activating 
properties. Thus, extra-platelet sources of TxA
2
 are potential contributing factors to aspirin 
resistance measured as inability of aspirin to block Tx formation. 
5.5 Expression of COX isoenzymes 
Earlier assumption in aspirin’s pharmacodynamics is that COX-1, not COX-2, is present in 
platelets and as platelets are anucleated they cannot produce new COX-1 when this enzyme is 
irreversibly inhibited by aspirin. However, in later studies COX-2 has been found to be present 
to some extent also in platelets and megakaryocytes, thus enabling the formation of TxA
2
 in 
aspirin treated platelets (Weber et al 1999, Rocca B et al 2002). This transient expression of 
COX-2 causes proportional increases in platelets containing COX-2 in situations of increased 
platelet turnover, such as surgery, inflammation and bleeding.
A variant of COX-1, “COX-3”, has been described. It is encoded by the COX-1 gene and 
has been detected in canine heart, aorta and brain (Chadrasekharan et al 2002). As it is more 
potently inhibited by aspirin than is COX-1, it seems an unlikely candidate for aspirin-resistant 
COX activity (see Szczeklik et al 2005).
Summary
COX-2 can be found in newly formed platelets and could contribute to aspirin resistance by 
enabling COX-1 independent TxA
2
 formation. Inadequate COX-1 inhibition has also been 
suggested to explain aspirin resistance; this could be caused by inadequate aspirin dosing or 
increased expression of COX-1 possibly caused by genetic differences.
5.6 Diabetes
Platelet hyper-reactivity has been reported in patients with diabetes. There are also reports that 
aspirin is not as effective in diabetics as in non diabetics (ATC 2002). It has been suggested 
that cross talk between circulating inflammatory mediators, the vessel wall and platelets may 
contribute to the failure of aspirin to adequately prevent cardiovascular events in diabetic 
patients. 
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Diabetic patients have been reported to have decreased aspirin efficacy in both in vitro 
studies as well as large clinical trials (Davi et al 1999, ATC 2002, Sacco et al 2003). However, 
negative findings have also been published (Albert et al 2005). Different reasons for decreased 
sensitivity to aspirin in diabetic patients have been proposed. As increased platelet activity and 
decreased response to aspirin have also been reported in patients with hypercholesterolemia, 
it has been suggested that metabolic differences in diabetes and metabolic syndrome might 
explain decreased aspirin efficacy in diabetics (Meade & Brennan 2000, Friend et al 2003). 
Poor response to aspirin in diabetic patients associates with decreased levels of high density 
lipoproteins (HDL) or increased levels of low-density lipoproteins (LDL) and total cholesterol 
(Sacco et al 2003, Watala et al 2004, Mehta et al 2006). In concordance with metabolic syndrome 
as an explaining factor, obesity and insulin resistance have been associated with increased 
platelet reactivity and decreased aspirin efficacy (Westerbacka et al 2002, Tamminen et al 
2003). The exact mechanism by which modification of cholesterol metabolism would affect 
aspirin efficacy and increase platelet activity are unknown.
Diabetic patients have increased levels of 8-iso-prostaglandinF
2α which could explain decreased 
aspirin response (Davi et al 1999, Mezzetti et al 2000). This was discussed more extensively 
in section 5.4.
Increased levels of HbA
1c
 and protein glycation in general associate with decreased aspirin 
efficacy in diabetics (Sacco et al 2003, Watala et al 2004 and 2005). It has been suggested that 
glucose and aspirin compete with each other in the course of non-enzymatic modifications 
and thereby increased glucose levels in blood decrease aspirin efficacy (Watala et al 2005). 
Thus, it has been suggested that increased aspirin doses would improve its efficacy especially 
in diabetics (Abaci et al 2005).
Endothelial dysfunction and inflammation as well as increased oxidative stress in diabetics 
cause progression of atherosclerosis and increase thrombogenity, both of which might explain 
decreased aspirin efficacy (Roffi & Topol 2004). Hyperglycaemia, hyperinsulinemia and 
increased oxidative stress induce inflammatory reactions by increasing expression of leukocyte 
and endothelial cell adhesive molecules and proinflammatory cytokines (De Vriese et al 2000, 
Marfella et al 2000, Biondi-Zoccai et al 2003). Insulin has been shown to down-regulate 
platelet activation and aggregation, an effect that is absent in insulin-resistant obese subjects, 
thus insulin resistance could be responsible for increased platelet reactivity (Trovati et al 1988, 
Westerbacka et al 2002, Tamminen et al 2003).
Circulating thrombogenic factors such as vWF, tissue factor, factors VII and VIII as well 
as plasminogen activator inhibitor are elevated in patients with diabetes (Bazzan et al 1998, 
Rao et al 1999, Diamant et al 2002, Biondi-Zoccai et al 2003). In diabetics platelet function, 
including procoagulation, is upregulated and levels of microparticles are increased (Davi et 
al 1989, Konieczkowski & Skrinska 2001).
Increased levels of inflammatory marker CD40 ligand have been shown to predict cardiovascular 
risk and are elevated in diabetic patients (Varo et al 2003). Platelets are the primary source of 
CD40, which is a ligand for GP IIb/IIIa receptor (Henn et al 1998, Prasad et al 2003). CD40 
ligand is a proinflammatory cytokine which mediates thrombosis by inducing tissue factor 
expression. It has been shown to stabilize arterial thrombi in an in vivo model (Andre et al 
2002). CD40L also has pro-atherosclerotic functions by mediating generation of reactive 
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oxygen species (ROS), generation and expression of adhesive molecules, macrophage 
chemoattractant protein-1 (MCP-1) and interleukin-8 (IL-8) (Henn et al 1998, Miller et al 
1998, Urbich et al 2002). 
Summary
Increased platelet activity and non-response to aspirin has been reported in insulin-resistant 
patients. Enhanced COX-independent 8-iso-prostaglandinF
2α excretion and subsequent Tx 
formation together with circulating inflammatory mediators and high glucose levels have been 
suggested as the underlying mechanisms.  Enhanced microparticle formation and shedding 
have been detected in atherosclerosis and inflammation and might contribute to increased 
COX-2 expression, platelet activity and aspirin resistance in patients with diabetes (Barry et 
al 1997 & 1998).
5.7 Genotype
Epidemiological studies have suggested that as much as one third of the variation in efficacy 
of antiplatelet drugs could be explained by genotype (O’Donnell et al 2001). 
The association of aspirin resistance with genotypic differences of COX-1 and different 
platelet receptors have been studied. In addition, hundreds of single nucleotide polymophisms 
(SNP´s) of genes involved in the Tx biosynthetic pathway have been identified (see Hankey 
& Eikelboom 2006). However, there is no data available on their role in aspirin resistance.
To date, 14 COX-1 gene polymorphisms have been identified (Halushka et al 2003, Hillarp 
et al 2003, Maree et al 2005a). Ten of these are in exons, seven of which predict amino 
acid substitutions.  Previous reports have suggested a correlation between COX-1 gene 
polymorphisms and aspirin resistance (Halushka et al 2003, Maree et al 2005a).
GP IIb/IIIa is responsible for aggregation of platelets and becomes active after initial activation 
of platelets. Aspirin has also been postulated to influence GP IIb/IIIa by interfering with 
COX-1 dependent signaling events. Interestingly, PLA1/A2 polymorphism of GP IIb/IIIa 
has been associated with aspirin resistance as well as increased risk for atherothrombotic 
complications (Weiss et al 1996, Walter et al 1997, Andrioli et al 2000, Szczeklik et al 2000). 
GP Ib, GP Ia and GP VI polymorphisms have also been associated with increased risk for MI 
(Gonzalez-Conejero et al 1998, Mikkelsson 1999 & 2001, Moshfegh et al 1999, Croft et al 
2001, Ollikainen et al 2004).  P2Y
1
-receptor polymorphism has been associated with aspirin 
resistance by mechanisms not exactly known (Jefferson et al 2005).
Summary
Genetic variance of COX-1 and platelet GP receptors could partly explain aspirin resistance.
5.8 Gender
It is know that males are at 2-3 times higher risk for CAD compared to females. Exact reasons 
for this are unknown, but known differences can be divided into those related to the hormonal 
milieu and those that cannot be explained by hormonal differences (Levin 2005). 
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In recent meta-analysis of studies of aspirin efficacy in the prevention of atherothrombotic 
events sex differences were found. In prevention of MI aspirin exerted no effect in females, 
but the incidence of stroke was decreased with aspirin treatment. Findings in males were 
opposite as aspirin treatment caused decrease in MI, but did not affect incidence of stroke 
(Berger et al 2006). Similar results were also obtained in the Hypertension Optimal Therapy 
trial (Kjeldse et al 2000).
The frequency of aspirin resistance has been reported to be higher among females. In a study 
by Gum et al (2001) it was found that patients who had impaired aspirin efficacy determined 
by ADP- and AA-induced aggregation were more likely to be females compared with aspirin 
sensitive patients. Alberts et al (2004) found in their study of 129 patients with cerebrovascular 
disease that women and older people were less likely to achieve aspirin response measurable 
with PFA-100®.
Decreased aspirin efficacy in females has been shown in in vitro studies (Harrison & Weisblatt 
1983, Escolar et al 1986, Spranger et al 1989). Reasons proposed to explain this phenomenon 
have included differences in metabolism of aspirin, platelet-subendothelium interaction, 
testosterone and estrogen levels as well as levels of anti-inflammatory mediator and the possible 
Tx generation-regulator 15-epi-lipoxin A4 (Escolar et al 1986, Spranger et al 1989, Durand 
& Blache 1996, Chiang et al 2006).
On the other hand, females have been shown to have enhanced platelet activity compared to 
males (Johnson et al 1975, Faraday et al 1997, Becker et al 2006). This might also partially 
explain increased frequency of aspirin resistance determined by platelet function tests in 
females. The finding implies that in females even though platelets are inhibited by aspirin, the 
inhibition is inadequate due to significantly increased basal platelet activity. This hypothesis 
is suggested by a study of 571 men and 711 women whose platelet function was assessed by 
PFA-100® and platelet aggregation induced by AA, ADP, and epinephrine. It was found that 
basal platelet activity was increased in females, but they had better response to aspirin than 
males when measured with aspirin specific AA-induced aggregation. Despite the aspirin efficacy 
in inhibiting AA-induced aggregation the general platelet activity of females measured with 
platelet function tests remained higher than that of males (Becker et al 2006).
Summary
Females have been reported to have increased platelet activity and decreased aspirin efficacy 
compared to males. However, data are scarce and conflicting reports have been published. The 
observations that aspirin resistance appears to be more frequent in females might be biased 
and as such at least partly explained by increased basal level of platelet activity.
5.9 Drug-drug interactions
Some NSAIDs have been shown to compete with aspirin for the serine residue of COX-1, 
thus preventing aspirin function (Catella-Lawson et al 2001). If NSAID with reversible action 
binds to COX-1 instead of irreversible aspirin, TxA
2
 generation is suppressed momentarily, 
but is recovered within hours. In a study by Catella-Lawson et al (2001) it was shown that if 
aspirin is administered at least 2 h prior to ibuprofen TxA
2
 generation remains inhibited for 
24 h. However, if ibuprofen is administered prior to aspirin, or as often as three times per day, 
TxA
2
 generation is inhibited reversibly. 
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Ibuprofen has been the most studied of the NSAIDs in relation to drug-interactions with 
aspirin and it seems to decrease its efficacy (Catella-Lawson et al 2001, Ray et al 2002, 
MacDonald & Wei 2003). Conflicting results have also been published (Kimmel et al 2004). 
Diclofenac, however, has not been shown to impede aspirin efficacy (Catella-Lawson et al 
2001, MacDonald & Wei 2003).
NSAIDs had no cardio-protective effect in a large study by Ray et al (2002). In fact, the more 
extensive inhibition by COX-2 of some NSAIDs instead of selective inhibition of COX-1 
has been postulated to increase the risk of atherothrombotic events as vasodilatory effects of 
prostaglandin I
2
 are inhibited but TxA
2 
formation is not (MacAdam et al 1999).
As aspirin is absorbed in the stomach and upper intestine some of it is hydrolysed to an inactive 
form by mucosal esterases. It has been postulated that use of protone pump inhibitors for acid 
suppression could cause enhanced hydrolysation and thus inactivation of aspirin, although 
conflicting data exist (Lichtenberger et al 1996, Iñarrea et al 2000).
Summary
Interaction between aspirin and ibuprofen seems likely on account of previous studies. A 
large, prospective, controlled trial is nevertheless needed, since clinical recommendations for 
avoidance of certain concomitant medication cannot be given based on current knowledge. 
6 Variability in clopidogrel efficacy on top of ongoing aspirin 
treatment
6.1 Definition, prevalence and relevance of non-response to clopidogrel
Definition 
In this study the term non-response to clopidogrel has been used to describe the inability of 
clopidogrel to cause the expected inhibition of platelet aggregation. After publication of the 
original articles presented here, the term clopidogrel resistance has become more established 
(see Cattaneo 2004, see Nguyen et al 2005, see Wang et al 2006). However, in the original 
articles we chose to use the less decisive term due to the continuous nature of the phenomenon. 
In the literature non-response and poor response to clopidogrel have been used as synonyms of 
clopidogrel resistance. It has been proposed that the term clopidogrel resistance would be used 
to describe the inability of clopidogrel to cause the expected platelet inhibition in laboratory 
measurements and the term treatment failure to describe failure of clopidogrel to prevent 
adverse clinical events (see Cattaneo 2004, see Nguyen et al 2005, see Wang et al 2006).
 
Clopidogrel non-response has been studied by several different methods. Nonetheless no 
uniform method has been established to determine non-response to clopidogrel. It is even 
argued that the existence of clopidogrel resistance as well as aspirin resistance is uncertain (see 
Cattaneo 2004). The general problem is that there is no effective, easily reproducible, reliable 
and easily executable method to define the phenomenon (see Cattaneo 2004, see Nguyen et 
al 2005, see Wang et al 2006). Platelet aggregation induced by ADP has been used widely, 
however its limitations are that it is labour-consuming, no uniform cut-off value has been 
established and the time chosen to measure platelet aggregation, agent used to anticoagulate 
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the blood samples as well as the concentration of the agonist used cause variation in results 
(Andre et al 2003, see Cattaneo 2004, see Nguyen et al 2005, see Wang et al 2006).
When defining clopidogrel resistance the cut-off levels of inhibition of ADP-induced platelets 
have varied between 0 and 40% in different studies (Gurbel et al 2004, Angiolillo 2004a). 
In addition, clopidogrel resistance has been defined not only by inhibition of ADP-induced 
aggregation, but also by GP IIb/IIIa receptor expression (Angiolillo et al 2004b, Gurbel et 
al 2004) and VASP phosphorylation (Schwarz et al 1999, Grossmann et al 2004, Aleil et al 
2005).  Additionally, expression of P-selectin, platelet/endothelial cell adhesion molecule-1 
(PECAM-1) and vitronectin receptor as well as formation of platelet-monocyte aggregates 
have been used to study clopidogrel effect in flow cytometry (Serebruany et al 2005). 
Prevalence
Järemo et al (2002), Gurbel et al (2003a) and Müller et al (2003b) were the first to report the 
phenomenon of clopidogrel resistance in patients with atherothrombotic disease. Järemö et al 
(2002) studied 18 patients with stable angina pectoris who were to undergo elective PCI, and 
found considerable interindividual variability in inhibition caused by 300mg clopidogrel loading 
doses administered after the procedure. Gurbel et al (2003a) assessed the clopidogrel efficacy 
in CAD patients undergoing PCI on ongoing aspirin treatment. They defined clopidogrel 
resistance as less than 10% decrease of 5 µM ADP-induced aggregation after clopidogrel 
administration when compared with baseline. By this criterion 31% of the patients were 
found to be clopidogrel resistant, but continuation of the medication decreased the number of 
clopidogrel resistant patients to 15%.
After the steady state in platelet inhibition has been achieved the phenomenon of clopidogrel 
non-response has been shown to be quite stable over time (Gurbel & Bliden 2003). Those 
patients who were non-responders after 300mg loading doses and 5 days of ongoing clopidogrel 
treatment 75mg/d remained so also after 30 days. Thus the clopidogrel efficacy did not change 
after 5 days, but remained at the same level.
Different studies using variable methods and dosing report the prevalence of clopidogrel 
resistance to vary between 4 and 55% in patients with CAD (Angiolillo et al 2004b & 2005a, 
Gurbel et al 2004, Grossman et al 2004, Wenaweser et al 2005). In larger study of 1001 CAD 
patients considered for PCI, the prevalence of non-response to clopidogrel was found to be 
one third (Hochholzer et al 2005). Similarly, 30 % prevalence has been reported by several 
other studies (Gurbel & Bliden 2003, Aleil et al 2005, Gurbel et al 2005a). 
Müller et al (2003b) reported that 4 h after 600mg clopidogrel loading doses 5% or 11% 
of patients had less than 10% inhibition of their ADP-induced aggregations and were thus 
defined as non-responder to clopidogrel. The variation in prevalence or non-response was 
caused by different ADP (5 or 20µM) concentrations used to induce platelet aggregation. As 
the prevalence of non-responders reported by Müller et al was lower than in previous studies 
executed with loading doses of 300mg, it seemed that increasing the clopidogrel loading doses 
decreased the number of non-responders.
It has been pointed out that clopidogrel resistance is not an on-off phenomenon, but that 
the platelet inhibition follows a normal, bell-shaped distribution (Serebruany et al 2005). If 
clopidogrel resistance is defined as more than two standard deviations from the median, its 
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prevalence would be approximately 5%. This is naturally a fact that needs to be remembered 
when considering clopidogrel as well as aspirin efficacy. 
Relevance
The purpose of studies of drug resistance is to understand the phenomenon of clinical treatment 
failure. If we understand the mechanisms behind treatment failure, it would be possible to 
prevent greater proportions of both thrombotic and bleeding events taking place during 
treatment with the antiplatelet medication of today. Even despite the dual antiplatelet regimen 
with aspirin and clopidogrel the incidence of adverse cardiac events after stent placement is 
1.2-1.5% (Bertrand et al 2000). In some small studies clopidogrel resistance has been shown to 
be associated with atherothrombotic events. Comparable with this have been previous reports 
in relation to GP IIb/IIIa inhibitors and aspirin, where associations between measurable platelet 
inhibition and adverse clinical effects in patients undergoing PCI have been shown (Steinhubl 
et al 2001, Chen et al 2004).
Müller et al (2003b) studied the prevalence of non-responders to clopidogrel after increased 
loading doses of clopidogrel of 600mg on top of aspirin. Retrospective analysis of these patients 
revealed that the 5 patients of 105 who developed stent thrombosis were non-responders to 
clopidogrel according to ADP-induced aggregation. Thus the investigators speculated that an 
association between clinical outcomes and non-response measured by laboratory test existed. 
However, the study was small, conducted retrospectively and was not designed to assess the 
association of clinical endpoints with measurement of clopidogrel response.
Matetzky et al (2004) studied patients undergoing PCI and divided them into four quartiles 
according to the inhibition of ADP-induced aggregation by clopidogrel. They found that 40% 
of patients in the first quartile with lowest clopidogrel-induced platelet inhibition suffered from 
adverse cardiac events within the 6-month follow up period compared to 7% of patients in the 
second quartile and no patients in third and fourth quartiles. The study was quite small with only 
60 patients, but the results were very interesting and among the first to show such correlation 
between clinical treatment failure and laboratory measurement of non-response to clopidogrel.
In another study of 1684 stented patients, 16 patients who suffered from subacute stent 
thrombosis were shown to have increased platelet activity despite combined aspirin and 
thienopyridine treatment compared to 30 control patients without stent thrombosis (Barragan 
et al 2003). However, in another study the platelet activity of 73 patients with CAD was 
assessed and no correlation between stent thrombosis and ADP-induced aggregation was 
found (Wenaweser et al 2005).
The incomplete correlation between clinical efficacy and ability of clopidogrel to inhibit platelet 
aggregation might be explained by other beneficial effects of clopidogrel. Other mechanisms 
besides P2Y12-receptor inhibition might explain the discrepancy between inhibition of platelet 
activation and beneficial effects of clopidogrel, which are not always parallel.  Clopidogrel causes 
decreased plasma tissue factor activity (Savi et al 1994a), endothelial passivation (Jacubowski 
et al 2005) vascular smooth cell effects (Wihlborg et al 2004), and anti-inflammatory effects, 
which are postulated to be related to effects on lymphocytes (Wang et al 2004).
 
Clopidogrel attenuates the post PCI increase of CRP and decreases the expression of activated-
platelet-dependent inflammatory markers, especially CD40 ligand and CD62 P-selectin 
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(Savcic et al 1999, Quinn et al 2004, Vivekananthan et al 2004). CD40 ligand stimulates 
vascular inflammation, which causes platelet-leukocyte interactions and induces tissue factor 
expression. Clopidogrel has been shown to decrease platelet-leukocyte conjugate formation 
in CAD patients Xiao & Théroux 2004).
Despite contradictory findings the majority of studies imply that clopidogrel non-response 
measured with laboratory test correlates with clinical efficacy. However, these findings need 
to be reinforced in larger prospective study settings.
Summary
In most studies clopidogrel resistance has been defined as the inability of clopidogrel to inhibit 
ADP-induced aggregation. Recently more specific methods, such as VASP phosphorylation, 
have been introduced to measure clopidogrel efficacy. Clopidogrel resistance measured in 
laboratory studies has not yet reliably been shown to associate with clinical endpoints. Thus 
large, prospective studies are needed to establish such relationships.
6.2 Reasons for variability in clopidogrel efficacy 
Clinical factors
Several mechanisms have been suggested to be behind non-response to clopidogrel (Table 7). 
Clinical mechanisms of non-response are caused mostly by inefficient availability of the active 
metabolite. This could be caused by inability to prescribe clopidogrel in a sufficient way or 
poor patient compliance. Patient compliance is an important factor in resistance to any drug, 
as described earlier in the case of aspirin. Drug-drug interactions, especially with atorvastatin, 
have been proposed as a significant cause behind decreased clopidogrel activity. Other factors 
shown to decrease the effect of clopidogrel are variability in hepatic cytochrome P450 3A4 
activity and intestinal absorption of clopidogrel (Lau et al 2004, Taubert et al 2004).
Severity of atherothrombotic disease correlates with the clopidogrel efficacy. Patients with 
higher Braunwald angina scores had less inhibition of platelet aggregation by clopidogrel 
(Soffer et al 2003). Also, diabetes and high body mass index (BMI) have been suggested to 
modify the clopidogrel efficacy (Mehta et al 2001, Steinhubl et al 2002, Angiolillo et al 2004a 
and 2005b).
Cellular factors
Increased levels of ADP in clopidogrel non-responders have been suggested, but not very 
much studied. As ecto enzymes NTPDase-1 and -2 (CD39/ectoADPase and CD39L1/ecto 
ATPase, respectively) modulate platelet activation via deletion and formation of ADP they 
may have important roles in individual sensitivity to clopidogrel together with other regulators 
of thrombogenity (Table 8)(Marcus et al 2005, Robson et al 2005). As ATP, also regulated by 
ectonucleotidases, acts as an antagonist to platelet purinergic receptors (Hechler et al 1998b), 
variability in its quantity may affect individual responses to clopidogrel. Increased ADP receptor 
P2Y
1 
function has been proposed to cause ADP-induced aggregations independent of P2Y
12
-
receptor inhibition. The P2Y
1
-receptor can mediate transient platelet aggregation even in the 
absence of P2Y
12
-receptor activation (Hechler et al 1998a). Thus, it has been postulated that 
variability in activity of P2Y
1
-receptor could cause at least part of the clopidogrel resistance 
(see Nguyen et al 2005).
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As platelets are activated via different pathways depending on the agonist, the inhibition of the 
ADP pathway by P2Y
12
 antagonists leaves possibilities for the platelets to be activated by eg. 
collagen, Tx, catecholamines and especially the potent agonist thrombin, which will be further 
discussed later. Stress reactions and elevated levels of epinephrine, which are known to have 
synergistic effects on platelet activation with other agonists, may also interfere with platelet 
activity and response to medication (Hjemdahl 1994, Mustonen & Lassila 1996, Mustonen et al 
2001). Epinephrine can also produce some features of P2Y
12
 signalling by repressing cAMP levels 
through its α2A-receptor (see Conley & Delaney 2003). Thus, failure to inhibit catecholamine-
mediated platelet activation could cause ADP-independent platelet aggregation.
Individual variability of P2Y
12
-receptor density has been proposed as an explanation for variable 
response to clopidogrel. There is no available data on P2Y
12
-receptor occupancy rate. Mills et 
al (1992) studied ADP-receptors found that the number of binding sites decreased 60% after 
clopidogrel treatment. In a review article Nguyen et al (see 2005) postulated that the results 
of Mills et al reflect that the surplus 40% of the receptors consist of other ADP-receptors such 
as P2Y
1
 and P2X1 as well as the P2Y
12
-receptors left uninhibited by clopidogrel. The mean 
number of P2Y
12
-receptors per platelet would be approximately >300 molecules. Differences 
in amounts of P2Y
12
-receptors could possibly cause clopidogrel non-response, especially if 
the doses are barely adequate. Defects in signalling pathways downstream from the receptor 
are also plausible mechanisms for drug resistance. 
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Genetic factors
Intrinsic mechanisms of clopidogrel non-response are postulated to be caused by individual 
variations in genotype and platelet activation pathways. Genotypes of the P2Y
12
-receptor, the 
target of clopidogrel, and of liver CYP3A enzymes responsible for metabolism of clopidogrel have 
been suggested as explanations for decreased clopidogrel response (Fontana 2003b, Lau 2003).
Summary
Several clinical, cellular, metabolic and genetic factors have been suggested to influence the 
variability in clopidogrel efficacy and are summarized in Table 7.
6.3 Clopidogrel dosing – loading, maintenance and timing of pre-treatment
Dosage – loading
The commonly used dose of once-daily 75mg clopidogrel was originally chosen since it 
inhibited platelet aggregation to an equal extent as twice-daily 250mg ticlopidine, a previously 
used ADP-receptor antagonist (CAPRIE 1996). Later, loading doses of 300mg were introduced 
for patients undergoing PCI as the steady state of antiplatelet efficacy with 75mg/d clopidogrel 
took several days to be achieved (Steinhubl et al 2002). After several larger studies the 300mg 
loading dose became the standard (CURE 2001, Steinhubl et al 2002). As non-responsiveness 
to clopidogrel became of interest later, inadequate dosing became one of the reasons proposed 
for deficient platelet inhibition.
Higher loading doses of clopidogrel, 375, 450, 600 and 900mg, have also been studied. The 
loading dose most commonly compared with 300mg has been 600mg.  The higher loading has 
increased efficacy in inhibiting platelet aggregation (Müller et al 2001, Gurbel et al 2005b). 
Decreased α-degranulation, GP IIb/IIIa activation and p-selectin levels have also been shown 
after the higher loading dose (Müller et al 2001, Seyfarth et al 2002, Angiolillo et al 2004b). In 
addition, the 600mg dose has a similar safety profile with the commonly used 300mg loading 
dose (Kastrati et al 2004, Hochholzer et al 2005, Patti et al 2005).
A 900mg loading dose has not been shown to be superior to 600mg, since limitations in 
clopidogrel absorption seem to block further appearance of the active metabolite in blood 
(Beckerath et al 2005b). The challenge for future research is to find a dose that would 
be at the same time effective and safe so that patients would not be exposed to bleeding 
complications.
Inefficient dosing has been proposed as a reason for limited response to clopidogrel and 
indeed, increased loading doses have been found to decrease the number of non-responders 
to clopidogrel (Gurbel et al 2005a). After 600mg loading doses of clopidogrel Müller et al 
(2003b) reported the prevalence of non-response to clopidogrel to be 5% compared with 30% 
prevalence reported after 300mg loading doses by others (Gurbel et al 2003a).
 Angiolillo et al (2004b) found that large interindividual variation of platelet responses were 
not reduced by increased loading dose. However, at the same time they reported that the 
proportion of responders to clopidogrel increased in parallel with elevated dosage.  Large 
variability in platelet activity even after 600mg was also seen by Hochholzer et al (2005) in 
a larger study of over 1000 patients, in which platelet activity was measured with receptor 
surface expression and platelet aggregation. 
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Clopidogrel resistance in the above mentioned studies has been defined as the inability 
to cause an antiplatelet effect measurable in a laboratory setting. Decreased inhibition of 
ADP-induced aggregation by clopidogrel has also been shown to correlate with incidence of 
recurrent cardiovascular events during a 6-month follow-up in relatively small study (N=60) 
by Matetzky et al (2004). In the clinical setting of the prospective, randomized ARMYDA-2 
trial (N=255) the efficacy of 600mg clopidogrel loading dose was demonstrated to be superior 
to 300mg in relation to clinical endpoints (Patti et al 2005). In that trial, higher loading doses 
of clopidogrel reduced the risk of MI by 50%.
Conflicting results have been reported by Wolfram et al (2006) who found no difference in 
adverse cardiac events within 30 days of PCI in 445 patients receiving either 300 or 600mg 
loading doses of clopidogrel. Although this was a larger study than ARMYDA-2 it was 
conducted retrospectively from patient records and is therefore not directly comparable, and 
patient groups were also more variable. 
Dosage – maintenance
In healthy individuals when daily doses of 25, 50, 75, 100 and 150mg clopidogrel were 
studied the plateau response was reached at 75mg dose (Thebault et al 1999b). However, 
supplementary 600mg clopidogrel loading doses in patients with ongoing, long-lasting 
treatment with 75mg/d clopidogrel has been shown to enhance the antiplatelet effect (Kastrati 
et al 2004). This suggests that increasing the maintenance dose could result in more effective 
platelet inhibition by clopidogrel.
The data comparing different clopidogrel maintenance regimens in patients with atherothrombotic 
disease are sparse. Müller et al (2001) studied the efficacy of both increased loading and 
maintenance dosing in a small population of patients undergoing PCI. A group of patients 
(N=10) received 300mg loading doses and 75mg/d maintenance doses and second group of 
patients (N=10) 600mg loading dose followed by 150mg/d maintenance dose. The platelet 
aggregation induced by ADP and platelet α-degranulation was measured. Significant 
improvement of efficacy was found with the higher loading dose as previously described, but 
after 48h of treatment with the higher maintenance dose (150mg/d) the platelet activation 
seemed to remain at a lower level when compared with the other group. Due to the short study 
period, it cannot positively be concluded whether this diminished platelet activity at 48 h was 
due to the initial higher loading dose or the increased maintenance dose. 
Timing of pre-treatment
In healthy volunteers treatment with 75mg has been shown to reduce ADP-induced aggregation 
within 2 h (Savcic et al 1999, Thebault et al 1999a). However, it takes 3 to 7 days for maximal 
platelet inhibition to be achieved (Thebault et al 1999b). Therefore, loading doses of 300-900mg 
clopidogrel have been introduced.
Inhibition by loading dose of clopidogrel (300mg) has been shown to decrease platelet 
aggregation in 2-3 h after administration in healthy volunteers and patients (Savcic et al 1999, 
Helft et al 2000, Gurbel et al 2003b). However, the primary analyses of the clinical CREDO 
trial suggested only >6 h pre-treatment to be effective in decreasing adverse effects (Steinhubl 
et al 2002). In further analyses of the data the preferable timing for the 300mg loading dose 
was found to be over 12h (Steinhubl et al 2006). 
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Inhibition of platelet activity seems to be achieved more rapidly with 600mg loading doses 
compared to 300mg clopidogrel (Gurbel et al 2005b, Angiolillo et al 2004b). In line with this 
Hochholzer et al (2005) claimed that the full antiplatelet effect of 600mg measured by platelet 
aggregation as well as levels of release of p-selectin and expression of activated GP IIb/IIIa 
is achieved 2 h after administration and no further effect was seen during 10 h of monitoring. 
In correlation with that in the ISAR-REACT study a 600mg loading dose seemed to achieve 
its potential within 2h in decreasing the adverse post-PCI events, as no difference was found 
between groups receiving the pre-treatment 2->12h prior to procedures (Kandzari et al 2004). 
However, further studies are needed to confirm these results.
Summary
The previously discussed studies imply that inadequate dosing might explain some of the non-
response to clopidogrel, but large variability in platelet activity remains. Increased loading 
doses of 600mg seemed generally beneficial, but its effect on non-response to clopidogrel 
remains unclear. Larger doses of clopidogrel (900mg) have not been found to cause further 
advantage. Studies of larger maintenance doses also remain to be carried out.  As the onset 
of action of clopidogrel takes at least 2h even a with high loading dose, platelet GP IIb/IIIa 
inhibitors continue to play an important role in acute atherothrombotic situations in addition 
to utilization in patients with limited response to dual antiplatelet medication. 
6.4 CYP 450 and drug-drug interactions
Clopidogrel is an inactive prodrug which requires in vivo conversion by liver enzymes to an 
active metabolite. The cytochrome P450 (CYP) 3A system is responsible for the majority of 
clopidogrel metabolism.  Especially CYP 3A4 and to lesser extent CYP 3A5 have major roles, 
but also CYP 2B6, CYP 2C19, CYP 2C9 and CYP 1A2 have been suggested to take part in 
converting clopidogrel to its active form (Savi et al 1994b, Richter et al 2004, Turpeinen et 
al 2005). 
Due to the large number of CYP enzymes involved in metabolism of clopidogrel there is an 
increased risk for interactions with concomitant medication in patients with atherothrombotic 
disease. This might partly explain the large individual variability of clopidogrel responses.
Other drugs metabolized by CYP 3A4 have been suggested as possible competitors for the 
formation of the active metabolite. Thus far atorvastatin has been the only drug more extensively 
studied in relation to drug-drug interactions. Lau et al (2003) showed an association between 
atorvastatin treatment and reduced platelet inhibition by clopidogrel in 44 patients undergoing 
PCI. They also found that other inhibitors of CYP 3A4 decreased the clopidogrel effect as the 
cytochrome inducer rifampisin enhanced inhibitory effects of clopidogrel on platelet activation 
(Lau et al 2003 and 2004).  Two in vitro studies have confirmed these results (Clarke & Waskell 
2003, Neubauer et al 2003) However, several other in vitro studies have been unable to identify 
significant interaction between clopidogrel and atorvastatin (Serebruany et al 2001, Müller et 
al 2003a, Gorchakova et al 2004, Mitsios et al 2004, Piorkowski et al 2004, Serebruany et al 
2004, Smith et al 2004, Vinholt et al 2005).
The effects of possible drug-drug interactions have also been retrospectively assessed in two 
clinical studies. Post hoc analyses of the CREDO trial showed no difference between clinical 
clopidogrel efficacy in patients receiving either CYP 3A4 or non-CYP 3A4 metabolized statins 
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(Saw et al 2003). Primary end points of clopidogrel treatment at 28 days and 1 year in this 
study were death, MI or stroke. However, as a limitation of the study the patient distribution 
was uneven as only 158 patients received non-CYP 3A4 metabolized statins compared with 
1001 patients who received CYP 3A4 metabolized statins. Although not significant, the 
incidence of adverse effects was smaller in the group with non-CYP 3A4 metabolized statins. 
In retrospective analyses of the Maximal Individual Therapy of Acute Myocardial PLUS 
(MITRA PLUS) registry no association between statin type and clopidogrel efficacy was found 
(Wienbergen et al 2003). In patients with coronary syndromes with clopidogrel treatment 833 
patients also had atorvastatin and 1203 patients had other statins (simvastatin, pravastatin, 
cerivasatin, lovastatin, fluvastatin) at the time of discharge. Between these groups there were 
no differences in atherothrombotic endpoints during follow up. However, this study is limited 
by the fact that no distinctions were made between CYP 3A4 metabolised statins and those 
metabolised via other CYP enzymes.
 
A recent prospective study of 1651 patients with coronary syndromes was unable to find 
clopidogrel-CYP 3A4 statin interaction (Mukherjee et al 2005). The use of a combination 
of statin and clopidogrel was associated with lower 6 month incidence of adverse effects 
than either clopidogrel or statin alone. There were no significant differences in event rates of 
patients when clopidogrel was combined with either CYP 3A4 metabolised or non-CYP 3A4 
metabolized statin.
 
In the PROVE-IT study (Pravastatin or Atorvastatin Evaluation and Infection Therapy) high 
dose atorvastatin was proven to be superior to standard dose pravastatin in patients of whom 
most (72%) had also clopidogrel or ticlopidine therapy (Cannon et al 2004). In yet another 
study of 1001 patients no correlation between clopidogrel efficacy (loading dose 600mg) and 
statins was found, neither were there correlation with any other medication used (Hochholzer 
et al 2005). 
Thus, it seems that there is no clinically relevant interaction between clopidogrel and 
atorvastatin. Results by Lau and colleagues (2003) have been questioned because of their 
use of non-conventional methods to assess platelet activation, small study size, patients 
also receiving GP IIb/IIIa inhibitor and the uncontrolled use of aspirin and other CYP 3A4 
inhibitors (see Poulsen et al 2005).  However, the other studies can also be criticized for similar 
limitations as well as that some considered all statins and did not differentiate between CYP 
3A inhibitors and others, the other potential CYP 3A4-inhibiting drugs were not taken into 
account (eg. ca-channel blockers, benzodiazepines and antidepressants) (Turgeon et al 2006). 
In some clinical studies sample sizes have been insufficient, especially to prove the absence 
of drug-drug interactions. In addition, most studies have assessed the effect of clopidogrel 
to inhibit platelet activation measured with different laboratory tests; however, the reduced 
antiplatelet effect has not been shown to be of clinical relevance.
Cholesterol levels have been shown to correlate with platelet activity (Rauch et al 2000). 
Thus, careful treatment of cholesterol itself will decrease platelet reactivity and reduce blood 
thrombogenicity in patients with atherothrombotic disease (Rauch et al 2000).
Smoking has been shown to correlate with increased clopidogrel efficacy. It has been suggested 
this phenomenon can be explained by activation by liver enzymes by the polycyclic aromatic 
hydrocarbons in cigarette smoke (Zevin et al 1999, Matetzky et al 2004).
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Summary
Conflicting reports have been published on possible interaction of clopidogrel with atorvastatin, 
which could interact with clopidogrel due to competitive metabolism by the CYP 3A system. 
Drug-drug interactions between clopidogrel and other drugs have not been studied. As 
clopidogrel is a prodrug requiring metabolism by liver enzymes possible interactions may 
prove to be clinically important. In addition the large number of CYP enzymes participating 
in metabolism of clopidogrel enhances the possibility of interactions.
Table 8. Factors which participate in thromboregulation and thus possibly affect efficacy of clopidogrel. 
Thromboregulator Released Action Aspirin sensitive
Thromboxane Yes Platelet activation, recruitment 
and secretion; vasoconstriction
Yes
Prostacyclin Yes Inhibition of platelet 
responsiveness; vasodilatiation
Yes
NO Yes Inhibition of platelet 
responsiveness; vasodilatation
No
NTPDase-1 No, membrane 
associated
Removes ADP, ATP, decreasing 
purinergic signalling
No
NTPDase-2 No, membrane 
associated
Converts competitive antagonist 
ATP of ADP-receptors to 
agonist ADP
No
ADP Yes Acts on purinergic receptors; 
may be involved in erythrocyte 
prothrombotic activity
No platelet effects; 
partial effect on 
erythrocytes
Modified from Marcus (2005) and Robson (2005). NO=nitric oxide, NTPDase=nucleoside triphosphate 
diphosphohydrolase/ ecto-adenosine phosphatase (ADPase)/CD39
6.5 Genotype
Polymorphisms of several platelet receptors, such as GP IIb/IIIa and GP VI, have been 
shown to correlate with enhanced platelet activity (Michelson 2000, Joutsi-Korhonen et al 
2003). Furthermore, genetic variation in receptors has been associated with increased risk for 
atherothrombotic complications (Moshfegh et al 1999, Mikkelsson et al 1999 and 2001, Croft 
et al 2001, Ollikainen et al 2004). Polymorphisms of both the P2Y
12
-receptor and CYP 3A 
system have been proposed to explain variable clopidogrel efficacy.
Originally five P2Y
12
-receptor polymorphisms were identified. Four of these were shown to 
be in complete linkage disequilibrium, thus determining haplotypes H1 and H2 (Fontana et 
al 2003a) (Table 9).  In 98 healthy volunteers H2 haplotypes seemed to be associated with 
increased ADP-induced platelet response (Fontana et al 2003a). However, in another study 
of 200 healthy individuals no association between platelet activation and P2Y
12
-receptor 
polymorphisms was found (Hetherington et al 2005).




-receptor polymorphisms have been shown to correlate with PAD in two independent 
studies. In a case-control study of 184 PAD patients and 330 age matched controls the P2Y
12
-
receptor H2 haplotype was more frequent in patients with atherothrombotic disease (Fontana 
et al 2003b). In another study of patients with advanced PAD P2Y
12
-receptor polymorphisms 
associated with the risk of thrombotic neurological events.  When 137 clopidogrel treated 
patients were studied carriers of the T allele of the C34T polymorphism had a 4-fold risk for 
occurrence of atherothrombotic events (Ziegler et al 2005). 
Association between P2Y
12
-receptor polymorphisms and clopidogrel response have been 
studied both in patients with atherothrombotic disease and in healthy individuals. In 96 
healthy volunteers clopidogrel efficacy was not found to associate with H1/H2 haplotype 
(Fontana et al 2006). In another study 416 patients with CAD were genotyped according to 
H1/H2 haplotype as well as the C34T polymorphism and ADP-induced platelet aggregation 
was assessed after administration of 600mg clopidogrel loading dose. Neither the haplotype 
nor the C34T polymorphism were associated with clopidogrel response (von Beckerath et 
al 2005a). In accordance, in a smaller study of 36 patients with 300mg loading doses and 83 
patients with ongoing 75mg/d clopidogrel the P2Y
12
-receptor haplotypes were not associated 
with clopidogrel response (Angiolillo et al 2005c).
As the CYP 3A system plays an important role in metabolism and activation of clopidogrel 
its polymorphisms have been proposed to explain variability in platelet inhibition exerted by 
clopidogrel. Extensive genetic differences in CYP 3A5 have been shown as well as remarkable 
variability in its function (Lee et al 2003). More than 30 CYP 3A4 SNPs have been identified, 
however their functional role has not been shown (Lamba et al 2002). Despite several studies 
an association between CYP 3A4 activity and genotype has not been found (Turgeon et al 
2006). Neither are there data on association of clopidogrel response and CYP 3A4 genotype.
 A CYP 3A5 gene polymorphism distinguishing expressor (*1) and non-expressor (*3) alleles 
has been shown to influence total CYP 3A activity (Kuehl et al 2001). A recent study showed 
that in clopidogrel treated patients atherothrombotic events occurred more frequently in patients 
with the non-expressor genotype (Suh et al 2006). 
In addition, polymorphisms of other platelet receptors have been studied in an endeavour to 
explain variability in clopidogrel responses. T allele carriers of the GP Ia receptor C807T 
polymorphism had increased platelet responses compared with C allele homozygotes despite 
dual antiplatelet medication with aspirin and clopidogrel (Angiolillo et al 2005d). This finding 
highlights the importance of other activation pathways behind resistance to the ADP-receptor 
antagonist clopidogrel. Conflicting results on the role of the GP IIb/IIIa PL A1/A2 polymorphism 
in clopidogrel resistance have been reported (Dropinski et al 2005, Angiolillo et al 2004c).
Summary
Several polymorphisms of the P2Y
12
-receptor have been determined. P2Y
12
-receptor genotype 
does not seem to correlate with clopidogrel response in patients with atherothrombotic disease. 
However, a correlation between clopidogrel efficacy and CYP 3A5 genotype was found in a 
single study. Thus far the subject of association between alleles of either P2Y
12
 or the CYP 
3A system and clopidogrel response has been inadequately studied. 
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Table 9. Description and allele frequency of the previously described polymorphisms of the P2Y
12
-receptor. 
The H1/H2 haplotype is defined by the i-C139T, i-T744C, i-ins801A, G52T polymorphisms. 
Name of SNP Amino Acid Region Allele Frequency
i-C139T … Intron C   86.2% T   13.8 %
i-T744C … Intron T   86.2% C   13.8 %
i-ins801A … Intron Insertion of an A   13.8 %
G52T G/G Exon 2 G   86.2% T   13.8 %
C34T N/N Exon 2 C   72.5% T   27.5%
Reproduced from Fontana et al (2003b), with permission.
6.6 Thrombin
Platelet activation due to thrombin has been suggested as a potential reason behind non-response 
to clopidogrel in some individuals. Thrombin is a potent platelet activator and normally such 
activations cause the release of ADP from dense granules. Thus ADP-receptors, including 
P2Y
12




-receptor antagonism has been shown to decrease thrombin-induced platelet activation, 
especially at lower thrombin concentrations (Adam et al 2003, Nylander et al 2003 & 2004). 
At concentrations of 0.25-2nM P2Y
12
-antagonism caused an inhibition of 70-86%, while at 
concentrations of 100nm the inhibition was 15-20% and the inhibitory effect was present even 
at extreme thrombin concentrations in flow cytometric studies (Nylander et al 2003). However, 
P2Y
12
-antagonism does not inhibit platelet activation caused by high thrombin concentrations 
in aggregations with washed platelets or in whole blood (Kim et al 2002, Adam et al 2003, 
Nylander et al 2003). Thus, the P2Y
12
-receptor plays a role in thrombin-induced activation, 




The activation of platelets by thrombin in spite of P2Y
12
-antagonism has also been reported in 
patients with CAD. Thrombin receptor activating peptide (TRAP)-induced platelet aggregation 
and degranulation was not inhibited by combination treatment with aspirin and clopidogrel, 
suggesting that platelet aggregation can not totally be inhibited in the presence of high levels 
of thrombin (Müller et al 2001).
The different roles of PAR receptors could explain the thrombin activation despite P2Y
12
-
antagonism. Activation of PAR-1 has been shown to be sufficient for complete ADP release 
(Covic et al 2002). At thrombin concentrations (>1.5nM) higher than those needed for PAR-1 
activation and complete ADP release PAR-4 takes part in platelet activation (Covic et al 2000, 
Nylander & Mattsson 2003). Thus Nylander et al (2003) have suggested that at higher thrombin 
concentrations the role of ADP would be significantly diminished. However, they reported 
that activation of PAR-4 was inhibited by P2Y
12
-antagonists (Nylander et al 2003). Again, 
at variance with flow cytometric measurements reported by Nylander et al (2003), a study 
by Adam et al (2003) showed no inhibition of PAR-4 related activation by P2Y
12
-agonists in 
platelet aggregation experiments. Interestingly, PAR-1 genotype has recently been associated 
with increased platelet activity which cannot be overcome with clopidogrel treatment (Smith 
et al 2005).
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Summary
Non-response to clopidogrel could, at least partly, be explained by the fact that in an 
environment where excess thrombin is generated the thrombin receptor PAR-4 could cause 
platelet activation. Interestingly, large variability in PAR-4 activation responses have been 
detected (Adam et al 2003). 
Thus, in acute thrombotic setups or in thrombophilic patients, thrombin could be generated 
despite antiplatelet medication and could bypass the inhibition of other platelet activation 
pathways and cause activation via the PAR-4 receptor.
6.7 Diabetes and increased BMI
Both diabetics and non-diabetics benefit from clopidogrel and its efficacy exceeds that of 
aspirin treatment (CAPRIE 1996, Bhatt et al 2002b). In the CREDO and CURE studies patients 
with diabetes tended to benefit from clopidogrel slightly less than non-diabetics (CURE 2001, 
Steinhubl et al 2002). In the CURE (2001) study 2840 diabetic patients were investigated 
and showed no significant difference in incidence of adverse events when treated with the 
combination of clopidogrel and aspirin (14.2%) or aspirin alone (16.7%) (Mehta et al 2001). 
Also in the CREDO trial the benefit from combination (aspirin and clopidogrel) treatment in 
diabetic patients was smaller than in non-diabetic patients (relative risk reduction 11% and 
33%, respectively) (Steinhubl et al 2002). However, only subgroup analyses of these clinical 
studies concerning the clopidogrel efficacy in diabetics versus non-diabetics and especially in 
association with insulin resistance have been published. Thus, diabetics seem to require potent 
antithrombotic medication especially during PCI or unstable angina. Despite their impaired 
prognosis in comparison with non-diabetics, patients with diabetes are reported to equally 
benefit from GP IIb/IIIa antagonists (Marso et al 1999).
The decreased clopidogrel efficacy in diabetic patients has also been proven with laboratory 
measurements of platelet activation (Angiolillo et al 2005b). Different explanations for 
decreased clopidogrel efficacy in diabetic patients have been suggested. Increased thrombogenic 
and arteriosclerotic activity could explain the phenomenon, as previously discussed in relation 
to aspirin. Glucose levels and formation of platelet microaggregates have been studied in 
attempts to explain the variability of drug efficacy.
 
Despite the fact that increased blood glucose concentration have been shown to enhance 
platelet  aggregation and platelet-subendothelium interaction, high concentrations of glucose 
did not decrease clopidogrel efficacy (De La Cruz et al 2004).  Another study assessed the 
formation of microaggregates in diabetic patients and healthy subjects (Matsuno et al 2005). 
In diabetic patients platelet activity was increased and microaggregates formed more easily 
than in controls. However, the P2Y
12
-receptor antagonism in vivo and in vitro inhibited the 
formation of microaggregates, unlike in healthy controls. Thus, diabetic patients were more 
sensitive to clopidogrel in relation to inhibition of microaggregate formation, but as the baseline 
platelet activity in diabetics was increased compared to non-diabetics the clinical significance 
of this finding is questionable.
In patients with high body mass index the benefit from combination treatment with clopidogrel 
and aspirin has been postulated to be reduced (Angiolillo et al 2004a). This could be 
explained by enhanced platelet function, increased levels of platelet cytosolic Ca2+ and plasma 
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catecholamines in overweight individuals (Scherrer et al 1991, Takaya et al 1997). Angiolillo et 
al (2004a) have suggested increased loading doses to overweight patients, especially because 
CYP 3A4 activity has been shown to be reduced in overweight individuals (Kotlyar et al 
1999). However, in subanalysis of the CAPRIE study (1996) there seemed to be no need for 
weight-adjusted dosing with the maintenance dose of 75mg/d studied. Benefits of increased 
loading doses in obese patients have not been studied.
Correlation between decreased response to clopidogrel and obesity could to some extent be 
explained by the fact that obesity is closely related to metabolic syndrome which has been 
associated with decreased clopidogrel efficacy. 
Summary
Diabetic patients seem to gain less benefit from clopidogrel treatment than non-diabetics. The 
exact reason for this is unknown. 
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AIMS OF THE STUDY
Atherothrombotic disease is major cause of mortality in developed countries. Antiplatelet 
medication is one of the cornerstones in its treatment. A considerable proportion of patients 
suffer from atherothrombotic events despite antiplatelet medication with aspirin, clopidogrel 
or their combination. This study was aimed to clarify the individual variability of platelet 
activity and responses to antiplatelet medication and its mechanisms by using different platelet 
function tests. 
The study focused on the following specific issues:
1) To compare the feasibility of different laboratory tests in detecting individual variability of 
platelet function and in vitro response to antiplatelet medication.
2) To assess the in vitro efficacy of ongoing aspirin in patients with coronary artery disease 
(CAD) and the efficacy of short term as well as steady-state treatment of clopidogrel on top 
of ongoing aspirin in CAD patients who were to undergo elective PCI.
3) To clarify whether genotype of platelet receptors is associated with individual variability 
in platelet functions and response to antiplatelet medication with aspirin or the combination 
of aspirin and clopidogrel as well as to determine clinical and metabolic factors which affect 
individual responses to antiplatelet medication with aspirin or the combination of aspirin and 
clopidogrel.
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SUBJECTS, MATERIALS AND METHODS
1 Subjects (I-IV)
Blood was collected from either healthy volunteers (I) or patients undergoing elective PCI 
with angiographically proven CAD (II-IV). Twenty-one healthy, non-smoking volunteers, 
who denied taking any medication during the past ten days, participated in the first study (I). 
Hundred and one patients undergoing elective PCI without treatment with insulin, warfarin, 
heparin or antiplatelet agents other than aspirin participated in the following studies (II-IV). 
Clinical endpoint data were collected from patients and confirmed from medical records 12 
months after the PCI (unpublished data).
The protocols of these studies followed our institutional guidelines and informed consent was 
obtained from each subject. The studies which included patients (II-VI) were approved by the 
Ethics Committee of Helsinki University Central Hospital and complied with the Declaration 
of Helsinki. 
2 Blood samples and anticoagulants (I-IV)
Blood was collected either with a free-flowing technique (I), via venipuncture or into evacuated 
tubes, from the antecubital vein (II-IV). The blood for platelet function assessments was 
collected in several anticoagulants depending on the platelet function test used: 1) in trisodium 
citrate (I-IV), 2) in acidic citrated dextrose (I) and 3) in either hirudin (II-IV) or 4) in D-
phenylalanyl-1-prolyl-1 arginine chloromethyl ketone (I), as monomer-induced aggregation 
depends on Mg2+, which is chelated by citrate (Siljander et al 1999).
3 Medication and time of specimen collection (II-IV)
The patients (II-IV) were being treated with a daily morning dose of aspirin at the time of 
admission to the outpatient clinic. The average dose was 100mg/d. Compliance with aspirin 
treatment was controlled by salicylate measurements and biological response in the form of 
plasma TxB
2
.  Blood samples were collected 2-120 h before the PCI. 
An additional platelet inhibitor, clopidogrel (methyl (S)-(2-(2-chlorophenyl)-2-(4, 5, 6, 7,-
tetrahydrothieno (3,2-c) pyridin-5-yl) acetate, hydrogen sulphate) was orally administered 
prior to the PCI. All blood samples were obtained before the actual procedure; 1) before 
the administration of clopidogrel, to study the effect of aspirin alone (II-IV) and either 2a) 
2.5±0.5 h after the administration of a loading dose of 300mg clopidogrel to study the early 
combined effect of aspirin and clopidogrel (III) or 2b) after a loading dose of 300mg followed 
by a daily dose of 75mg for five days to study the combined effect of aspirin and ongoing 
clopidogrel (IV). 
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4 Whole Blood Perfusions (I)
4.1 Preparation for Perfusion and Labelling of Platelets 
To standardize rheological conditions hematocrit was adjusted in the blood for the perfusions, 
if required (Turitto et al 1980). Depending on the hematocrit the final plasma concentration 
of citrate was adjusted (Sakariassen et al 1989). Platelet-rich plasma (PRP) was separated 
from blood after centrifugation and platelets in PRP were labelled with 3H-serotonin. At 
this low serotonin concentration platelet membranes are labelled without the contribution 
of the 5HT
2
A-receptor (unpublished data).  Before the perfusions the labelled PRP and the 
remaining blood cells were recombined and incubated (Sakariassen et al 1989, Mustonen et al 
1996). Coverslips for perfusion procedure were coated either with collagen fibrils or collagen 
monomers (Siljander et al 1999). 
4.2   Perfusion procedure
A parallel-plate perfusion chamber was used under a shear rate of 1600 s-1 (Turitto 1975, Hall et 
al 1998). Blood was prewarmed at 37oC and perfused in a single passage through the chamber. 
Experiments were done in either duplicates or triplicates. After perfusion the 3H-scintillation 
activities of the coverslips were analysed using liquid scintillation counter (Mustonen et al 
1996). Intraindividual reproducibility of the perfusion was assessed on two subsequent days. 
The coefficient of variation was 20% in perfusions in PPACK-anticoagulated whole blood 
over collagen monomers (N=6), and 16% over collagen fibrils (N=14).
5 Platelet aggregations (I-IV)
Blood was prepared for aggregation experiments in PRP by centrifuging. The PRP platelet count 
of was adjusted to 300 x 106/mL with platelet-poor plasma, also prepared by centrifuging. 
For aggregations with gel filtrated platelets (I), PRP separated after centrifugation from blood, 
apyrase and PGE
1
 added to PRP to prevent activation while a platelet pellet was separated 
from plasma by further centrifugation. Platelets were then resuspended and eluted through a 
Sepharose CL-2B column (Timmons et al 1989). Prior to the experiments 2 mM MgCl
2
 was 
added to enhance GP Ia/IIa functions and to provide physiological concentration of divalent 
cations for the platelets.
Aggregations were induced with 1) soluble collagen monomers (I-IV), 2) collagen fibrils (I), 
3) adenoside 5´-diphosphate ADP (II-IV), 4) arachidonic acid (II-IV) and 5) epinephrine (II-
IV). The additional effect of subthreshold concentrations (0.2 µM) of ADP or epinephrine 
was determined in some experiments by adding the agonist to PRP prior to either the collagen 
monomers or fibrils (I). 
A specific P2Y
12
-receptor antagonist AR-C69931MX (ARMX) (generously provided by 
Astra Zeneca, Loughborough, UK) and P2Y
1
-receptor antagonist adenosine 3,5 diphosphate 
(A3P5P, 200µM) (Sigma, St. Louis, MO, USA) were used in certain ADP-induced aggregations 
(IV). 
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Aggregation was traced with a traditional, turbidometric aggregometer, either a Payton 
turbidometric aggregometer (Payton Associates Inc.; Buffalo, NY, USA) (I) or PPACKS-4 
aggregometer (Helena Laboratories, Beaumont, Texas, USA) (II-IV). Maximal aggregation 
(I-IV), rate (I) or slope (II-IV) and lag time (I) were assessed.  The inhibition of platelet 
aggregation in response to clopidogrel and ARMX was calculated as a reduction of maximal 
ADP-induced aggregations (III, IV).
6 Platelet function analyser PFA-100® (I-IV)
PFA-100® (Dade-Behring AG, Düdingen, Switzerland) is a platelet function analyser that 
measures primary hemostasis in whole blood, under capillary flow conditions, with a high shear 
rate (4000 1/s). Platelets interact with a collagen mesh of the same origin as used in perfusion 
studies (I) spiked with either ADP (CADP) or epinephrine (CEPI), resulting in occlusion of an 
aperture in the respective cartridge. The results are expressed as closure times. In preparation 
for platelet function analyses the hematocrit was adjusted when applicable.
The PFA-100® method has been suggested to be useful in the assessment of the antiplatelet 
effects of aspirin, and the closure time of an epinephrine-stimulated cartridge should be 
prolonged in aspirin-treated patients (Mammen et al 1998, Homoncik et al 2000, Gum et al 
2001, see Favaloro 2002). The manufacturer of the PFA-100® refers to 170 s as the limit of 
aspirin efficacy with a sensitivity of 95%. In our laboratory the intraindividual method- and 
donor-dependent variability of PFA-100® in CADP and CEPI was found to be 7% and 11%, 
respectively (3 repeated samples from 8 healthy donors over 3 weeks).
7 Definition of responders and poor responders to aspirin 
and clopidogrel (II-IV)
Non-responders to aspirin were defined with two alternative methods: 1) for the PFA-100® 
method, patient samples with a closure time shorter than 170 s in the CEPI cartridge (Mammen 
et al 1998, Homoncik et al 2000, Gum et al 2001, see Favaloro 2002) and 2) for the AA-induced 
aggregation method, patient samples with an aggregation slope >12% during the first minute 
of the test, as this cut-off level dichotomized patients as clear non-responders (maximal 
aggregation >80%) and responders (maximal aggregation < 40%).
Poor response to clopidogrel was defined by inhibition of ADP-induced platelet aggregation. 
Aggregations were performed before and after clopidogrel administration and if the inhibition 
of aggregation was less than 10% (post value subtracted from the pre value), these patients 
were defined as poor responders to clopidogrel. 
8 Genotype Analyses (II, IV) 
DNA was extracted from blood samples using a non-enzymatic method (Lahiri et al 1991). 
Genotypes for GP IIIa, GP VI, GP Ib (HPA2/Kozak) and GP Ia (C807T/HPA5) polymorphisms 
were determined. Genomic regions containing variant sequences were amplified via PCR and 
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then incubated with restriction enzymes. Genotypes were determined by staining the DNA 
fragments with ethidium-bromide and separation by agarose gel electrophoresis (for details see 
Mikkelsson et al 1999, 2001 and 2002, Moshfegh et al. 1999, Ollikainen et al 2004). COX-1 
genotypes were also assessed. Fragments containing the single nucleotide polymorphisms 
(SNP) -A842G, C22T, C714A and C644A were amplified with primers and the resulting PCR 
products digested with enzymes and separated on agarose gel. The -A842G SNP is in complete 
linkage disequilibrium with the C50T SNP, therefore this polymorphism was not studied.
 
Genotypes for the P2Y
12
-receptor G52T polymorphism and the CYP 3A5 enzyme A6986G 
polymorphism were determined. The G52T polymorphism has been previously reported to 
be part of the H1/H2 haplotype (Fontana et al 2003a). Genomic regions containing variant 
sequences were amplified via PCR and then incubated with restriction enzymes. Genotypes 
were determined by staining the DNA fragments with ethidium-bromide and separation by 
agarose gel electrophoresis (van Schaik et al 2002, von Beckerath 2005a).
9 Laboratory Analyses (II-IV)
Several laboratory measurements were performed: blood cell counts, levels of von 
Willebrand factor (vWF), fibrinogen, glycosylated hemoglobin (Hb A1c), C-peptide, C 
reactive protein (CRP), blood glucose levels, activated partial thromboplastin time (APTT), 
epinephrine and norepinephrine (HPLC-EC) (Scheinin et al 1991), plasma thromboxane B
2
 
(Tx B2) (EIA, Cayman Chemical, USA) (Ojanen et al 2003) and salicylate levels (liquid 
chromatography)(Brandon et al 1985).
10 Statistical Analyses (I-IV)
The data are presented as mean ± SD. Spearman’s non-parametric test was used to assess the 
correlations between variables. The differences between groups were assessed with Mann-
Whitney U-tests and Wilcoxon tests were used for paired samples. The level of significance 
used was 0.05. The genotype effects were studied with stepwise binary logistic regression 
analyses with appropriate covariate factor data (hematocrit, age, sex, smoking and diabetes, as 
well as C-peptide, fibrinogen and vWF levels) (II). The efficacy of antiplatelet medication was 
studied by using previously determined parameters of poor ASA response and by comparison 




1 Platelet function tests and individual variability in platelet 
functions (I)
1.1 Individual variability in platelet functions
Large variability between donors was observed in whole blood perfusions, PFA-100®-system 
and platelet aggregations (Table 10). Collagen monomer-induced platelet activation was 
more sensitive to individual differences in platelet function than collagen fibril-induced 
activation. 
Table 10. Interindividual variability detected in different platelet function tests, as well as the 
coefficient of variation for duplicates or triplicates. (I)




MC/PPACK 45-fold 29 (10.8-53)
FC/PPACK 3-fold 15.7 (1.9-47.7)
FC/citrate 7-fold 16.6 (2.7-44.2)
Platelet function analyses PFA-100®
CEPI/PPACK 2-fold 13.8 (3.5-39.2)
CEPI/citrate 3-fold 13.8 (0.6-47.8)
CADP/PPACK 4-fold 11.8 (0-32.4)
CADP/citrate 2-fold 13.1 (1.3-44.2)
Aggregations
MC/PPACK     lag time (s) 3-fold
rate (1/min) 7-fold
max (%) 3-fold*
FC/PPACK lag time (s) 2-fold
rate (1/min) 2-fold
max (%) 1.3-fold*
CV=coefficient of variation between duplicate or triplicate samples, MC= collagen monomers, FC= 
collagen fibrils, CEPI=collagen/epinephrine cartridge, CADP= collagen/ADP-cartridge, *= the 
calculation of variation is limited by the fact that maximal aggregation can not reach values above 
100%
1.2 Associations between platelet function tests
Perfusions and PFA-100® (I)
Results of the perfusions correlated with those of PFA-100®. The epinephrine-enhanced closure 
times in PFA-100® correlated with platelet deposition on collagen fibrils in citrated blood (r= 
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-0.45, p<0.05) and collagen monomers (r= -0.49, p<0.05). The ADP-enhanced closure times 
correlated with platelet deposition on collagen fibrils both in PPACK- and citrate-anticoagulated 
blood (r= -0.47, p<0.05 and r= -0.43, p<0.05 respectively). 
Platelet aggregation and PFA-100® (I-IV)
The platelet aggregations induced by collagen fibrils or collagen monomers did not correlate 
with PFA-100® closure times in healthy donors (N=21) (r=-0.05-0.26, P=0.17-0.96). 
Association between PFA-100® and platelet aggregations was found in CAD patients (N=101) 
with either aspirin or aspirin and clopidogrel medication. (I-IV) When platelet functions of 
patients with ongoing aspirin treatment were studied CEPI closure times associated with 
extent of aggregations induced by ADP and epinephrine (r=-0.23 and r=-0.24, P<0.030, 
respectively) (II).  Measurements from PFA-100® and platelet aggregations correlated with 
each other better in patients who had ongoing platelet suppression by combinations of aspirin 
and clopidogrel medication. In these patients closure times in CEPI cartridge associated not 
only with those previously mentioned aggregation studies but also with the extent of collagen-
induced aggregation (r=-0.31, P=0.03, N=50) (III).  In these patients closure times in CADP 
associated with collagen and ADP as well as epinephrine induced aggregation (r=-0.28, P=0.05, 
r=-0.29, P=0.41, r=-0.34, P=0.02, respectively) (unpublished data).
1.3 Factors associating with variability in platelet functions (I)
Donors with C807T genotype of GP Ia/IIa had 8-59% larger deposition of platelet on collagen 
in perfusion studies than the ones with wild type, but this was not statistically significant 
(P=0.60-0.71).
Lag times of platelet aggregations, both monomer- and fibril-induced, correlated with the 
genotype. The donors homozygous to the C allele presented longer lag time, by 30% in 
monomer-induced and by 22% in fibril-induced aggregations, than the donors heterozygous 
to the platelet receptor GP Ia gene (90±16 s vs. 69±18 s, and 84±14 s vs. 69±12 s, respectively, 
both p<0.04).
2 Variability in aspirin efficacy (II-IV)
2.1 Prevalence of poor aspirin response
Response to aspirin treatment evaluated by AA-induced aggregation 
When platelet aggregation was induced by AA 5% of the patients had a slope steeper than 
12%/min and were categorized as aspirin non-responders (Fig 11). Two of these patients had 
both low salicylate and high Tx B
2
 levels suggesting pharmacokinetic resistance or possible 
non-compliance. Non-responders to aspirin according to AA-induced aggregations also had 
shorter closure times in the PFA-100® CEPI-cartridge than the responders (193±90 vs. 257±69 
s, P=0.03). In patients with sustained AA-induced aggregation limited platelet inhibition by 
aspirin could also be detected by epinephrine- or ADP-induced platelet aggregation, as they 
had enhanced responses to these agonists in comparison with responders (epinephrine 76±13 
vs. 62±14 %, P=0.04 and ADP 91±7 vs. 84±7 %, P=0.02). There were no significant differences 
in collagen-induced aggregations between responders and non-responders.
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Figure 11. Prevalence of non-response to antiplatelet medication in 101 patients with coronary artery 
disease. A) Prevalence of non-response to ongoing aspirin and 300mg loading dose of clopidogrel 
2.5 h after administration of the latter (N=49). B) Prevalence of non-response to ongoing aspirin and 
ongoing clopidogrel (300mg loading dose followed by daily 75mg for five days) (N=51) (II-IV).
Response to aspirin treatment evaluated by PFA-100® 
When whole blood was applied to the CEPI cartridge 21% of the patients had closure times 
shorter than 170 s and were categorized as aspirin non-responders (Fig 12). One of these 
patients had low salicylate and high Tx B
2
 levels suggesting pharmacokinetic resistance or 
possible non-compliance. The population of non-responders had enhanced maximal platelet 
aggregation induced by ADP when compared with responders to aspirin (84±6% vs. 87±9%, 
P=0.01). No difference between the non-responders and responders to aspirin according to 
PFA-100® was observed when aggregation was elicited by AA, epinephrine or collagen. 
2.2 Methodological aspects of measurement of aspirin response
Aggregations and PFA-100® detect different populations as non-responders 
The present study (II-IV) revealed that the common methods used to detect aspirin response, 
AA-induced aggregation and PFA-100®, indicate different populations as being aspirin-resistant 
with a modest overlap. Of the five non-responders according to AA-induced aggregation only 
two were non-responders according to PFA-100® (Fig 12). PFA-100® detected 21% as aspirin 
non-responders, while AA-induced aggregation detected only 5% as non-responders.
Compliance to aspirin treatment
All patients affirmed aspirin intake, when assessed by questioning on the day of PCI. Salicylate 
levels measured varied between 0-31846 ng/ml (mean 2479±3770 ng/ml). Thirteen patients 
had plasma salicylate levels which were under the detection limit, possibly due to the short half 
life of salicylate or poor compliance (Fig 13). However, most patients had low plasma TxB
2
 
levels compatible with aspirin use. Tx B
2

















pg/ml). The Tx B
2
 levels of the 13 patients with no measurable salicylate varied between 56-
455 pg/ml (mean 212±119 pg/ml) and those with measurable salicylate levels between 40-331 
pg/ml (mean 133±62 pg/ml)(P=0.01). There were two patients with no measurable levels of 
salicylate and higher Tx B
2
 levels (436 and 455 pg/ml) than in salicylate positive patients 
indicating possible non-compliance.
3 Variability in clopidogrel efficacy administered on top of 
aspirin
3.1 Prevalence of poor clopidogrel response
Limited early response to loading dose of clopidogrel on top of aspirin (III)
Although at the population level clopidogrel exerted inhibitory effect, in a subgroup of patients 
clopidogrel treatment did not inhibit platelet aggregation. There were 2 patients in whom 
ADP-induced aggregation did not attenuate after administration of clopidogrel. Furthermore, 
we identified 20 patients in whom maximal aggregation decreased by less than 10%. As 
ADP-induced aggregations were used to define limited clopidogrel response, 40% (N=20) of 
the study population were defined as poor responders to clopidogrel (Fig 11). The effect of 
clopidogrel was not associated with the time between drug administration and blood sample 
collection (P=0.6). 
Limited response to ongoing clopidogrel on top of aspirin (IV)
In the whole population clopidogrel exerted inhibition of platelet activity measured both with 
platelet aggregations and PFA-100®. However, in a subgroup of patients clopidogrel treatment 
was found not to inhibit platelet aggregation. There were 10 patients (20%) in whom maximal 
aggregation was decreased by less than 10% (Fig 11). These patients were defined as poor 
responders to clopidogrel according to limited inhibition of ADP-induced aggregation. Patients 
who had poor response to aspirin according to AA-induced aggregation (N=2) responded 
to clopidogrel better than responders to aspirin when measured with ADP (5 µM) -induced 
aggregations (41±14 vs. 19±10 %, P<0.033). 
Efficacy of loading dose of clopidogrel in non-responders to aspirin (III)
In the group of patients receiving only the loading dose of clopidogrel (N=50) 9 patients 
presented measurable response to AA in aggregation studies (measurable slope). Of the 9 
patients, 4 patients benefited from a loading dose of clopidogrel, whereas 5 patients did not. 
These 5 patients, 10% of the entire patient group, did not achieve any measurable antiplatelet 
effect from either aspirin (measured with AA-induced aggregation) or clopidogrel (measured 
with ADP-induced aggregation). Of these 9 patients 3 had aggregation slope >12%/min and 
where thus labelled non-responders to aspirin. One of the non-responders to aspirin was also 
non-responder to clopidogrel. 
In patients with poor response to aspirin according to PFA-100® (N=14), clopidogrel inhibited 
ADP-induced maximal platelet aggregation by more than 10% in 10 patients. Thus, 4 patients 
remained poor responders to both aspirin and clopidogrel.
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4 Factors associating with variability in efficacy of antiplate-
let medication
4.1   Factors associating with variability in aspirin efficacy
Poor response to aspirin associates with genotype (II)
According to AA-induced aggregation, 60% of the aspirin non-responders in the sample of 101 
patients carried the rare G allele for the COX-1  -A842G polymorphism in comparison with 
only 17% of aspirin responders (P=0.02). In other words, 2.5% of the patients homozygous 
for the common A allele were aspirin non-responders, whereas as many as 16% of the rare G 
allele carriers were aspirin non-responders (P=0.02). None of the other three common COX-1 
polymorphisms studied associated with aspirin response with either method. Plasma Tx B
2
 
levels did not correlate with different COX-1 polymorphisms.
Patients heterozygous for the GP VI C13254T polymorphism had shorter closure times in PFA-
100® than did patients homozygous for the common C allele (218±86 vs. 262±65 s, P=0.02). 
Of the aspirin responders according to PFA-100®, 13% had the rare T allele whereas this allele 






















Figure 12.  PFA-100® and AA-induced aggregations detect different populations as aspirin non-
responders. PFA-100®-closure times in aspirin responders and non-responders by AA-induced 
aggregation in 101 patients with coronary artery disease. The closure time 170s has been used as cut 
off line for aspirin resistance assessed by PFA-100®. The maximal measured closure time by PFA-100® 
is 300s. Short horizontal lines represent the mode of closure times (II).
Results
79
Other factors explaining variation in aspirin efficacy (II)
Other factors related to non-response to aspirin according to AA-induced aggregation were 
increased Tx B
2
-levels, type II diabetes, previous AMI and surprisingly, low levels of fibrinogen. 
In addition, levels of vWF did not influence aspirin response. Non-responders to aspirin 
according to AA-induced aggregation had higher Tx B
2
-levels than the responders (298±159 
vs. 135±60 pg/ml, P=0.02). Of the 5 non-responders, 2 had type II diabetes in contrast to 10 of 
the responders to aspirin (N=95) (P=0.05). Four of five non-responders had suffered previous 
AMI in contrast with 39% of responders (37 of 95) (P=0.07). Non-responders to aspirin had 
lower fibrinogen levels (3.1±0.3 g/L) than responders (3.8±0.6 g/L) (P=0.01). 

















































Figure 13. Thromboxane and salicylate levels of 101 coronary artery disease patients of which 5 were 
defined as non-responders to aspirin according to AA-induced aggregation (.).Thromboxane and 
salicylate levels of 5 non-responders are given in the table. The mean thromboxane and salicylate levels 
in the whole patient group were 143±76 pg/ml and 2479±3770 ng/ml, respectively (II).
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compared to responders (186±90 vs. 131±68 pg/ml, P=0.00). Interestingly, 36% of females 
were non-responders in comparison with 16% of males (P=0.04). Moreover, females had an 
overall decreased response to aspirin as their PFA-100® closure times were shorter than those 
of males (225±79 vs. 263±66, P=0.02) (4.4 odds ratio, 1.3-15.4 95% confidence interval). The 
plasma levels of salicylate and TxB
2
 did not differ according to gender. 
4.2   Factors associating with variability in clopidogrel efficacy
Differences at the receptor level (IV)
The P2Y
12
-receptor inhibition by clopidogrel correlated with the inhibition exerted by ADP-
receptor antagonist AR-C69931MX (ARMX) (r=0.43, P=0.00). Adding the P2Y
1
-receptor 
antagonist A3P5P before and after clopidogrel, as expected, inhibited the extent of aggregation 
having synergistic effect with either one of the P2Y
12
-receptor antagonists clopidogrel or 
ARMX. Inhibition of P2Y
1
-receptor by A3P5P attenuated the ADP-induced aggregation to 
a similar extent in both non-responders and responders to clopidogrel, thus suggesting that 
clopidogrel resistance is a P2Y
1
-independent phenomenon.
Clopidogrel non-responders did not achieve as great inhibition of ADP-induced aggregation
by in vitro P2Y
12
-receptor antagonist ARMX as clopidogrel responders (25±7 vs. 32±7%, 
P<0.02), suggesting a common reason behind attenuated response to clopidogrel and ARMX. 
There were no differences in basal platelet activity between clopidogrel responders and non-
responders (P>0.55). 
Efficacy of loading dose of clopidogrel and insulin resistance (III)
Attenuated early response to a loading dose of clopidogrel correlated with insulin resistance. 
Patients with poor long-term glucose balance measured with glycosylated hemoglobin (Hb 
A1c) and elevated insulin levels measured with C-peptide, did not benefit from clopidogrel 
as much as the normoglycemic patients. Clopidogrel-induced inhibition of aggregation 
triggered by ADP was lower in patients with high levels of glycosylated hemoglobin (Hb 
A1c) or C-peptide (r = -0.33, P=0.03, r= -0.36, P=0.01). The patients with limited responses 
(change in aggregation <10%) to clopidogrel had higher serum C-peptide levels than patients 
who responded well to clopidogrel. As expected, increased C-peptide levels correlated with 
increased body mass index (r=0.51, P=0.00). 
However, response to ongoing clopidogrel was not associated with Hb A1c, C-peptide or blood 
glucose levels (P> 0.15). So the association was lost during prolonged medication, suggesting 
interference at the time of early metabolism.
Other factors associating with clopidogrel efficacy (III, IV)
The higher the level of catecholamines the less the early prolonging effect of clopidogrel loading 
dose in closure times of CADP (r = -0.37, P=0.01) (III).  Epinephrine levels also correlated with 
the efficacy of ongoing clopidogrel. The higher the level of epinephrine the less the prolonging 
effect of ongoing clopidogrel in closure times of CEPI (r = -0.30, P=0.03) (IV).
 
There was no association with the antiplatelet efficacy of clopidogrel and any statin used 
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(P>0.1) (Table 11) (III, IV). Neither did the genotypes of liver enzyme CYP 3A5 or P2Y
12
 
associate with clopidogrel efficacy (IV).
Table 11. Mean inhibition of ADP (2 and 5µM)-induced aggregation by either loading dose of clopidogrel 
or ongoing clopidogrel in patients with different lipid lowering medication. 
Statin Loading dose of clopidogrel 
(300mg)
Ongoing clopidogrel 
(300mg + 75mg/ for 5 days)
N ADP 2 µmol/L ADP 5 µmol/L N ADP 2 µmol/L ADP 5 µmol/L
Atorvastatin 8 21±12 15±8 18 24±9 22±9
water-soluble 
statins




20 19±16 19±16 18 23±10 19±9
No statin 19 17±10 15±11 5 14±16 19±20
None of the differences were significant (III-IV).
5 Poor responses to antiplatelet medication and clinical 
treatment failure (unpublished data)
When 101 CAD patients assessed in studies III and IV were followed up for 12 months 19% 
(N=19) had undergone repeat PCI, 3% (N=3) CABG and 4 % (N=4) had died. Three out 
of the 20 patients with poor response to clopidogrel loading dose died during the follow up 
whereas there was no deaths is in patient group with measurable clopidogrel effect (P=0.03). 
Re-PCI within the first 12 months seemed to be more common in patients with poor response 
to aspirin (2 out of 5) than in patients with measurable response (17 out of 95, 18%) (P=0.22). 
(See also table 12). 
Table 12. Frequency of adverse events in responders and non-responders to aspirin, measured with 
either AA-induced aggregation of PFA-100® as well as loading dose or ongoing clopidogrel 
Clopidogrel: loading dose 300mg
Endpoint Responders N=30 Non-responders N=20 P
% N % N
Re-PCI 27 8 25 5 0.90
CABG 0 0 5 1 0.22
Death 0 0 15 3 0.03*
Combined 
endpoints
27 8 35 7 0.53
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Clopidogrel: ongoing treatment 75mg/d
Endpoint Responders N=41 Non-responders N=10 P
% N % N
Re-PCI 12 5 10 1 0.85
CABG 5 2 0 0 0.48
Death 2 1 0 0 0.62
Combined 
endpoints
20 8 10 1 0.480
Aspirin response: assessed with AA-aggregations
Endpoint Responders N=95 Non-responders N=5 P
% N % N
Re-PCI 18 17 40 2 0.22
CABG 3 3 0 0 0.69
Death 4 4 0 0 0.62
Combined 
endpoints
23 22 40 2 0.39
Aspirin response: assessed with PFA-100® 
Endpoint Responders N=78 Non-responders N=21 P
% N % N
Re-PCI 22 17 10 2 0.21
CABG 4 3 0 0 0.36
Death 5 4 0 0 0.29
Combined 
endpoints
28 22 10 2 0.08





Despite current antiplatelet regimens with aspirin, clopidogrel or their combination, several 
patients suffer from atherothrombotic events, the incidence of which are enhanced by increased 
platelet activity, inflammation, lipid levels and vasoactivity. Therefore, growing interest has 
been focused on this treatment failure and the phenomena of aspirin and clopidogrel resistance 
have become subjects of increasing research. The terms non-response or resistance to either 
of these antiplatelet drugs have been used to describe lack of platelet inhibition in laboratory 
tests. On the other hand, treatment failure describes the occurrence of adverse effects in patients 
despite antiplatelet medication. The goal of this area of study is to determine whether drug 
resistance measurable in laboratory tests associates with treatment failure and could thus be 
used as a predictor of risk of atherothrombotic events. Identifying these patients at greater 
risk, and more importantly understanding the mechanisms behind the increased risk, would 
enable us to tailor individual antithrombotic treatment to these patients. 
1 Individual variability of platelet functions
As platelet activity varied markedly between individuals, we studied the usability of different 
laboratory methods in detecting this variance (I). When compared with PFA-100®, perfusions 
induced by collagen fibrils and platelet aggregations, platelet deposition on collagen monomers 
was found to be the most sensitive method for assessing individual variability. However, the 
measurement of platelet deposition on collagen monomers might be influenced by the fact that 
it is mostly GP Ia/IIa-dependent and thus does not entirely correspond to the normal function of 
platelets. PFA-100® was found to be less sensitive to individual variability but was proved to be 
valuable as it was shown to correlate with sophisticated functional assays of perfusion, and has 
better availability, usability and reproducibility than traditional methods. Individual variability 
in platelet functions has been postulated to associate with increased risk for atherothrombotic 
events (see Michelson 2004). The large individual variability in platelet functions could also 
partly explain differences in responses to antiplatelet medication. Thus, in the future, platelet 
function tests might prove to be useful in detecting patients at increased risk for adverse events 
and in need of targeted antiplatelet medication. However, optimal function test are yet to be 
developed as some of the sensitivity and most of the versatility of the methods are lost when 
traditional but laborious methods are substituted by modern apparatus.
2 Measurement of aspirin resistance
Due to the variety of methods used to detect aspirin resistance and the number of studies 
published during the past few years, an effort to unify the terminology and methodology 
has recently been made (see Cattaneo 2004, see Hankey & Eikelboom 2006). It has been 
suggested that aspirin resistance measured with TxA
2
-dependent methods would be defined as 
pharmacological or “true” aspirin resistance and that methods which measure platelet activity 
inducible also via TxA
2
-independent pathways would be labelled functional or “unproven” 
aspirin resistance (see Cattaneo 2004, see Wong et al 2004).
Apart from two studies in the 1990´s the interest in this question was not provoked until 
recently (Helgason et al 1994, Mueller et al 1997, Buchannan et al 2000, Peters et al 2001). 
In the beginning aspirin resistance was determined by several methods, including tests which 
were either independent of or dependent on TxA
2
 production. We measured the antiplatelet 
effect of aspirin with TxA
2





-independent pathways of platelet activation had been reported to detect 
aspirin use in previous studies (Feuring et al 1999, Homoncik et al 2000). In the present study 
the two methods were observed to indicate different populations as being aspirin-resistant 
with a modest overlap (II). Of the 5 non-responders according to AA-induced aggregation 
only 2 were non-responders according to PFA-100®. Similar findings were reported by Gum 
et al (2003). 
Measurement of AA-induced aggregation directly evaluates the capacity of COX-1 to produce 
TxA
2
 subsequent to platelet aggregation (Gum et al 2003). Therefore, this method, although 
time-consuming, is a valuable determinant of aspirin efficacy. In addition, sustained AA-
induced aggregation has been associated with clinical endpoints in aspirin-treated patients 
(Gum et al 2003). This tendency could also be detected in our studies (unpublished data). It 
has also been confirmed by others (Wenaweser et al 2005). 
Despite the fact that PFA-100® has been reported to detect aspirin use, other mechanisms 
compensate and surpass the need for TxA
2
 production when platelets are challenged in the 
PFA-100® system. It is well accepted that aspirin does not affect shear stress-induced platelet 
aggregation, one of the important features in the PFA-100® system (see Cattaneo 2004). Data 
are too scanty to draw any conclusions about clinical associations. The presence of collagen 
and epinephrine in the cartridges could pinpoint collagen, vWF and adrenergic receptors as 
possible modulators of differences in aspirin sensitivity (Poujoul 1998, Chakroun et al 2004). 
In fact, it has been shown that under flow conditions such as those of the PFA-100® analyzer, 
platelet aggregation is mainly mediated by specific interactions between vWF and GP Ib 
as well as GP IIb/IIIa, and between collagen and GP Ia/IIa as well as GP VI. VWf has been 
shown to play an important role in PFA-100® (Chakroun et al 2004). Thus, PFA-100® has 
been found useful for detecting variation in defects of vWf, such as von Willebrands disease, 
as well as in general platelet activity, which is not necessarily related to specific function of 
aspirin (Cattaneo et al 1999, Favaloro et al 1999).
Measurement of TxB
2
 formation from serum, plasma or urine has been suggested as a TxA
2
-
dependent method of measuring aspirin efficacy (Eikelboom et al 2002). In our study, plasma 
Tx levels were associated with enhanced platelet functions and aspirin resistance measured 
with AA-induced aggregation, and more so with PFA-100® (II). This could indicate that basal 
systemic Tx acts as a synergistic preactivating agonist, as has been suggested for epinephrine 
and thrombopoietin (see Akkerman 2006). A limitation of our study is, however, the lack of data 
on serum TxB
2
 production which would better reflect the Tx-dependent platelet responses. 
Thus, it seems that division of aspirin resistance into at least two different types is justified. 
The type directly related to aspirin’s pharmacological mechanism of action, inhibition of 
TxA
2
 formation, could possibly be labelled as pharmacological resistance as Wong at al (see 
2004) suggested. However, despite the fact that current methods of measuring AA-induced 
aggregation and formation of TxA
2
 seem the best possible options at this time, both have 
limitations leaving clinicians without a definitive test for pharmacological aspirin efficacy. 
Measurement of Tx levels ignores the fact that while aspirin might block COX-1-induced Tx 
formation in platelets, it could be formed in other cells or in platelets by COX-1-independent 
mechanisms, thus making a patient appear aspirin resistant in contrast to reality. In addition, 
increased levels of TxB
2
, the stable metabolite of TxA
2
, could also reflect enhanced F
2
-
isoprostanoid function and not specifically formation of TxA
2
 from AA via COX enzymes 
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(Cipollone et al 2000). The recent findings of Frelinger et al (2006) also support the role of 
COX-independent Tx formation in aspirin resistance, as in aspirin treated patients a residual 
AA-induced aggregation could not be inhibited by additional in vitro aspirin. 
In conclusion, AA-induced aggregations, preferably in combination with serum TxB
2
 
measurements, are at the moment best available method in detecting true, pharmacological 
aspirin resistance, whereas PFA-100® could be used to assess the general platelet activity, but 
is not specific to aspirin efficacy. 
3 Prevalence of aspirin resistance
In this study PFA-100® detected 21% as aspirin resistant patients, while AA-induced aggregation 
detected only 5% as aspirin-resistant (II). This is in accordance with previous and later reports 
by others (Table 5). The variability in prevalence of aspirin resistance in previous studies can 
be explained by the variety of methods as well as differences in severity of atherothrombotic 
disease in the patients studied. In addition, variable doses of aspirin have been used. The 
present results are comparable to studies with similar patients and methodologies (Gum et al 
2003). However, AA-induced aggregation has seldom been used to detect aspirin resistance, 
instead studies with PFA-100® or combination of aggregations with different agonists are more 
common. Likewise, PFA-100®, ADP- and collagen-induced aggregations are not specific to 
the mechanism of action of aspirin, but measure general platelet activity (see Cattaneo 2004, 
see Hankey & Eikelboom 2006). 
4 Reasons for variability in aspirin efficacy 
Several reasons for aspirin resistance, such as non-compliance, inadequate dosing, drug-
interactions, diabetes, gender, genotype and increased TxA
2
 production have been suggested. 
As recent studies found 2-3% of CAD patients non-compliant to aspirin (Tantry et al 2005, 
Frelinger et al 2006), in this study the compliance was assessed with questioning as well as 
salicylate measurement. In line with these previous findings, 2 of our patients had increased 
AA-induced aggregation, elevated Tx levels and no measurable salicylate in their plasma, 
suggestive of poor compliance or aspirin resistance (II). Nonetheless, the whole phenomenon 
of aspirin resistance is not explainable by poor compliance as we found measurable salicylate 
levels in patients with aspirin resistance measured with AA-induced aggregation (II). In 
addition, aspirin resistance has been reported despite supervised aspirin administration 
(Grundmann et al 2003). 
Until further information is gained on factors affecting aspirin resistance also possible drug 
interactions should be considered. More information is needed on possibilities to overcome 
aspirin resistance with increased dosing. In light of current limited information it seems that 
some of the patients could benefit from increased dosing, but inadequate dosing is unlikely 
to explain the whole phenomenon. Patients with apparent states of increased platelet turnover, 
such as during post-operative periods, could be the ones to benefit from increased and more 
frequent dosing (Zimmermann et al 2003).
Interestingly, we found that type II diabetes seemed to be associated with non-response to 
aspirin measured with platelet function tests (II). Previously diabetics have been reported 
to gain less clinical benefit from aspirin than non-diabetics (ATC 2002, Sacco et al 2003). 
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Increased platelet activity and non-response to aspirin have been reported with insulin-resistant 
patients (Westerbacka et al 2002, Tamminen et al 2003), and enhanced COX-independent 
8-iso-prostaglandinF
2α excretion and subsequent Tx formation have been suggested as the 
underlying mechanisms (Davi et al 1999).  Increased inflammatory reactions and different 
inflammatory markers such as CD40 ligand in diabetics have been proposed to affect platelet 
activity (Varo et al 2003). However, in this study CRP was measured from half of the patients, 
but was not found to associate with aspirin response (III).
Females more frequently responded poorly to aspirin than males when measured with the high-
shear dependent PFA-100® method (II). This phenomenon has also previously been reported 
both in clinical trials as well as laboratory measurements of aspirin resistance and platelet 
activity (Harrison & Weisblatt 1983, Escolar et al 1986, Gum et al 2003, Berger et al 2006). 
As female gender was found to be associated with shortened closure times in PFA-100®, but 
not with AA-induced aggregation, it is possible that this finding might reflect the increased 
basal level of platelet activity in females and not specifically the sensitivity to aspirin. Indeed, 
in a study of 711 women and 571 men it was found that though females had increased levels 
of platelet activity compared to males, they gained better inhibition by aspirin (Becker et al 
2006). However, despite good inhibitory effects, the platelet reactivity of females remained 
increased compared to males (Becker et al 2006). In concordance with this is also our finding 
that individual variability in platelet activity is vast and thus might explain some of the 
variability in responses to antiplatelet medication (I).
Non-response to aspirin measured with AA-induced aggregation was associated with the rare 
G allele of the -A842G polymorphism of COX-1. On the other hand, the rare T allele of the 
C13254T polymorphisms of GP VI was common in non-responders to aspirin according to PFA-
100®. This finding might reflect the differences in methods of measuring aspirin efficacy. As 
AA-induced aggregation is specific to COX-1 inhibition by aspirin the finding of an association 
between COX-1 polymorphism and aspirin resistance suggests that genotype influences 
individual’s drug response (II). COX-1 polymorphisms might modulate the generation of TxA
2
 
in platelets and increased levels of TxA
2
 have been suggested to influence aspirin resistance. 
In addition, extra-platelet formation of TxA
2
, transient expression of COX-2 in platelets and 
formation of TxA
2
 by COX-independent methods, such as via 8-iso-prostaglandinF
2α have 
been reported (Davi et al 1997, Weber et al 1999, Rocca et al 2002, Ziegler et al 2004). In 
contrast to AA-induced aggregations, PFA-100®, which measures platelet activity inducible 
also by TxA
2
-independent mechanisms, associated with polymorphisms of GP VI. GP VI is 
a platelet receptor which mediates adhesion to collagen under high shear conditions, such as 
PFA-100®. The observations that different platelet function tests used for assessing the aspirin 
efficacy associated with two different polymorphisms is in concordance with the nature of these 
methods; AA-induced aggregation as a measurement of TxA
2
-dependent platelet activation 
associated with COX-I polymorphisms and the PFA-100® as a measurement of more general 
platelet function, inducible by several different pathways including high shear rates associated 
with polymorphisms of GP VI receptor responsible with shear-induced activation and adhesion 
to collagen. 
In conclusion, individual variability in aspirin efficacy has been shown, but the mechanisms 
behind it are yet to be resolved. The phenomenon seems multifactorial and this study showed 
that genotype is one of the underlying factors. 
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5 Measurement of clopidogrel resistance
Aspirin resistance became a hot topic due to increased knowledge of platelet functions, better 
availability and usability of tests to measure it and because clopidogrel with acceptable 
efficacy and safety profile was introduced as the first feasible option for aspirin. This 
situation also evoked interest in clopidogrel efficacy. Clopidogrel acts as an inhibitor of ADP-
induced aggregation by blocking the P2Y
12
-receptor. Thus its efficacy has most often been 
studied with assessment of ADP-induced platelet activity. Most recently measurement of 
intracellular activation such as VASP phosphorylation has been suggested to be more specific 
for determination of clopidogrel efficacy, but it too has limitations (Schwarz et al 1999, see 
Conley & Delaney 2003). In previous studies, patients have been regarded as resistant if 
clopidogrel has been unable to inhibit ADP-induced activation significantly. Different cut-off 
points for this dichotomy have been used. This has been objected to, since inhibition exerted 
by clopidogrel has been shown to follow a normal bell-shaped curve (Serebruany et al 2005). 
However, in our studies a strict criterion of 10% change in maximal aggregation induced by 
ADP was used to illustrate the minimal effect of clopidogrel in certain patient groups (III, IV). 
Despite this dichotomy to responders and non-responder in our study, the continuous nature 
of the phenomenon has been acknowledged.
6 Prevalence of clopidogrel resistance after loading dose in       
addition to ongoing aspirin
As clopidogrel administered on top of aspirin has proven beneficial in acute coronary syndromes 
and in a PCI setting we set out to study the variability in inhibition exerted by clopidogrel in 
CAD patients. Thus, a study involving 50 elective PCI patients using permanent aspirin was 
designed to study the efficacy of short-term clopidogrel in a setup mimicking an acute PCI setting 
(III). In healthy subjects a loading dose of clopidogrel (300 mg) was found to inhibit ADP (5 
µM)-induced platelet aggregation by 70% within 2 h (Savcic et al 1999). However, in our study 
40% of patients showed persistent aggregation to ADP (III). Therefore, we concluded that under 
acute PCI the inhibition exerted by the clopidogrel loading dose (300 mg) will not be complete 
in all patients and further antiplatelet medication, such as GP IIb/IIIa inhibitors, are needed. This 
prevalence of 40% is in concordance with studies by others, where prevalence of 30% is most 
often reported. The increased proportion of limited response in our study can be explained by 
the fact that we specifically determined clopidogrel efficacy shortly (2.5h) after administration. 
This was done to assess its usefulness in acute situations. Consequently, the clinical clopidogrel 
efficacy administered prior to PCI has been reported to be decreased compared to administration 
more than 6 h prior to the surgical procedure (Steinhubl et al 2002).
7 Prevalence of clopidogrel resistance in patients with ongo-
ing treatment
As limited response to clopidogrel was frequently found shortly after administration, we 
then wanted to study the effect of an ongoing combination of aspirin and clopidogrel (IV). 
In addition, despite the fact that prolonged clopidogrel administration had been reported to 
improve its efficacy, recurrent thrombotic events still occur in patients with atherothrombotic 
disease (Steinhubl et al 2002, Gum et al 2003). We found 20% of patients with stable CAD to 
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have limited response to clopidogrel when measured with platelet function tests. Thus, it seems 
that there are significant individual differences in responses to antiplatelet medication.
8 Reasons for variability in the clopidogrel efficacy
Previously suggested explanations for variability in effectiveness of clopidogrel have been 
under-dosing, drug-interactions, insulin resistance, differences in the genotypes of platelet 
receptors or enzymes responsible for liver metabolism of clopidogrel, differences in metabolism 
and availability of antiplatelet drugs, increased levels of ADP, enhanced baseline function of 
P2Y
1
-receptor, defects in signalling pathways downstream from the ADP-receptors and platelet 
activation via other pathways such as collagen, thrombin, or Tx.
Over-expression or -activity of P2Y
1
-receptors has been reported to cause hyper-reactivity of 
platelets (Hechler et al 2003). Thus such state could be speculated to cause poor responses to 
clopidogrel. However, in our study the extent of P2Y
1
-dependent ADP-induced aggregation did 
not vary between clopidogrel responders and resistant patients. Interestingly, the patients with 
poor response to in vivo clopidogrel were the ones with the least in vitro response to ARMX, 
suggesting that the limited response to clopidogrel emerges at or downstream of the receptor 
and not, for example, at the metabolism of the prodrug clopidogrel to its active metabolite. 
Indeed, unlike Lau et al (2002), but in accordance with Müller et al (2003a), we did not find 
impaired clopidogrel responses to associate with any statin. Enhanced basal platelet activity 
has also been suggested to explain limited responses to clopidogrel (Aleil et al 2005). However, 
in our study the basal platelet activity did not associate with clopidogrel response (IV).
The extent of clopidogrel response did not correlate with the polymorphisms of the CYP3A5 
enzyme, which is responsible for most of liver metabolism of the prodrug (Savi et al 1994b). 
The different P2Y12-receptor G52T polymorphism did not seem to explain the individual 
variability in responses to clopidogrel, a finding in concordance with previous studies (von 
Beckerath et al 2005a) (IV).
As activation of platelets by thrombin has been suggested to overcome inhibition of the P2Y
12
- 
receptor at high concentrations, high thrombogenic burdens in patients with atherothrombotic 
disease could explain non-response to clopidogrel. However, in our study the responders 
and poor responders did not differ in their F
1+2 
levels while on aspirin before the induction of 
clopidogrel treatment (IV).
We found that the inhibition of ADP-induced aggregation by clopidogrel was not complete 
in CAD patients. Addition of in vitro P2Y12-receptor antagonist ARMX further attenuated 
platelet functions on top of in vivo clopidogrel (IV). However, clopidogrel and ARMX have 
different modes of action, which complicates the direct comparison of these drugs. In addition, 
it could be argued that the results of these studies might have been influenced if larger doses 
of ARMX or clopidogrel would have been used. In latest studies which contradict the original 
ones, increasing the concentration of ARMX above 100 nM has been beneficial. ARMX, named 
cangrelor, has been proposed in clinical use as an intravenous drug with acceptable efficacy 
and safety profile (see Storey 2001, Greenbaum et al 2006). In previous studies ARMX has 
also been found to be more effective in inhibiting platelets than clopidogrel. However, in these 
comparisons a fixed dose of clopidogrel was used and there are no studies comparing larger 
doses of clopidogrel with ARMX. Recently, conflicting reports have appeared on the efficacy 
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of 600mg clopidogrel loading doses compared with 300mg. Larger loading doses intensify 
platelet inhibition, decrease the lag of effect after drug administration and reduce the number 
of patients with poor clopidogrel response (Müller et al 2001, Gurbel et al 2005b). However, 
the effect of increasing the daily clopidogrel dose has been poorly studied. Kastrati et al (2004) 
showed that loading dose of 600mg on top of ongoing 75mg/d clopidogrel caused additional 
inhibitory effect of platelet activation, which suggests to the fact that further benefits might 
be achieved by increasing daily dosages. In our study the effect of clopidogrel was studied 
in patients on aspirin treatment after 300mg loading doses followed by 75mg daily doses of 
clopidogrel, which represents the stable state drug effect with the current dosing regimen. 
Under-dosing is a possible contributor to clopidogrel resistance, but increased loading and 
especially maintenance doses of clopidogrel have not yet been widely studied.
When efficacy of the 300mg clopidogrel loading dose on top of ongoing aspirin was assessed 
in CAD patients who were to undergo PCI, increased body mass index and levels of C-peptide 
were found to be associated with decreased response to clopidogrel (III). However, when 
patients where treated with ongoing dual antiplatelet medication, clopidogrel response did 
not correlate with increased glycosylated hemoglobin levels, nor C-peptide levels (III).  A 
possible explanation for this could be that these factors cause a delay, rather than suppression, 
in effect of clopidogrel. Activity of CYP 3A4 has been shown to be reduced in overweight 
patients and obesity is often related to type II diabetes (Kotlyar & Carson 1999).
In conclusion, varying clopidogrel efficacy has been found. The adequate dosing and timing 
of the clopidogrel treatment decrease the prevalence of non-response to clopidogrel. As in the 
case of aspirin, the reasons behind this phenomenon are many. It is seems that certain patient 
groups eg. diabetics would benefit from monitoring of their antiplatelet treatment. 
9 Limitations of the study
This thesis consists of studies on the in vitro efficacy of antiplatelet medication with aspirin or 
the combination of aspirin and clopidogrel. While, the phenomenon of resistance to antiplatelet 
medication has been shown in patients with CAD the clinical significance of these findings remain 
to be confirmed in larger, prospective studies. Interestingly, the COX-1 -A842G polymorphism 
associated with decreased aspirin efficacy. However, most of the patients were either homozygous 
for the common A allele or heterozygous for the -A842G polymorphism. Only one patient was 
homozygous for the rare G allele for the -A842G polymorphism, precluding any conclusions on 
the functional role of this genotype. The limited prevalence of rare -A842G genotypes produced 
relatively small material for the study and thus, these results need to be confirmed in a larger study. 
We found no drug interactions which could have explained decreased efficacy of antiplatelet 
medication. However, this could have been influenced by limited study size.
10 Variability in efficacy of antiplatelet medication
Patients with atherothrombotic disease have variable inhibition of platelet function as measured 
in vitro.  Taking notice of this is vital as the response to certain medications might vary from 
inadequate to excessive in different patients, thus exposing them to risk of an atherothrombotic 
event or bleeding, respectively. Some patients treated with either aspirin or the combination of 
aspirin and clopidogrel have suffered from clinical events and the risk of major bleeding in 
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these patients varies from 1-2%, but can be significantly higher in certain patient groups.
Restrictions in the efficacy of antiplatelet medication suggest a need for enhanced or alternative 
antiplatelet medication in aspirin- or clopidogrel-resistant patients. Further studies in larger 
patient populations are needed to confirm our results. In addition, larger prospective studies 
are needed to determine how these platelet responses in functional tests associate with patient 
outcome.  In the future, platelet function tests or pharmacogenetics may be applied to identify 





This study was designed to assess the individual variability of platelet activity and responses 
to antiplatelet medication. It was found that a considerable number of CAD patients were non-
responders either to aspirin, clopidogrel or both when measured with platelet function tests.
1) Large individual variability in platelet functions was found. Different methods of assessing 
platelet function under shear conditions correlated with each other. PFA-100® and whole blood 
perfusions are useful in assessing individual variation of platelet activity. 
As platelet aggregation tests and PFA-100® represent dissimilar environments and use different 
platelet activating agents the results between them are not comparable. Indeed, they detected 
two different populations as being aspirin resistant. AA-induced aggregations, unlike PFA-100®, 
can be used to detect pharmacological aspirin resistance. However PFA-100® detects enhanced 
platelet activity, also considered as functional aspirin resistance.  PFA-100® failed to detect 
variability in responses to short-term clopidogrel and thus cannot be used for monitoring of 
its efficacy.
2)  There seems to be a patient population that fails to achieve full platelet inhibition by aspirin 
treatment or combination of aspirin and clopidogrel. Considering the worldwide prevalence 
of atherothrombotic disease size this patient group is considerable. In future platelet function 
test might prove beneficial in tailoring individual antiplatelet medication.
3)  Mechanisms behind decreased aspirin efficacy or combination of aspirin and clopidogrel 
are multifactorial. Both genetically determined factors such as gender and platelet receptor 
genotype as well as acquired factors such as type II diabetes influence platelet activity and 
efficacy of antiplatelet medication. In future, special care could be used when administrating 
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